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Abstract 
The involvement of proteases in the metastatic spread of tumor cells and in tumor-
related processes, such as angiogenesis and ulceration has been known for some time. 
This chapter reviews the involvement of one proteolytic system - the plasminogen 
activation system - in tumor progression. In recent years, many biochemical properties 
of the various components of the plasminogen activation system have become known. 
These properties and the functional relationship between the components are discussed 
in the first section. Since the interfering with proteolysis by tumor cells and by newly 
formed endothelial cells can be an objective for future therapy, experimental tumor 
models have been used to study the effects of inhibitors of plasminogen activation. The 
second section deals with this issue. Finally, the presence of the various components of 
the plasminogen activation system in human tumors is reviewed. Following the 
availability of specific ELISAs, antibodies and probes, the content and the cellular 
distribution of the components of the plasminogen activation system has recently been 
mapped for various human tumors. 
1. Basic properties of the components of the plasminogen activation system 
The plasminogen activation system consists of two plasminogen activators, tissue-type 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-ΡΑ) which 
convert plasminogen into the active zymogen plasmin. u-ΡΑ can bind to a specific 
receptor, u-PAR. Several plasminogen activator inhibitors have been described, of which 
two (PAI-1 and PAI-2) will be reviewed here. The basic properties will be mentioned 
briefly, the inter-relationship between the components u-ΡΑ, u-PAR and PAI is outlined 
in section le, the involvement of these components in experimental models for tumor 
invasion and metastasis and their presence in human tumors are considered in sections 2 
and 3. 
la. Plasminogen activators t-PA and u-PA 
t-PA and u-ΡΑ are produced as single serine proteases and can be converted into two-
chain proteases upon cleavage by plasmin. The two-chain forms of plasminogen activators 
are held together by a disulfide bridge. Both single-chain and two-chain t-PA are 
enzymatically active. Single chain u-ΡΑ (pro-u-PA) however, is inactive and can be 
converted into active two-chain u-ΡΑ upon binding to the cell surface receptor u-PAR. 
Structural charactensties for both t-PA and u-ΡΑ are a) similarities in the serine protease 
domain and b) the presence of kringle domains (t-PA has two, u-ΡΑ has one). (Pro-)u-PA 
contains a growth factor domain, necessary for binding to u-PAR (see 198, 214). 
Apart from structural differences, t-PA and u-ΡΑ differ in their presumed (patho-) 
physiological functions. t-PA plays mainly a role in fibrinolysis: t-PA specifically binds to 
fibrin. t-PA is also the plasminogen activator of the adult brain (193) and is thought to 
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play a role in plasticity and long term memory (171). Also, t-PA is expressed by oocytes 
(190) whereas u-ΡΑ is expressed by spermatocytes (81). u-ΡΑ but also t-PA are involved 
in wound healing (65, 176). Compared to t-PA, u-ΡΑ is thought to play a more dominant 
role in tissue remodeling processes such as spermatogenesis (81), trophoblast invasion 
(190), wound healing (65), monocyte invasion (94) and angiogenesis (5, 156), often in 
concert with u-PAR (158, 180) and PAI (5, 157). u-ΡΑ is the predominant plasminogen 
activator involved in tumor invasive processes and metastasis (see sections 2 and 3). 
lb. Urokinase receptor u-PAR 
Pro-u-PA can bind to cells via u-PAR, the cell surface receptor for u-PA (11, 220). 
u-PAR consists of three domains and is linked to the membrane via a glycosyl-
phosphatidylinositol anchor. The role of u-PAR in plasminogen activation at the cell 
surface is exphcited in section le. 
le. Plasminogen activator inhibitors PAI-1 and PAI-2 
The two plasminogen activator inhibitors focused on in this chapter, PAI-1 and PAI-2, 
belong to the group of serpins: serine protease inhibitory. Other PAIs are PAI-3 and 
protease-nexin. Both PAI-1 and PAI-2 are capable of inhibiting t-PA and u-ΡΑ (reviewed 
in 106, 200) but do not bind to pro-u-PA (1). 
PAI-1 is found in high concentrations in blood, where it plays a role in fibrinolysis. 
Uncomplexed PAI-1 becomes rapidly latent due to its instability (131). PAI-1 is secreted 
and sticks extracellularly to vitronectin (68, 104). PAI-2 is found in placental tissue (52, 
77) and in blood of pregnant women (4). Unlike PAI-1, PAI-2 is not secreted into the 
extracellular matrix and is localized mainly in the cytoplasm (8). 
Id. Plasminogen 
Plasminogen is the substrate for plasminogen activators. Cleavage of plasminogen by 
plasminogen activators forms the active enzyme plasmin. Plasminogen binds to various 
proteins of the extracellular matrix, like fibronectin (188), laminin (187), type IV collagen 
(203) and tetranectin (32, see also section If 1) Plasmin is capable of degrading a broad 
spectrum of matrix molecules. Furthermore, plasmin can convert inactive pro-
collagenases into the active form Plasmin/plasminogen binds to the cell surface of MCF7 
cells (36, 239), but a receptor for plasmin has not been cloned. It has been reported that 
binding of plasminogen to cell surfaces occurs in the proximity of binding sites for t-PA 
(53) or u-PA (239). 
Little is known about the presence of plasmin/plasminogen in cancerous tissues. In colon 
carcinomas, it is reported to be present in stromal cells (21, 227) Specific inhibitors of 
plasmin activity, a2-macroglobulin (120) and a2-antiplasmin (21) are found both in 
(normal) plasma and in tumor tissues. Recently, it was described that a plasminogen 
fragment containing the knngle 1-3 domains, named angiostatin, is capable of inhibiting 
11 
tumor angiogenesis (146). 
le. Urokinase-mediaíed plasminogen activation at the cell surface 
u-PA activity can be focalized on the cell surface by binding to u-PAR (11, 205). 
Moreover, u-ΡΑ activity can be modulated by interaction of u-ΡΑ with its receptor: 
binding to the receptor accelerates the conversion of pro-u-PA to active u-ΡΑ on the cell 
surface (48, 175) possibly by close interaction with the receptor bound plasmin (124, 
204). Binding of pro-u-PA to u-PAR is facilitated when u-PAR is glycosyl-
phosphatidylinositol-anchored (129) and when the ligand binding site of u-PAR is 
glycosylated (130). Upon binding to u-PAR, pro-u-PA is converted into active u-ΡΑ after 
cleavage by plasmin or cathepsins (95). The active enzyme complex, in close proximity 
of plasmin/plasminogen (239) can convert plasminogen to plasmin, a broad substrate 
protease, capable of degrading various components of the extracellular matrix. u-PA 
bound to u-PAR is essential for migration of monocytes (94) and tumor cells (17, 201). In 
migrating cells, u-PAR is concentrated at the ruffled edge of cells (6) and in caveoli 
(202). Caveoli, which are in the proximity of focal adhesion sites, are essential for u-PA 
mediated proteolysis at the cell surface, since drugs disturbing the specific caveolar 
structures abolish plasminogen activation (202). u-PA (161) and u-PAR (135) are both 
expressed at focal cell-cell or cell-substate adhesion sites. This concentration of proteases 
at focal adhesion sites, suggests that a delicate balance exists between adhesion and 
proteolysis (see also 101). Indeed, adhesion molecules are found to co-localize with u-PA 
and u-PAR: both u-PA and u-PAR co-localize with avß3 in cultured glioblastomas (61), 
and u-PAR co-localizes with avß3 in metastatic melanoma cells (141). Furthermore, u-
PAR is found in the same membrane fragments as ß2-integnns (13). In cultured 
keratinocytes, u-PA co-localizes with another adhesion molecule, E-cadherin (91). The 
delicate balance between adhesion and local proteolysis can be shifted towards u-PA 
production and invasion when adhesion is hampered, for instance by an antibody capable 
of blocking ligand binding of the adhesion molecule (58). In light of the delicate balance 
between adhesion and local proteolysis, it is very interesting that u-PAR can perform both 
functions. u-PAR not only focalizes proteolysis at the cell surface by binding pro-u-PA, 
but unoccupied u-PAR can also function as an adhesion molecule for vitronectin (222, 
226). Furthermore, binding of u-PA to u-PAR can start a signal transduction pathway, 
since cytokeratin 8 is phosphorylated upon binding, resulting in phosphorylation and 
redistribution of cytokeratin filaments in human epithelial cells (22). Protein tyrosine 
kinases are localized in the same membrane receptor complex as u-PAR (13). 
Active u-PA bound to u-PAR can be inactivated by PAI. The u-PAR:u-PA:PAI complex, 
especially the u-PA:PAI part (143), is recognized by low density lipoprotein receptor-
related protein (LRP, see also section lf2). The complex of u-PAR:u-PA:PAI:LRPcan be 
internalized via a clathrin coated pit mechanism. u-PA and PAI are degraded in lysosomes 
and LRP and u-PAR are redistributed to the plasma membrane (39, 50, 76). 
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Figure 1 shows the sequential events, proposed to take place at the cell surface 
Figure 1. Model for plasminogen activation at the cell surface. 
The sequential events at the cell surface are depicted from left to right Pro-u-PA binds 
to free u-PAR, is activated through cleaveage by plasmin or cathepsim (not shown in this 
diagram). The activated u-ΡΑ can convert plasminogen to plasmin and can be inhibited by 
PAL The u-PARu-PA PAI-complex is efficiently bound and internalized by LRP. Upon 
internalization, u-ΡΑ and PAI are degraded and u-PAR is recycled to the cell surface (nor 
shown). See text for details 
If. Proteins related to the plasminogen activation process 
Proteins recently described to be related to the plasminogen activation system are the 
plasminogen binding protein tetranectin and members of the LDL receptor family, 
enabling internalization of (inactivated complexes of) plasminogen activators 
Ifl. Tetranectin 
Tetranectin is a 68 kD protein that was purified from plasma and binds to the kringle 4 
domain of plasminogen (32) Plasma of cancer patients contains significantly lower levels 
of tetranectin compared to age and sex matched control groups (78, 89, 139) Tetranectin 
is present in a variety of cells, including monocytes (140), neutrophils (14) and fibroblasts 
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(33). In breast (31), ovarian (78) and colon (221, 227) tumors, tetranectin is present in 
the stroma surrounding the tumor. Moreover, plasma tetranectin content and stromal 
immunoreactivity are of prognostic relevance in patients with о агіал cancer (78). 
1/2. LRP and RAP 
Two proteins involved in the clearence and cellular uptake of inactivated proteases are the 
low density lipoprotein receptor-related protein (LRP)/a2-macroglobulin receptor(a2MR) 
and its receptor-associated protein (RAP). 
LRP is a member of the LDL receptor family (105, 207). LRP/a2MR is named after its 
homology with the low density lipoprotein receptor (74) and after its capability to bind 
the activated forms of a2-macroglobulin (3). The gene encoding the enormous protein 
comprizes 89 exons (219), revealing a 15 kb mRNA transcript, from which a 600 kD 
precursor protein is translated which is cleaved into a 515 kD α-chain and an 85 kD ß-
chain. In addition to activated complexes of a2-macroglobulin, many other ligands can be 
internalized upon binding to LRP, including ApoE and various proteins or complexes of 
proteins of the plasminogen activation system (reviewed in 2). t-PA can bind to LRP (18) 
and complexes of t-PA with PAI-1 can be internalized mediated by LRP (147). LRP-
mediated internalization of complexes of u-ΡΑ with inhibitors occurs most efficiently 
when u-ΡΑ is bound to its receptor (34, 76, 143). Gp330 (= gp600), another member of 
the LDL receptor family, is also capable of internalizing similar ligands as LRP, 
including plasminogen activators (229). 
RAP is a 39 kDa protein which co-purifies with LRP and other members of the LDL 
receptor family (206) and co-localizes with LRP (20). RAP is restricted to the 
endoplasmatic reticulum and serves as a chaperone for LRP (20, 230). RAP can bind to 
LRP and thereby prevent binding of all other known ligands, including (complexes of) 
plasminogen activators (75, 84, 142, 224). 
Little is known about LRP and RAP expression in human tumor cell lines or in human 
tumors. In human tumor cell lines, it seems that LRP expression decreases with agressi-
veness because a) tumor cells make no or less receptor for a2-macroglobulin when 
compared to non-tumor cell lines (90, 185-187, 218), b) monocytes grown without the 
tumor promotor PMA start making LRP (35), c) LRP is present in photodynamic therapy 
sensitive tumor cells and not in therapy resistant cells (116) and d) invasive cells make 
less LRP than non-invasive cells (92). In human tumors, LRP was detected in blood 
samples of monocyte-derived malignant blood cells and not in other hematologic tumor 
cells (126), it is present in glioma cells (115), and is decreased or absent in malignant 
lymphomas (127) and in hepatocellular carcinomas (62). 
2. Plasminogen activation in experimental models /or tumor invasion and metastasis 
The process of metastasis is a complex multistep process involving detachment of tumor 
cells from the primary tumor, invasion of surrounding host tissue, invasion through basal 
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membranes, intravasalem into the circulatory system, adherance to endothelium or 
subendothelial basement membrane, extravasation at a distant site and outgrowth of a 
secondary tumor (54) A role of proteases has been postulated in various steps of this 
process (40, 113, 123, 162, 217) First, invading tumor cells need proteases to degrade 
the surrounding tissue and extracellular matrix, and second, proteases are required for 
intravasation and extravasation 
Various in vitro and in vivo model systems have been developed which can be employed 
to study and manipulate various aspects of the complex process of metastatic spread 
Matnx degradation assays can be used to study the activity of proteases (174, 175) 
Invasion assays, either employing reconstituted matnx (152) or chicken membranes (149, 
151) or human placenta membranes (122) or chick heart (117) can be used to study true 
invasion of tumor cells Finally, immunodeficient mice can be used to study experimental 
metastasis by injecting tumor cells in the tail vein (96, 97, 148, 174), or to study 
spotaneous metastasis from a tumor grown upon injecting tumor cells subcutaneously (96, 
97, 174) 
Figure 1 illustrates that if the plasminogen activation system is indeed crucial in invasive 
processes and in metastatic spread of tumor cells, effects of interference at two places in 
this process could prove this By preventing pro-u-PA to bind to u-PAR, no cell surface 
plasminogen activation can occur (Figure 2a) Also, anti-catalytical substances such as 
anti-u-PA antibodies, exogenously added PAI and chemical substances binding to the 
catalytical domain of u-ΡΑ can prevent plasminogen activation (Figure 2b) 
Disturbance of pro-u-PA binding can be achieved by molecules which can compete for the 
pro-u-PA binding site of u-PAR (Figure 2a) Blocking the pro-u-PA binding site with an 
anti-u-PAR antibody demonstrated that cell surface plasminogen activation can be 
abolished (181) Glioblastoma cells thus treated are less invasive in matngel (128) Also, 
cells of which u-PAR is saturated with the amino terminal fragment (ATF) of u-ΡΑ (not 
containing the catalytic site) are less invasive in matngel (96) Synthetic peptides 
compnsing the binding domain of u-ΡΑ are able to inhibit spontaneous metastasis 
formation in a nude mouse metastasis model (97) A most dramatic reduction of 
metastasis formation from a tumor by preventing pro-u-PA to bind to its receptor has 
been shown by Crowley and co-workers (38) By transfecting u-ΡΑ and u-PAR producing 
tumor cells with ATF, an enormous reduction of metastasis formation could be achieved 
Smaller chemical substances can prevent pro-u-PA binding Low doses of suramin, for 
instance, prevent cell surface binding of u-PA (7) Also, by applying the bactenophage 
display technique, small 15-mer peptides could be identified as u PAR antagonists (63) 
Apart from blocking the cell surface u-PAR, pro u-ΡΑ binding can be competed with a 
soluble form of u-PAR, thereby preventing pro-u-PA to bind to its cell surface receptor 
Addition of the soluble form of u-PAR to u-ΡΑ and u-PAR positive tumor cells can 
indeed inhibit invasion (228) In summary, invasive properties of tumor cells can be 
reduced by interference with u-ΡΑ u-PAR binding This interference may lead to new 
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Figure 2. Prevention of u-ΡΑ mediated plasminogen activation. 
Invasive properties of tumor cells can be reduced by intervention of the plasminogen 
activation system. Ibis can be achieved by either of two ways a) Preventing pro-u-PA to 
bind to u-PAR. Ibis can be achieved either by blocking the receptor with antibodies or 
with (truncated) molecules which block the u-ΡΑ binding site of u-PAR, or by competing 
with soluble forms of u-PAR. b) Blocking the active site of u-ΡΑ. Active u-ΡΑ can be 
inhibited by anti-catalytic antibodies, by endogenous or exogenously added PAI, or by 
chemical substances which block the catalytic domain See text for detail 
therapeutic approaches in the near future (reviewed in 51) u-ΡΑ conjugated to a cytotoxic 
agent can be used to specifically destroy u-PAR positive cells (29) 
The first evidence however, that the plasminogen activation system is involved in tumor 
invasive and metastatic processes, arose from experiments designed to block the active u-
PA (Figure 2b). Antibodies blocking the catalytic site of u-ΡΑ do not block tumor 
growth, but can inhibit metastasis formation (71, 79, 148). Also, invasive properties of 
tumor cells can be reduced when they are pretreated with anti-catalytic antibodies against 
u-PA (122, 149) Matrix degradation of u-ΡΑ positive tumor cells is reduced when tumor 
cells are pretreated with anti u-ΡΑ antibodies (174, 178) In addition to anti-catalytic 
antibodies, the catalytic domain of u-ΡΑ can be blocked with PAI-1 or PAI-2 PAI-1 or 
PAI-2 added to cultures of u-ΡΑ and u-PAR positive cells, effectively inhibits matrix 
dagradation (178). Furthermore, HT1080 fibrosarcoma cells producing a surplus of PAI-2 
are less invasive (112) and melanoma cells transfected with PAI-2 give nse to 
significantly less metastases in nude mice (132) Smaller organic chemical substances like 
benzo(b)thiophene-2-carboxamidines (218) and low doses of suramin (49, 209) can 
specifically inhibit u-ΡΑ activity 
Inhibition of invasion and metastasis formation can also be obtained by reducing the 
amount of u-PAR available at the cell surface Tumor cells transfected with antisense u-
PAR are less tumongenic and less invasive (103, 172) B16 melanoma cells transfected 
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with the antisense construct of u-ΡΑ make fewer metastases (238) 
Inversely to experiments inhibiting or preventing invasiveness by intervention with u-PAR 
or u-ΡΑ, actively invading and metastasizing cells can be obtained by overexpressing u-
PAR (93) or by overexpressing u PA (238) In general, cell lines expressing high levels 
of u-ΡΑ are more invasive than cell lines expressing low levels of u-PA (16, 73). 
All the above described experiments suggest a role for the plasminogen activation system 
in tumor invasion and metastasis formation The simultaneous presence of not only u-PA 
and u-PAR but also of PAI in highly metastatic melanoma cells (174), the required 
presence of u-PA, u-PAR and PAI-1 in highly invasive lung cancer cells (114) and 
elevated levels of u-PA, u-PAR and PAI - simultaneously present in the same lesion (47, 
177) in human tumors suggests that a subtle balance of receptor, protease and inhibitor 
is required for effective invasiveness of tumor cells 
3. The plasminogen activation system in human tumors 
Proof that the plasminogen activation system plays a role in tumor invasion and metastasis 
not only stems from experimental evidence, but also from evidence found in human 
tumors Elevated levels of u-PA, u-PAR and PAI-1 compared to normal tissues are 
consistently found in tumors of different origin (e g 23, 42, 61, 196) Elevated levels of 
t-PA (42, 107, 119) and PAI-2 (196) are found in some tumors, but an inverse 
relationship (lower levels in tumor tissue compared to the normal tissue) often exists for 
t-PA (196, 235, 236) and PAI-2 (15, 208) Techniques with which the presence of the 
components of the plasminogen activation system have been studied in human tumors are 
ELISAs, immunohistochemistry and RNA in situ hybridization with reagents specific for 
the various components With zymographic techniques, enzyme activity of t-PA and u-PA 
can be studied either in frozen tissue sections or upon electrophoretic separation of the 
enzymes 
3a. ELISA determinations 
When larger tumor lesions are available, ELISAs specific for the various components can 
be performed on tissue extracts of these tumors The level of u-PA, but also of PAI-1 and 
u-PAR has been shown to be of prognostic relevance For breast cancer, for instance, the 
level of u-PA and PAI-1 surpasses prognostic parameters for relapse of the disease used 
sofar, including lymph node involvement and estrogen receptor status (44, 45, 55, 67, 85, 
88) High levels of both u-PA and PAI 1 are also associated with poor survival in patients 
with colorectal cancer (59), gastric cancer (138), uterine cervical cancer (98), and lung 
cancer (153, 154) Upon the first description of the prognostic relevance of u- PAR by 
Ganesh and co-workers (60) in colorectal cancer, high u-PAR levels were also found to 
be associated with poor survival in patients with breast cancer (47, 183) and squamous 
and large cell lung cancer (154) 
Apart from measuring in tumor homogenates, elevated levels of components of the 
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plasminogen activation system were reported for body fluids such as tumor ascites and 
plasma of patients Huber et al detected elevated levels of u-ΡΑ in plasma of patients 
with colorectal cancer (83) and in patients with primary liver cancer (82) and found that 
the u-ΡΑ value in combination with tumor marker measurement, contributed to the 
sensitivity of the diagnosis High levels of a soluble form of u-PAR (155), u-ΡΑ, PAI-1 
(30) and of PAI-2 (30, 111) have been detected in ascites of patients with ovarian cancer 
3b. Immunohistochemistry and mRNA in situ hybridization 
The cellular distribution of the mRNAs and the proteins can be studied with mRNA in situ 
hybridization (e.g. 42, 61, 165, 166, 191) and with immunohistochemistry (eg. 66, 125) 
respectively. From recent literature, it is evident that the components of the plasminogen 
activation system are localized in tumor cells and in various tumor-associated cell types, 
probably depending on the tumor studied For instance, u-ΡΑ mRNA and protein is 
reported to be present in tumor surrounding fibroblasts in colon cancer (66, 165) whereas 
u-ΡΑ is localized in tumor cells in squamous cell carcinoma (125, 191) The presence of 
serine proteases in tumor stroma is a phenomenon also reported for other proteases 
Metalloproteases for instance, primarily localize in the stroma of tumors (134, 145, 167, 
231) The system may function in an autocrine way, e g saturation of u-PAR by tumor 
cells (205). Also paracrine interactions between u-ΡΑ producing stroma cells and u-PAR 
positive tumor cells can occur (reviewed in 12) Indeed, it has been shown in in vitro 
experiments that matrix degradation (175) and invasion (150) is facilitated when u-PA 
positive cells are mixed with u-PAR positive cells Similar cooperative interactions could 
occur in colon cancer, where u-PAR positive tumor cells bordering u-ΡΑ positive stroma 
cells could pick up u-ΡΑ from these stroma cells (165) Paracrine interactions between 
tumor cells and fibroblasts are in agreement with many reports suggesting that fibroblasts 
facilitate invasion (184) and metastasis formation (159, 212) Furthermore, it has been 
reported that fibroblasts in tumor cell-fibroblast co-cultures are capable of inducing the 
production of u-ΡΑ and metalloproteinases (37, 112) 
Reports on the localization of the various components in any particular tumor are not 
unanimous. For instance, u-ΡΑ protein has been found in some reports in colon cancer 
exclusively in fibroblastic cells (66, 211) but also mainly in tumor cells (133, 195) 
Likewise, u-ΡΑ localization has been reported in tumor cells (85, 88) but also exclusively 
in fibroblastic cells (231) in mammary carcinoma 
3c. (In situ) zymography 
Plasminogen activator activity can be detected either in a frozen section (in situ 
zymography) (42, 191, 192) or upon electroforetic separation of the zymogens, allowing 
visualization of enzymatic activity of plasminogen activators complexed with PAI (196, 
199) t-PA and u-ΡΑ can be distinquished through adding anti-catalytic anti-t-PA or 
u-ΡΑ antibodies, or by adding specific synthetic inhibitors against t-PA or u-PA 
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4.1. t-PA in human tumors 
When comparing the two types of plasminogen activators with respect to their putative role 
in human tumors, u-ΡΑ seems to be the most important plasminogen activator, since levels 
of t-PA are often either undetectable (125) or similar (208) or lower (23, 59, 136, 164, 
196, 199) in tumor tissue compared to corresponding normal or benign precursor tissue. 
Also primary cultures of tumors (118) and tumor cell lines (173) produce predominantly u-
PA In contrast to t-PA, u-ΡΑ is consistently increased in every tumor Nevertheless, t-PA 
levels in tumor homogenates can be of particular prognostic interest Yamashita et al. found 
that breast cancer patients with a disease-free survival had significantly lower levels of t-PA 
in the tumor as compared to patients which developed metastases (236). Also in colon 
cancer a low level of t-PA but now in the normal mucosa is associated with poor prognosis 
(59) 
With regard to decreased t-PA expression in human tumors, melanoma is an interesting 
exception. Firstly, t-PA can be isolated from cultured melanoma cells (179) In vitro, 
melanomas make more t-PA (173, 174), enabling these cells to degrade extracellular matrix 
(174) and to migrate through reconstituted matrix (121) Secondly, malignant melanomas 
but not benign nevi express t-PA (42) High levels of t-PA have also been reported in 
carcinoma of the cervix by Larsson et al (109) t-PA has been found in endothelial cells in 
benign precursor and in tumor lesions (23, 99), consistent with a role for t-PA in 
fibrinolysis 
4 2 u-ΡΑ in human tumors 
Of the various proteins of the plasminogen activation system, the presence of u-ΡΑ in 
human malignancies has been most extensively studied (reviewed in 46) u-ΡΑ levels of 
tumor homogenates have been found of prognostic significance for various types of tumors 
The presence of u-ΡΑ in colon cancer has been well documented Controversy exists on 
where the protein is localized It has been claimed that u-ΡΑ is localized in tumor cells (99, 
100, 133, 195). Others found u-ΡΑ mRNA (165) and protein exclusively (66) or mainly 
(211) in the tumor stroma Significant for the localization of u-ΡΑ and for its possible 
implications for metastatic spread, is the finding by Tan (211) that invasive parts of a tumor 
are u-ΡΑ positive, whereas pushing edges hardly displayed u-ΡΑ positivity On paraffin 
sections, Mulcahy et al (133) found that tumor cell-associated u-ΡΑ and not stromal cell 
associated u-ΡΑ is of prognostic relevance Also for the u-PA/t-PA ratio a prognostic 
significance has been reported in colon carcinomas (59) In addition, patients with colon 
carcinomas exhibit higher levels of u PA in plasma (83) 
In breast cancer, the level of u-ΡΑ measured in tumor extracts is a prognostic indicator for 
relapse of the disease (15, 45, 55, 85-87, reviewed in 194) Janicke et al could correlate 
intensity of u-ΡΑ tumor cell staining to ELISA values measures in parallel samples (85) 
Others also found u-ΡΑ in mammary carcinomas localized in tumor cells (28, 88), but a 
fibroblast localization has also been described (231) 
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In brain tumors, u-ΡΑ is detectable in high grade astrocytomas and gliomas (23, 61, 108, 
233). u-ΡΑ mRNA (61, 233) and protein (23, 233) localize in tumor cells and in the 
frustrated vasculature, characteristic for these lesions. 
Carcinomas of the oesophagus and the stomach consistently exhibit higher u-ΡΑ levels 
compared to the normal surrounding tissue (137, 197), irrespective of the localization of the 
tumor (197). Futhermore, in gastric carcinomas, u-ΡΑ staining of tissue sections (72) and 
u-ΡΑ values of tumor homogenates (138) yield prognosticaily useful information. 
In bladder cancer higher levels levels of u-ΡΑ is correlated with recurrent disease (69, 70). 
u-ΡΑ is detectable in tumor cells of various forms of lung cancer (64, 144). Levels of u-PA 
are significantly higher in these tumors compared to normal lung tissue (136) and are of 
prognostic importance (153-154). 
In skin cancers, u-ΡΑ is not expressed in the relatively benign basal cell carcinomas, but it 
is expressed in squamous cell carcinomas (125, 191). 
Stromal u-ΡΑ staining has also been reported in cervical cancer of the uterus (98, 109). In 
Patients with lymph node involvement exhibited more prominent u-ΡΑ staining and higher 
antigen values in the primary tumor compared to tumors of patients without lymph node 
involvement (98). 
Abundant u-ΡΑ activity is found in mononuclear cells of leukemia patients. These high 
levels of u-ΡΑ could contribute to bleeding disorders, often found in patients with leukemia 
(214). 
4.3. u-PAR in human tumors 
The role of u-PAR in tumor development has recently been described by Dane et al. (41). 
Specific ELISAs for u-PAR have only recently been developed and used to study the levels 
of u-PAR antigen in human tumor tissues (60, 182). Initial studies report that high u-PAR 
levels are associated with poor survival in colon cancer (60), in squamous cell and large 
cell lung cancer (155), and breast cancer (47). 
Limited visualization of u-PAR in immunohistochemistry by antibodies can be due to 
masking of epitopes, due to u-ΡΑ bound to u-PAR (thereby preventing binding of the 
antibody to u-PAR). u-ΡΑ can be released from its receptor by mild acid treatment of the 
tissue section. A much brighter u-PAR staining can thus be obtained (28, 43). Free u-PAR 
can further be visualized with autoradiography after incubation with radioactive u-PA (43, 
223). 
The distribution of u-PAR mRNA and protein has been studied most extensively in tumors 
of the mammary gland (10, 28, 43, 88, 168). u-PAR mRNA is produced mainly by tumor-
associated macrophages (168), but it has also been reported that the protein is 
predominantly present in tumor cells (10, 28, 43, 88) in addition to tumor-associated 
macrophages (10). In colon cancer, u-PAR mRNA and protein is present in macrophages 
and tumor cells (165, 170), possibly basally expressed by tumor cells towards the stroma 
(223). In astrocytomas, u-PAR mRNA is expressed by proliferating vessels and by tumor 
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cells in the vicinity (234) Also in gliomas, u-PAR is expressed by tumor cells (61) It has 
been reported for ovarian cancer however, that u-PAR is already present in the normal 
epithelium (237). Surprizing, and not consistent with a general rule that levels of u-PAR 
are elevated in cancer, is the absence or the reduced presence of u-PAR in various 
hematological malignancies like B- and T-cell malignancies and in Hodgkin's disease (160). 
4.4. PAI-1 in human tumors 
It has been postulated that high levels of PAI in cancer tissue might be beneficial for the 
patient, since surplus PAI might inactivate all plasminogen activators present Apart from a 
rare report of decreased PAI-1 in more aggressive tumors compared to the milder forms 
(64), PAI-1 levels are consistently increased in tumors of diverse origin. High levels of 
PAI-1 are associated with worse prognosis in patients with breast cancer (67, 87) gastric 
cancer (72), various forms of lung cancer (153) and in cervical cancer (98) Furthermore, 
higher levels of PAI-1 in cancer tissue compared to benign or normal tissue is encountered 
in colorectal tumors (59, 199) and in brain tumors (108) PAI-1 mRNA has been localized 
in endothelial cells (165) in the tumor surrounding stroma but also in tumor cells (213) of 
colorectal cancer, both in endothelial cells and tumor cells of brain tumors (23, 102, 232) 
and in tumor cells in mammary carcinoma (10, 88, 177) PAI-1 staining of the extracellular 
matrix was observed in breast cancer (10) 
4.5. PAI-2 in human tumors 
At least in some tumors, the presence of PAI-2 is correlated with better survival Higher 
levels of PAI-2 are associated with good prognosis in breast cancer (15, 56, 208) Similar 
tendencies exist for gastric cancer (137), squamous cell carcinoma (64, 136), pancreatic 
cancer (210) and in homogenates of ovarian cancer (164), although high levels of PAI-2 
have been found in the cystic fluid and in peritoneal fluid of ovarian cancer patients (24, 
25, 30) 
In some tumors however, elevated levels of PAI-2 are associated with progression of the 
disease Increased PAI-2 is seen in colon cancer compared to colon adenomas and normal 
mucosa (196) and is associated with poor survival in these patients (59) Incidentally, PAI-2 
maps to a chromosomal region which is deleted in 70 % of colon cancer cases (225) 
Gliomas exhibit increased levels of u PA and PAI-1, but hardly any PAI-2 is found in 
gliomal extracts (108) PAI-2 is localized in adenocarcinoma cells or in tumor cells in all 
malignancies studied with immunohistochemistry 
4. Concluding remarks 
The last five years, the presence and localization of components of the plasminogen 
activation system has well been documented for a large group of tumors In order to clarify 
a putative mechanism of plasminogen activation in tumors, consensus is needed on the exact 
localization of the proteins Therefore, the controversies regarding the localization of the 
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various components have to be cleared. Since the staining encountered in tissue sections can 
be prognosticaily relevanct, it is important that the applied staining procedures are 
reproducible. Futhermore complementary techniques should be used to confirm the results. 
Additional studies on the functional state of the components of the plasminogen activation 
system would be of interest. Antibodies which discriminate between inactive free pro-u-PA, 
active u-ΡΑ bound to its receptor, u-ΡΑ inactivated by PAI, etc. might elucidate the true 
mechanism of plasminogen activation, as revealed in the tissue section, can be unmasked. 
Whether modulation of the plasminogen activation system can indeed be applied in human 
tumor therapy, remains to be seen. Knock-out mice lacking both t-PA and u-ΡΑ and knock­
out mice lacking PAI-1 are viable, healthy and are capable of sexual reproduction (26, 27). 
Apparently, back-up mechanisms exist for physiological processes like wound healing, 
fibrinolysis, and embryo-implantation. In analogy, one can envisage that tumors where 
plasminogen activation is blocked, can still invade and metastasize by using other proteases. 
However, the knock-out experiments also teach us that depletion of plasminogen activation 
can be obtained without causing serious side effects for the patient. In future, knowlegde of 
the plasminogen activation status of a tumor can also be used in choosing the more effective 
therapy (55, 57). In this respect, it is well worth persueing treatment objectives based on 
knowledge of the plasminogen activation system. 
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Abstract 
A large body of evidence suggests a role for the proteolytic plasminogen activation 
system in invasion and metastatic spread of tumor cells including melanoma cells. 
Plasminogen activation by human melanoma cell lines and mouse melanoma cell lines 
has been extensively studied. Apart from expression of urokinase-type plasminogen 
activator (u-ΡΑ), melanoma cells differ from cells derived from other types of tumors in 
the abundant expression of tissue-type plasminogen activator (t-PA). The possible role 
of both types of plasminogen activators in metastatic spread of melanoma cells is 
discussed. 
1. Introduction 
Cutaneous melanoma is one of the most aggressive human tumors Patients presenting 
with a primary tumor with a thickness as small as 1 5 mm already have a significantly 
reduced probability of survival (20,21,47) Worrying is the still increasing incidence of 
melanoma. In the USA, it is estimated that by the year 2000, one out of 90 Caucasians 
will develop cutaneous melanoma (56) One of the alarming features of cutaneous 
melanoma is its rapidly assessed capability of metastatic spread. Circulating melanoma 
cells have been detected in the blood of melanoma patients at very early stages of the 
disease (5). The mechanism of metastatic spread is thought to be universal for solid 
tumors of diverse ongin (18,34). This mechanism involves detachment of tumor cells 
from the primary tumor, invasion of surrounding tissue, invasion through basement 
membranes, intravasation in the circulatory system, adherance to endothelium or 
subendothehal basement membrane, extravasation at a distant site and outgrowth of a 
secondary tumor. A role for proteases has been postulated in various steps of this process 
(10,37,43). Invading tumor cells need proteases to degrade the surrounding tissue and 
extracellular matrix Furthermore, proteases are required in the degradation of the basal 
membrane, enabling them to intravasate into and to extraversate out of the blood stream 
The role of one proteolytic system - the plasminogen activation system - in tumor 
invasion and metastasis has recently been reviewed (15) In 1979, it was reported that 
extracts of primary melanomas and melanoma metastases contain significantly higher 
levels of plasminogen activator compared to extracts of nevi (19) Since then, various 
groups have studied the presence of plasminogen activators and their putative involvement 
in metastatic spread using various human and mouse melanoma cell lines This review 
focusses on the involvement of the plasminogen activation system in melanoma tumor 
progression. 
2. Melanoma cell-mediated plasminogen activation 
Two functionally and structurally different plasminogen activators, tissue-type 
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plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-ΡΑ) have been 
characterized. u-ΡΑ is secreted as an inactive pro-enzyme and is activated efficiently upon 
binding to its specific receptor, u-PAR (16). It has been described that t-PA sticks to and 
is active at cell surfaces, including melanoma cell surfaces (2,3,17). Although several 
putative receptors for t-PA have been described, a potentiation mechanism comparable to 
that for u-ΡΑ binding does not exist. Figure 1 shows a putative mechanism of 
plasminogen activation at the melanoma cell surface by u-ΡΑ (Figure la) or t-PA (Figure 
lb). Conversion of plasminogen is crucial in this scheme, since plasmin can either 
activate inactive collagenases or directly break down the extracellular matrix. Two 
specific plasminogen activator inhibitors, PAI-1 and PAI-2, have been described. 
Figure 1. A model for cell surface plasminogen activation by melanoma cells. 
Melanoma cells can either use u-ΡΑ bound at the cell surface to u-PAR (a), or secreted 
or cell bound t-PA (b). See text for details. 
3. Melanoma: the t-PA tumor? 
It is generally believed that mainly u-ΡΑ and not t-PA plays a crucial role in metastatic 
spread of tumor cells (10,15). This is supported by the fact that in tumors of diverse 
origin, t-PA levels are often decreased in tumor tissue compared to benign tissue, whereas 
u-ΡΑ levels are consistently increased in various tumors (15). Interestingly, cutaneous 
melanoma is an exception when compared to other tumors, since human melanoma 
lesions (11-13), primary melanoma cultures (70) and cell lines (2,3,25-
27,36,40,55,60,65,66) make considerable amounts of t-PA. Indeed, melanoma cells are 
often the source for large scale purification of t-PA (7,57). Primary cultures of 
melanocytes also produce t-PA (23), but this could be a tissue culture artifact since 
melanocytes in normal skin nor when grouped as nevus produce t-PA. Some human and 
mouse melanoma cells however, are also capable of secreting u-ΡΑ (Table 1). 
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Apparently, this high production of t-PA by tumor cell lines is unique for melanoma and 
neuroblastoma cell lines (65). One could speculate, since melanocytes and melanoma cells 
are neural crest-derived cells, that this feature is typical for neural tissue-derived cells. It 
is noteworthy that recent findings suggest a role for t-PA rather than u-ΡΑ in various 
brain processes, like learning and plasticity (52,58). 
The crux of the matter is whether melanoma cells can utilize the secreted (40) or cell-
bound (3) t-PA for matrix degradation, invasion and ultimately for metastatic spread. 
Melanoma cells can use secreted t-PA to generate cell surface-bound plasmin activity 
(41). Also, Quax et al. showed that, by adding a polyclonal antibody against t-PA in a 
matrix degradation assay, that melanoma cells can use t-PA for degradation of 
extracellular matrix (53). t-PA levels can be induced considerably by matrix fragments, as 
shown by Stack and co-workers, who found a 10-fold increase of t-PA activity in 
conditioned medium of B16F10 cells incubated with laminin A fragments (60). Herlyn et 
al., using WM 164 cells and a metastatic variant 451-LU, showed that the metastatic 
subline contained 3-fold higher t-PA levels (26). Invasion of both cells lines could be 
inhibited significantly by anti t-PA polyclonal antibodies in an invasion assay. Similar 
results were obtained by Meissauer and co-workers. Using a melanoma cell line which 
produces t-PA and no u-ΡΑ, they could inhibit invasion into various extracellular matrices 
with polyclonal antibodies against t-PA (40) and they could inhibit migration through a 
keratinocyte layer (41). Invasion in a Boyden-chamber assay by the metastatic mouse 
melanoma subline M2 can be reduced when t-PA antibodies are added to the upper 
chamber (55). 
In summary, various reports suggest that t-PA can be involved in matrix degradation and 
invasive processes of melanoma cells However, to our knowledge, no experimental 
evidence (using t-PA (anti-)sense transfectants or t-PA inhibitory antibodies) exists on the 
role of t-PA in metastatic spread of melanoma cells derived from primary cutaneous 
melanomas or derived from metastases using a nude mouse model. Although a subtle, 
supporting and possibly slower acting role for t-PA in metastatic spread of melanoma 
cells cannot be ruled out, evidence against a role for t-PA comes from various sources 
Comparing cell surface plasmin generation by u-ΡΑ producing MelJuso cells with cell 
surface plasmin generation by t-PA producing MeWo cells, it was concluded that u-PA 
mediated plasmin generation is a much more efficient process (41). Also, when 
comparing xenografts of non-u-PA producing melanoma cell lines, xenografts of non-
metastatic melanoma cells IF6 and 530 contain approximately 8 times more t-PA than 
xenografts of moderately metastatic M14 and Mel57 cells (53). Others found no inhibitory 
effect by anti-t-PA antibodies on invasion of B16 cells (42) 
In uveal melanoma however, involvement of t-PA in metastatic spread is more likely 
Contrasting cutaneous melanoma lesions, t-PA is the more abundant plasminogen 
activator in uveal melanoma lesions (12,13). Uveal lesions with worse prognosis (12) and 
primary cultures of them (8) produce higher amounts of t-PA Futhermore, it was 
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recently demonstrated that t-PA transfected melanoma cells injected in the eyes of mice, 
give rise to a higher frequency of metastases in these mice (1) The effect could be 
inhibited upon incubation with inhibitory anti-t-PA polyclonal antibodies. 
4. The role of u-PA and u-PAR in migration and metastasis of melanoma cells 
Focal proteolysis at the cell surface by the u-ΡΑ: u-PAR complex can create gaps for 
directed motion of the cell (reviewed in 4) Apart from focalizing proteolysis, the u-PAu-
PAR complex and the two independent proteins can exert various other functions. For 
GUBSB melanoma cells, it has been described that endogenously produced u-ΡΑ can act 
as an (autocrine) mitogen It could be demonstrated that inhibition of u-ΡΑ binding causes 
inhibition of cell proliferation (32) From a similar experiment, using the M24met cell 
line which produces high amounts of u-PA, it was concluded that binding of u-ΡΑ to its 
receptor is essential for migration and invasion Interestingly, the effect of u-ΡΑ on 
migration could be mimicked by adding the amino-terminal fragment (ATF) of u-PA 
lacking the catalytical domain. Thus, it was concluded that u-ΡΑ binding can lead to 
signal transduction in melanoma cells in vitro (61) 
In metastatic spread, adhesion and proteolysis are closely linked An additional, recently 
descnbed function of u-PAR is its capability to act as a receptor for vitronectin (67,69) 
In a recent study, expression of a better known receptor for vitronectin, avß3, was linked 
to expression of u-PAR in metastatic melanoma cell lines Antisense oligonucleotides for 
or, resulted in downregulation of u-PAR expression (49) 
In melanoma cells, at least in M24met cells, u-ΡΑ u-PAR-mediated plasminogen 
activation takes place in flask-like membrane invaginations called caveoh Both u-ΡΑ and 
u-PAR co-localize with caveolin, a protein characteristically localized in these 
invaginations. Furthermore, plasminogen activation can be abolished with drugs which 
interfere with these structures (62) 
Can, and does u-ΡΑ exert a function in metastatic spread of melanoma cells7 Evidence 
for a role for u-ΡΑ rather than t-PA in matrix degradation, invasion and metastatic spread 
of melanoma cells is compelling (Table 1) Various authors have reported that melanoma 
cells can utilize u-ΡΑ for matrix degradation (53,61,63) and invasion (42,61,63,64) With 
respect to matrix degradation and invasion, t-PA and u-ΡΑ can exert similar functions 
However, unlike t-PA, the role of u-ΡΑ in true metastatic spread of melanoma cells in 
nude mice has well been established Metastatic subclones express higher levels of u-PA 
compared to non-metastatic parental melanoma cell lines (49,73) Anti catalytic antibodies 
against u-PA inhibit metastatic spread of B16F10 melanoma cells (24) Sense transfection 
of human u-PA in u-PA negative B16F1 cells results in a more metastatic phenotype and 
antisense transfection of human u-PA in (mouse) u-PA producing B16F10 results in a less 
metastatic phenotype (73) Interestingly, since human u-PA does not bind to mouse u-
PAR, evidence is provided for a role for free/unbound u-PA (not bound to the cell) 
surface in the metastatic process In a panel of human melanoma cell lines, 
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Table 1. Plasminogen activation in human and mouse melanoma cell lines 
a) Human melanoma cell lines. 
Cell lines PA Ref. Findings1 
UCT-Mel 1-5, 7 t-PA 
UCT-Mel 6 u-PA 
24 cell lines t-PA 
CaC174-36,WM46 t-PA 
27 
66 
36 
WM115, WM164 t-PA 
GUBSB u-PA 32 
WM164, 451-LU t-PA 26 
A375, A375P, 
A375P-5, A375M 
530, IF6, 
M14, Mcl57 
BLM, MV3 
MeUuso 
MeWo 
MeUuso 
MeWo 
665/2 clones 
t-PA 
t-PA 
t-PA 
t-PA 
u-PA, 
u-PA 
t-PA 
u-PA 
t-PA 
u-PA 
25 
53 
t-PA 
40 
41 
63 
M3Dau, MIDo, t-PA 
M4Beu, M2Ge, t-PA 
Bowes, HMB-2 t-PA 
UCT-Mel 1 to 5 and 7 produce l-PA, the M-18 antigen and are tumongemc 
UCT-Mel 6 produces u-PA, no M-18 melanoma antigen and is non-tumongenic 
22 melanoma cell lines make only t-PA, 2 melanoma cell lines make u-PA 
t-PA present in all 4 cell lines and in derived xenografts. 
u-PA can act as an autocrine mitogen in melanoma cells 
Metastatic subline 451-LU produces more t-PA than the non-metastatic WM164 
Invasion can be inhibited with anti t-PA antibodies 
All four cell lines - differing in metastatic capacity - make l-PA at comparable 
levels 
Metastatic behavior of melanoma cell lines in mice correlates with u-PA 
Melanoma cells can use both the u-PA and the t-PA mediated pathways for 
plasminogen dependent matrix degradation and invasion 
Plasmin generation on the surface of melanoma cells both by t-PA and u-PA 
Correlation between u-PA levels and invasion. 
Inverse relation u-PA and pigmentation 
Bowes is a high producer of t-PA t-PA binds to the cell surface of melanoma 
cells 
M24met 
M24met 
u-PA 45 
665/2 clones u-PA 64 
u-PA 61 
MeWo.MeWoLN u-PA2 49 
MIM/8,MIM/8LN u-PA2 
Both u-PA mediated and collagcnasc mediated pathways of invasion play 
a role in M24met cells u-PA/plasmin is not required for MMP activation' 
2/60 clone is highly invasive, u-PA producing and lacks melanin 
2/21 clone is non-invasive, low u-PA producing and melanized 
u-PA bound to u-PAR not only fascihtates matrix degradation but also 
migration u-PA has a role in signal transduction 
Metastatic variants make more o ,^, u-PAR and u-PA mRNA Expression 
of u-PAR is linked to expression of av 
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b) Mouse melanoma cell lines. 
Cell lines PA Ref. 
B16B16, B16F10 PA' 22 
B16, B16met 
B16F1, B16F10 
B16F10 
B16B16 
M2 
Cl-10 
PA' 
PA1 
u-PA 
t-PA 
t-PA 
u-PA 
68 
50 
42 
55 
B16F10 
B16F1 
B16F10 
u-PA 
u-PA 
24 
73 
B16F10, B16F1 t-PA 60 
Findings' 
Metastatic B16F10 make less plasminogen activator than the more invasive clone 
B16B16 
Higher levels of plasminogen activator and fibrinolytic activity in metastatic lines 
Inhibitors of plasminogen activators do not inhibit invasion. 
Antibodies against u-PA and not against t-PA inhibit invasion. 
Antibodies against l-PA inhibit invasion Non-melastalic Cl-10 makes u-PA 
Antibodies against u-PA inhibit metastasis, pretrealment of B16F10 cells with 
plasmin increases metastasis 
Transfeclion with human u-PA in B16F1 enhances metastatic capacity, anti-sense 
human u-PA transfeclion in B16F10 decreases metastatic capacity 
Speculation on role of free u-PA (not bound to u-PAR) in metastatic spread 
Metastatic B16F10 cells grown with laminin fragments produce 10-fold more 
t-PA, no effect on u-PA production Non-metastatic B16F1 do not respond to 
laminin fragments 
1
 See text for details 
2
 Traces of u-PA in metastatic, no u-PA in non-melastatic variants 
3
 PA indicates that no discrimination between u-PA and t-PA was or could be made 
Quax and co-workers demonstrated that u-PA expression and expression of PAI correlates 
with metastatic capability in nude mice (53). Dissemination and metastatic spread of the 
highly metastatic M24met cells, which produce high levels of u-PA and no t-PA (45), can 
be inhibited when these cells are transfected with PAI-2 (48). All these data clearly 
exhibit a role for u-PA in metastatic spread of melanoma cells. 
Tumor progression is accompanied with loss of differentiation markers and gain of 
progression markers like u-PA. In this respect, it is interesting that various groups 
reported that u-PA producing melanoma cell lines are unpigmented. In a panel of 7 cell 
lines of which 6 were t-PA producers and one was a u-PA producer, the u-PA producer 
was amelanotic and the only cell line without the melanocytic differention antigen M-18 
(27). In subclones of the same cell line, Supino et al. found an inverse relationship 
between melanin production and u-PA production. Invasiveness was correlated with u-PA 
secretion and inversely correlated with melanin content (63,64). Other known producers 
of u-PA, the M24met (45) BLM and MV3 (53) cell lines are amelanotic. BLM and MV3 
do not express any of the melanocytic markers gp-100, tyrosinase or MART-1 
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(unpublished results) Also in amelanotic mouse melanoma lesions (14), u-ΡΑ enzyme 
activity was present at higher levels than in melanotic melanomas 
5. Plasminogen activation in human melanocytie tumors 
The various stages of cutaneous melanocytie tumor progression comprise common 
naevocellular nevi, dysplastic or atypical nevi, primary melanoma and melanoma 
metastasis. Primary melanoma lesions can be subdivided into thin or early lesions with a 
Breslow thickness smaller than 1 5 mm, and thick or advanced lesions with a Breslow 
thickness greater than 1 5 mm Another distinction often made is horizontally growing 
superficial spreading melanoma versus vertically growing nodular melanoma (6). 
Many years ago, elevated levels of plasminogen activators were found in extracts of 
primary melanomas and metastases compared to extracts of nevi (19). Until recently 
however, although the possible role of the plasminogen activation system in metastatic 
spread of melanoma cell lines had been well established, no extensive study on 
plasminogen activation comprizing all stages of melanocytie tumor progression existed 
The first few studies on plasminogen activation included limited series of lesions 
(36,38,71). In these early studies, the presence of both t-PA and u-ΡΑ in melanoma tissue 
was well recognized (38,71) In a small series, Markus et al could attribute 77% of the 
plasminogen activator activity to u-PA (38) 
6. Other proteases implicated in melanoma invasion and metastasis 
Although this thesis concentrates on the role of the plasminogen activation system in 
melanomas, it is important to recognize that other proteases can also play a role in 
metastatic spread of melanomas This paragraph briefly summarizes their importance with 
regard to melanoma 
One important group of proteases involved in the metastatic process, is the group of 
matrix metalloproteases (MMPs) Their activity can be regulated by tissue inhibitors of 
metalloproteases, TIMP-1 and TIMP-2 Other names are collagenases and gelatinases 
(reviewed in 39) Various groups have characterized different MMPs in melanoma cell 
lines (9,29,33,44,45) Monsky et al have shown that in various melanoma cell lines, 
when the cells are grown on a gelatin matrix, two MMPs, seprase and gelatinase A, are 
localized in membrane structures called invadopodia (44) 
Analogous to the plasminogen activator system using PAI, in the metalloprotease system 
the effect on extracellular protease activity, adhesive properties and metastatic spread has 
been studied using TIMPs B16F10 cells transfected with TIMP-1 have reduced ability for 
invasion (30) and metastasis (31), although the time course for extravasation was not 
altered (35) TIMP-1 further reduces growth of B16F10 melanoma cells (35) MMP-
mediated degradation of extracellular matrix by highly metastatic M24met melanoma cells 
could be reduced with addition of TIMP-2 (45) Like with TIMP-1-transfected B16F10 
cells (35), a similar reduction of growth was seen with these M24met cells when 
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transfected with TIMP-2 (46) However, the metastatic capability was not effected (54) 
As shown recently, TIMP-2 overexpression contributes to improved adhesive properties 
of human melanoma cells to extracellular matrix components (54) 
Although the presence of collagenases in extracts of melanocyte lesions was noted a long 
time ago (72), the localization of the different components of the MMP system have not 
been described in human melanocyte tumor progression 
Another group of proteases involved in tumor progression, are the cathepsms (reviewed in 
59) Recently, two independent groups have described the presence of cathepsms in 
human cutaneous melanocyte lesions (28,51) Both groups describe an increased staining 
for cathepsin D with progression (28,51) and for cathepsms B,H, and L (28), starting in 
dysplastic nevi. 
Scope of the thesis 
This thesis desenbes the presence and localization of the various components of the 
plasminogen activation system and associated components in three types of melanocyte 
tumors, human cutaneous melanoma (chapters 2,3 and 4), a transgenic mouse model for 
cutaneous melanoma (chapter 5) and in human uveal melanoma (chapter 6) The overall 
results are discussed in chapter 7 
Based on previous work, where metastasizing capacity of human melanoma cell lines m 
nude mice correlated with expression of u-ΡΑ and PAI, we addressed the question 
whether a similar correlation exists for cutaneous melanocyte tumor progression In 
chapter 2, the localization of t-PA, u-ΡΑ, u-PAR, PAI-1 and PAI-2 is described in 
cutaneous melanocyte lesions comprizing all stages of cutaneous melanocyte tumor 
progression (common nevi, atypical nevi, early and advanced stages of primary melanoma 
and metastases of cutaneous melanoma) Localization of the various proteins was studied 
with immunohistochemistry, often using more than one antibody per component as a 
confirmation of the results mRNA in situ hybridization and in situ zymography were 
used as complementary techniques 
Upon this characterization, we studied the distribution of proteins closely associated with 
the plasminogen activation system in human cutaneous melanocyte lesions (chapters 3 
and 4) First, the question was addressed where plasminogen (e g the zymogen for 
plasminogen activators) and the plasminogen binding protein tetranectin were localized in 
cutaneous melanocyte tumor progression (chapter 3) 
Very recently, proteins involved in the internalization of (inactivated) plasminogen 
activators were described One of these proteins is the low density lipoprotein receptor 
related protein (LRP) The presence of LRP and its receptor associated protein (RAP) in 
human melanoma cells lines and in cutaneous melanocyte lesions is presented in chapter 
4 
If therapeutic intervention of the plasminogen activation system is a serious objective in 
the treatment of cutaneous melanoma, an animal model for human cutaneous melanoma is 
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required. All ал i mal models based on melanoma cell lines are hampered by the fact that 
cell lines injected into nude mice do not reflect the heterogeneity of a primary tumor. A 
mouse melanoma model with remarkable heterogeneity is the transgenic Tyr-SV40E 
mouse melanoma model. In chapter 5, the question is addressed whether expression of 
plasminogen activators and plasminogen activator inhibitors correlates with the human 
situation. 
Finally, it was investigated whether expression of components of the plasminogen 
activation system correlate with prognosis of patients with uveal melanoma (chapter 6). 
Chapter 7 contains a general discussion, where the overall results of this thesis are 
discussed. 
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Abstract 
Degradation of the extracellular matrix and other tissue barriers by proteases like 
plasminogen activators (PAs) is a prerequisite for neoplastic growth and metastasis. 
Recently, we reported that highly metastatic behavior of human melanoma cells in nude 
mice correlates with urokinase-type PA (u-ΡΑ) expression and activity and with PA 
inhibitor type 1 and 2 (PAI-I, PAI-2) expression. Here, we report on the occurence of 
components of the PA system in the various stages of human melanocytic tumor 
progression in situ. We studied the protein distribution on freshly frozen lesions of 
common nevoceUular nevi (n=25), dysplastic (= atypical) nevi (n=16), early primary 
melanomas (n=8), advanced primary melanomas (n=U) and melanoma metastases 
(n=17). Tissue-type PA (t-PA) was present in endothelial cells in all lesions, whereas in 
metastases it could be detected in tumor cells in a minority of the lesions. u-ΡΑ, its 
receptor u-PAR, PAI-1 and PAI-2 could not be detected in benign and in early 
malignant stages but appeared frequently in advanced primary melanoma and melano­
ma metastasis lesions. 
u-ΡΑ was detected in stromal cells and in tumor cells at the invasive front, u-PAR and 
PAI-2 in tumor cells and PAI-1 in the extracellular matrix surrounding tumor cells. 
Localization of the corresponding mRNAs and enzyme activities revealed a similar 
distribution. We conclude that plasminogen activation is a late event in melanocytic 
tumor progression. 
Introduction 
Migration of tumor cells is an essential step in metastasis. Tumor cells detach from a 
primary tumor, migrate through the surrounding tissue towards the circulation and spread 
through the body. Eventually they will invade a target tissue to form a distant metastasis. 
During several steps of this process proteolytic degradation of the extracellular matrix is 
required. Different proteolytic enzyme systems are involved (30,50), including the matrix 
metalloprotease system (28) and the plasminogen activation system (10,36) 
At least two distinct plasminogen activators are known, tissue-type plasminogen activator 
(t-PA) and urokinase-type plasminogen activator (u-ΡΑ). The activity of u-ΡΑ and t-PA 
can be modulated by two specific inhibitors, PAI-1 and PAI-2 (47) u-ΡΑ activity can be 
focalized on the cell surface by a specific receptor (u-PAR) (4,49) Moreover, the u-PA 
activity can also be modulated by the interaction of u-ΡΑ with its receptor u-PAR, since 
recent experiments have shown that binding to the receptor accelerates the conversion of 
pro-u-PA to active u-ΡΑ on the cell surface (14,40) possibly by close interaction with the 
receptor bound plasminogen (31,48) Furthermore, the receptor ensures the availability of 
active u-ΡΑ on the cell surface by rapid internalization of inactive u-ΡΑ PAI complexes 
(9,15). 
Elevated levels of u-ΡΑ have been reported for a number of human malignancies, 
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including colon (11,23,24), breast (13,17), urinary bladder (21) and prostate cancer (18). 
For the colon we have reported before that the sequential steps in colon tumor progres­
sion, i.e. adenomatous polyp, adenoma with atypia and adenocarcinoma, is reflected by 
discrete stepwise increase of u-PA (11). u-ΡΑ antigen levels as estimated in tissue 
sections and by ELISA might be used as prognostic markers in colon and breast cancer 
(11,13,17,46). The actual involvement of plasminogen activators in tumor cell migration 
or metastasis has been demonstrated in several model systems (1,22,29,34,35). 
Localization studies have been performed in several malignancies using lmmunohistoche-
mistry or RNA in situ hybridization. A rather heterogeneous pattern of distribution was 
found. Surprisingly, u-ΡΑ was not only found in tumor cells (32,43,45), but also in 
stromal cells surrounding the tumor cells (19,38), depending on the malignancy studied. 
u-PAR was found to be tumor cell-associated (38), PAI-1 endothelial cell (37) or tumor 
cell-associated (42,43). 
We recently demonstrated, using a nude mouse model system, that in human melanoma 
cell lines differing in metastatic potential, u-ΡΑ, PAI-1 and PAI-2 could only be found in 
those cell lines which were able to form lung metastases after subcutaneous inoculation in 
nude mice (41). The non-metastatic cell lines did not produce u-ΡΑ, PAI-1 or PAI-2 but 
produced only t-PA. However, little is known about the involvement of the plasminogen 
activation system in fresh human cutaneous melanocyte lesions (26,27). 
In the present study different stages in melanoma tumor progression, common nevocellu-
lar nevi, dysplastic (= atypical) nevi, early and advanced primary melanoma and 
melanoma metastases, were analyzed for the occurrence of the different components of 
the plasminogen activation system. The presence and distribution of protein, mRNA and 
enzymatic activity were studied using immunohistochemistry, RNA in situ hybridization 
and in situ zymography on tissue sections. 
Material and Methods 
ftssue specimens 
Representative tissue samples were freshly received from cutaneous melanocyte lesions 
excised from patients at the University Hospital, Nijmegen, The Netherlands, snap-frozen 
in liquid nitrogen and stored at -70°C until sectioning Based on conventional histopatho­
logic examination on paraffin sections, lesions were divided into 5 classes: common 
nevocellular nevus (n=25), dysplastic (atypical) nevus (n = 16), early primary melanoma 
(Breslow thickness < 1.5 mm) (n = 8), advanced primary melanoma (Breslow thickness 
> 1.5 mm) (n = 11) and distant melanoma metastasis (n=17). Other frozen tissue 
specimen, used for the characterization of the antibodies, were from the archives of the 
Pathology department. 
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Antibodies 
Rabbit anti-human t-PA and u-ΡΑ polyclonal antibodies have been used in earlier work 
(3,41). Monoclonal antibodies against human t-PA (5) were kindly provided by R Bos, 
Gaubius Laboratory IVVO-TNO, Leiden, The Netherlands Monoclonal antibodies against 
human u-PA (0 3689), human u-PAR (# 3936) and human PAI-1 (if 380) (16) were 
purchased from American Diagnostica Inc., Greenwich CT, USA The rabbit and goat 
polyclonal antibodies against human PAI-2 were a generous gift from E Schuler, Behring 
Werke AG, Marburg, Germany A polyclonal antibody against human heparan sulphate 
proteoglycan (51) was kindly provided by L van den Heuvel, Department of Biochemis­
try, Nijmegen University, Nijmegen, The Netherlands 
Characterization of anti-t-PA and anti-PAl-2 antibodies for use in immunohis-
tochemistry 
Monoclonal antibody 5 1 against human t-PA was incubated with Western blot strips 
containing purified human t-PA and a cell lysate of a human melanoma cell line IF6 (41) 
The antibody recognized t-PA and did not cross-react with other proteins of the lysate 
We furthermore characterized the antibody for its use in immunohistochemistry on fresh 
tissue sections of 20 different human organs Blood vessel endothelium stained intensely 
in all tissues studied and the staining pattern compared well with the staining pattern 
obtained with the polyclonal antibody 
Two polyclonal antibodies against human PAI-2 were tested on Western blot strips 
containing recombinant PAI-2 and IF6 cell lysate Both polyclonal antibodies recognized 
PAI-2 and neither of the two cross-reacted with other proteins of the cell lysate In 
immunohistochemistry, the antibodies stained syncytiotrophoblasts in sections of fresh 
postnatal placenta lesions 
Immunohistochemistry 
For immunohistochemistry, 4 μπι cryostat sections were air-dried overnight at room 
temperature and stored at -80°C until use Prior to incubation with the primary antibody, 
sections were fixed for 10 minutes in acetone at -20°C For monoclonal antibodies, a 
three step ABC-method (avidin-biotin-peroxidase-complex) was applied (Vectastain 
ehtekit, Vector laboratories, Burhngame CA, USA) Dilutions of antibodies were in 
phosphate-buffered saline (PBS) pH 7 4 with 1 % BSA and all incubations took place in a 
humidified chamber at room temperature Monoclonal antibodies were applied in a 
concentration of 10 /ig/ml, except for monoclonal antibody 5 1 (50 μg/ml) After incuba­
tion with the monoclonal antibody for 60 minutes, sections were washed three times for 5 
minutes in PBS and biotinylated goat anti-mouse Ig was added for 30 minutes Subse 
quently, the slides were washed again three times for 5 minutes in PBS and the avidin-
biotin-peroxidase complex was added for 45 minutes and sections were washed three 
times for 5 minutes in PBS 
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Polyclonal antibodies were applied on the sections for 60 minutes, washed three times for 
5 minutes in PBS, incubated with peroxidase-labeled goat anti-rabbit Ig for 30 minutes 
and washed again three times for 5 minutes in PBS 
Bound antibodies were visualized by using 3-amino-9-ethylcarbazole as a substrate for 
peroxidase. After counterstaining with Meyers haematoxylin sections were mounted with 
Kaisers glycerin (Merck, Darmstadt, Germany). 
An incubation where the first antibody was omitted, served as a negative control. For 
each section, the percentage of positive melanocyte cells was estimated. Each section was 
assigned to one of the following categories. 0%, 1-5%, 5-50% and 50-100% positivity 
Notes were taken of other staining components (e g fibroblast-like cells, extracellular 
matrix) among the melanocyte areas 
Probes and labeling 
For the RNA in situ hybridization experiments, DNA probes were used applying the 
following cDNA fragments (39) a 2 2 kb Kpnl-Hindlll fragment of human t-PA, a 1 0 
kb EcoRI-Hindlll fragment of human u-ΡΑ, a 1 3 kb BamHI fragment of human u-PAR, 
a 2 5 kb EcoRI fragment of human PA1-1 and a 0 9 kb EcoRI-Hindlll of human PAI-2 
cDNA coding for nbosomal RNA and phage lambda HindlH fragments were used as posi­
tive and negative controls The cDNAs were labeled with "S-dCTP (600 Ci/mmol, 
Amersham International, Amersham, UK) by random priming (random primed DNA 
labeling kit, Boehnnger Mannheim GmbH, Mannheim, Germany) Finally, the probes 
were purified by gel filtration on Sephadex G-50 and phenol extraction. The probes were 
stored at -20°C until use 
RNA in situ hybridization 
For in situ hybridization, 8 μτη frozen sections were mounted on organo-silane coated 
slides and fixed for 5 minutes in 4% PBS buffered paraformaldehyde The sections were 
washed in PBS and stored in 70% ethanol at 4°C until use 
The hybridization procedure was adapted from published procedures (12,44) Briefly, 
sections were nnsed three times in 2xSSC Acetylation was performed for 10 minutes in 
0 IM tnethanolamine pH 8 0 containing 0 25% acetic acid anhydride The slides were 
rinsed briefly in 2xSSC and in PBS and incubated for 30 minutes in 0 IM TnsHCl pH 
7 0, supplied with 0 IM glycine Finally, the sections were rinsed in 2xSSC for 10 
minutes and dehydrated in ethanol 
Heat-denatured "S-dCTP labeled probe was added to the hybridization mixture (50% 
formamide, 2xSSC, 10% dextran sulphate, 0 1% BSA, 0 1% polyvinylpirrohdone, 0 1% 
Ficoll 400, 1 mg/ml yeast tRNA and 10 mM DTT) at a concentration of 2xl05 dpm per 
section The mixture was applied on the sections and spread equally by a coverslip Prior 
to hybridization, sections were put in a humidified box at 65°C for 10 minutes Hybrid­
ization was performed overnight in a humidified box at 42CC After hybridization, the 
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coverslips were removed by submerging in a solution of 2xSSC, 50% formamide with 
lOmM DIT. The slides were then washed for 45 minutes in 2xSSC in 50% formamide 
supplied with lOmM DTT at 42°C. Two washes of 45 minutes in lxSSC, 50% formami­
de with lOmM DTT at 42°C and one wash of 45 minutes in 0.5xSSC, 50% formamide 
with lOmM DTT at 42°C followed. The sections were quickly rinsed in lxSSC, dehydra­
ted in alcohol and air-dried. Subsequently, the sections were dipped in Kodak NTB2 film 
emulsion and autoradiographed for 7 or 14 days at 4°C. The emulsion was developed in 
Kodak D19 developer and fixed in 24% sodium thiosulphate. Finally, the sections were 
counterstained by hematoxylin or by hematoxylin and eosin and were mounted with 
synthetic resin. 
In situ zymography 
Cryostat sections were covered with an overlay mixture containing 2% (w/v) commercial 
instant nonfat dry milk solution (an 8% (w/v) stock solution in PBS was heated at 95°C 
for 30 minutes, briefly centrifuged at Sxltfg, the supernatant was used), 0.9% agar (w/v) 
and 30 /ig/ml plasminogen as described by Sappino et al. (44). The overlay solution was 
prepared at 50CC and 130 μΐ was applied on freshly defrosted 8 μπι sections, spread 
evenly under 24x32 mm glass coverslips. Slides were incubated at 37°C in a humidified 
air box. Development of lysis was allowed for up to 20 hours, with photography at 
intervals. Experiments with addition to the overlay mixture of 2 mM amiloride or 
polyclonal antibody against u-ΡΑ to inhibit u-ΡΑ activity or with addition of polyclonal 
antibody against t-PA to specifically inhibit t-PA activity were performed to discriminate 
between the two types of plasminogen activator activities. 
Results 
Protein localization 
Tissue sections of nevocellular nevi, dysplastic nevi, primary melanoma and of melanoma 
metastases were stained for t-PA, u-ΡΑ, u-PAR, PAI-1 and PAI-2. Typical examples of 
immunohistochemical staining of all PA components are shown in Figure 1. 
Figure 1. Immunohistochemistry of components of the plasminogen activator system in 
fresh human melanocytic lesions. Typical examples are shown, a: t-PA protein in blood 
vessels of a nevocellular nevus, b: t-PA present in tumor cells of melanoma metastasis 
lesion, с and d: u-ΡΑ is present in fibroblast-like cells in the stroma (S), not in the tumor 
(T), and occasionally in invading tumor cells (arrow) in this primary melanoma lesion, e: 
u-PAR is located in the membrane of tumor cells in this primary melanoma, f: network­
like PAI-1 distribution in the extracellular matrix surrounding tumor cells in a melanoma 
metastasis lesion, g: PAI-2 was found in tumor cells and in fibroblast-like cells of the 
stroma in this primary melanoma. Magnifications: a,e: 480x; b-d,f,g: 600x. 
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Figure 1. See also color display on page 153. 
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No immunohistochemical staining of melanocytic cells for any of the five PA components 
was observed in all benign or premalignant lesions studied (common nevocellular nevi and 
dysplastic nevi) nor in the early primary melanoma lesions. Staining of tumor cells for u-
PA, u-PAR, PAI-1 and PAI-2 was observed in a number of advanced primary melanoma 
and melanoma metastasis lesions. Tumor cells expressing t-PA were observed in a few 
melanoma metastases only (Table 1). Although u-ΡΑ, u-PAR, PAI-1 and PAI-2 were 
frequently detected, the percentage of immunoreactive cells varied in the different lesions 
(Figure 2). Immunoreactivity for u-ΡΑ, u-PAR and PAI was mostly encountered in the 
same lesion (Table 1). 
In all stages of melanoma tumor progression, t-PA immunoreactivity was found in 
endothelial cells of blood vessels (Figure la), but immunoreactivity of tumor cells was 
restricted to melanoma metastases only (Figure lb and 2). The results obtained with both 
polyclonal and monoclonal antibodies corresponded. 
t-PA u-PA u-PAR 
1 
PAI-1 PAI-2 
tyo* ùl lesion type of і«зюл 
j 1-5 % ^ B 5-50 % ^ Н 50-100 %, melanocytic staining 
l total percentage of lesions with immunoreactivity 
Figure 2. Percentage of immunohistochemically stained melanocytic cells and per­
centage immunoreactive lesions including staining of extracellular matrix and stroma 
cells, expressed as percentage of the total number of lesions. NN = nevocellular nevus 
(n=25), DN = dysplastic nevus (n = 16), ePM = early primary malignant melanoma with 
Breslow thickness < 1.5 (n=8), aPM = advanced primary malignant melanoma with 
Breslow thickness ^ 7.5 (n = ll), MM = melanoma metastasis (n = 17). For t-PA the 
results with the polyclonal antibody are shown, for u-ΡΑ the results with the monoclonal 
antibody and for PAI-2 the results obtained with the goat polyclonal antibody are shown. 
Results with the other t-PA, u-ΡΑ and PAI-2 antibodies were comparable. See also Table 
1. 
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Table 1. Immunohistochemical staining of the components of the plasminogen activation system in 
advanced primary melanomas and metastases of melanoma 
l-PA u-ΡΑ u-PAR PAI-1 
Lesion 
Advanced primary melanoma, 
Breslowä 1.5mm 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
Case 6 
Case 7 
Case 8 
Case 9 
Case 10 
Case 11 
Melanoma metastases 
Case 12 
Case 13 
Case 14 
Case 15 
Case 16 
Case 17 
Case 18 
Case 19 
Case 20 
Case 21 
Case 22 
Case 23 
Case 24 
Case 25 
Case 26 
Case 27 
Case 28 
t,s 
t.s 
t 
t,s 
l,s 
ι,s 
t,s 
t,s 
t,s 
t.s 
t.s 
s 
t,s 
t,s 
t,s 
t,s 
t.s 
I.s 
t 
t.s 
t,s 
t 
e 
t.s 
e 
t.s 
e 
PAI-2 
t 
t 
t 
t,s 
s 
t.s 
t = slainmg of tumor cells, e = extracellular matrix staining, s = stromal staining, - = no staining observed 
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In general, u-ΡΑ immunoreactivity was confined to stromal, fibroblast-like cells (Figure 
lc and d) and a minority of tumor cells (1-5% category) in primary melanoma and 
melanoma metastasis lesions (Figure 2, Table 1). Stained tumor cells were often localized 
at the tumor-stroma interface at the invasive front (Figure Id). Results with monoclonal 
antibody #3689 were identical to the results obtained with the polyclonal antibody. 
u-PAR protein was found in the same lesions as u-ΡΑ protein. u-PAR immunoreactivity 
was mainly membrane-associated and was observed primarily in tumor cells (Figure le). 
Occasionally stromal cells also stained. The percentage of u-PAR positive tumor cells was 
similar to the percentage of u-ΡΑ positive cells (Figure 2). 
PAI-1 protein was mainly localized in the extracellular matrix around tumor cells (Figure 
If, Table 1). This localization was confirmed by staining parallel tissue sections with a 
polyclonal antibody against heparan sulphate proteoglycan, which is an extracellular 
matrix component (results not shown). More scarcely, immunoreactive PAI-1 was found 
in a minority of tumor cells (1-5% category, Figure 2). 
In contrast to the PAI-1 localization, the PAI-2 protein was localized in tumor cells and 
some stromal cells (Figure lg, Table 1). When present, high percentages of tumor cells in 
advanced primary melanomas and melanoma metastases stained (Figure 2). Results 
obtained by both polyclonal antibodies were comparable. 
mRNA localization 
RNA in situ hybridization was performed on parallel sections of the lesions used for 
immunohistochemistry to establish whether the mRNAs for the components of the 
plasminogen activation system could be assigned to similar cells as the proteins. For none 
of the components mRNA could be detected in melanocyte or other cells in nevocellular 
nevi, dysplastic nevi and early primary melanomas. 
Figure 3. RNA in situ hybridization of components of the plasminogen activation system 
in fresh human melanocytic lesions. Examples are shown obtained from sections from the 
same specimen as the immunohistochemistry examples shown in figure 1. a,b: t-PA mRNA 
present in tumor cells of this melanoma metastasis lesion. c,d: u-ΡΑ mRNA present in 
fibroblast-like cells in the stroma of this primary melanoma lesion, e J: u-PAR mRNA is 
present in a ridge (arrow) of tumor cells in this primary melanoma lesion. g,h: PAI-1 
mRNA is present in two groups of tumor cells in a melanoma metastasis. No signal is 
present in the separating stroma nor in the lymphocytes present in this lesion, b,dj and h 
are darkfield images ofa,c,e and g respectively. Abbreviations: S = stroma, Τ = tumor. 
Magnifications: a.b.g.h: 480x; c-f: 960x, exposure time; one week (c-h) or two weeks 
(a,b). 
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In those lesions where expression was found, the mRNA was localized in similar cells 
and areas as the protein (Figure 3). t-PA mRNA was localized in tumor cells of some 
melanoma metastasis lesions corresponding with the t-PA protein (Figure la and b). As 
for the u-ΡΑ protein, u-ΡΑ mRNA could be detected in a minority of tumor cells (results 
not shown) and in fibroblast-like cells (Figure 3c and d). u-PAR, PAI-1 and PAI-2 
mRNAs were exclusively found in tumor cells (Figure 3e-h, results for PAI-2 not shown) 
in the same lesions where the protein could be detected. 
Using a ribosomal RNA probe as a positive control for the hybridization, we found the 
signal localized in tumor cells as well as in fibroblast-like cells (Figure 4 a). Labeled 
phage lambda fragments were used as a negative control for the hybridization and did not 
hybridize to any cell type (Figure 4b). 
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Figure 4. RNA in situ hybridization: positive and negative controls. Sections of the same 
malignant melanoma specimen as shown in figure 3 c-f were hybridized with a cDNA 
probe for ribosomal RNA (a) or with labeled phage lambda DNA fragments (b). Abbrevia­
tions: S = stroma, Τ = tumor. Magnification: 1200x; exposure time: one week. 
Figure 5. In situ zymography on fresh melanocytic lesions. t-PA mediated plasminogen 
activation in bloodvessels in nevocellular nevus (NN) and dysplastic nevus (DN). Tumor 
cell associated plasminogen activation was encountered in one advanced primary melano­
ma with areas of t-PA (arrow head) and u-ΡΑ (arrow) mediated plasminogen activation 
and in two metastases of melanoma (MM) with t-PA mediated plasminogen activation 
(fourth row) and u-ΡΑ mediated plasminogen activation (fifth row). Columns: neg. 
control: casein layer without plasminogen, u-PA + t-PA: casein layer with addition of 
plasminogen, u-ΡΑ: casein + plasminogen + polyclonal antibody against t-PA, t-PA: 
casein + plasminogen + polyclonal antibody against u-ΡΑ, which shows a similar result 
as casein + plasminogen + amiloride (not shown) . Magnification: 4x. Incubation times 
at 37°C: 60 minutes (MM case 5), 90 minutes (MM case 13), 150 minutes (NN and DN) 
and 18 hours (PM). 
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Localization of plasminogen activation 
In situ zymography was performed on section* of 4 nevocellular nevi, 6 dysplastic nevi, 6 
advanced primary melanomas and 7 melanoma metastases. In all lesions studied, the 
plasminogen activation pattern corresponded with the immunohistochemical staining. 
Plasminogen activation was t-PA mediated in nevocellular and dysplastic nevi and could 
be assigned, by comparison with the hematoxylin and eosin section, to areas with blood 
vessels. In the advanced primary melanomas, plasminogen activation was u-ΡΑ mediated 
and could be assigned to groups of tumor cells or stromal areas. When no immunohis­
tochemical staining of u-ΡΑ or t-PA was observed, the same lesion also did not display 
plasminogen activation. In one advanced primary melanoma, areas with both t-PA and u-
PA mediated plasminogen activation were observed (Figure 4) In tumor cells of 
melanoma metastases, both t-PA and u-ΡΑ mediated plasminogen activation was detected 
(Figure 4). Apart from t-PA mediated plasminogen activation in blood vessels, plasmin­
ogen activation in malignant lesions was always in areas with tumor cells 
Discussion 
In a recent study, we investigated the involvement of the plasminogen activation system in 
six human melanoma cell lines. u-ΡΑ, PAI-1 and PAI-2 mRNA and protein levels were 
elevated in cell lines which highly metastasized in nude mice. Furthermore, matrix 
degradation by these cell lines was u-ΡΑ mediated (41). In the current study, we investi­
gated the presence of components of the plasminogen activation system in different stages 
of cutaneous melanocytic tumor progression. 
We found t-PA protein and activity present in blood vessels of benign, premalignant and 
malignant lesions. All other components, however, were expressed only in the most 
malignant lesions: u-ΡΑ protein, mRNA and activity were observed only in advanced 
primary melanomas and in melanoma metastases, u-PAR, PAI-1 and PAI-2 protein and 
mRNA were also restricted to advanced primary melanomas and melanoma metastases. 
Mostly, u-ΡΑ, u-PAR and PAI proteins were co-expressed in the same lesion. t-PA 
protein, mRNA and activity was observed in tumor cells of some of the metastasis lesions 
only. 
Although in an earlier study t-PA was detected immunohistochemically in all five primary 
melanomas, all five metastases and all four cell lines and derived xenografts analyzed 
(26), we now demonstrate that t-PA can only be detected in metastases We used two 
different antibodies against t-PA on 77 melanocytic lesions and the staining pattern of the 
two antibodies corresponded in all lesions Moreover, the use of two complementary 
techniques (mRNA in situ hybridization and in situ zymography) confirmed our histoche-
mical findings. The differences found could be due to differences in sensitivity of the 
antibodies used. 
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From recent literature, the view emerges that in various malignancies, neoplastic 
(23,24,32,43,45,48) as well as boardenng stromal (fibroblast-like) cells (19,38) are 
producers of u-ΡΑ Markus et al (27) previously visualized u-ΡΑ protein in a few 
primary melanoma sections They found strong staining of u-ΡΑ at the cell membranes of 
tumor cells and weak staining of stromal cells. We located u-ΡΑ mainly to stromal cells, 
with a minority of u-ΡΑ positive tumor cells at the invasive front 
With the novel antibody #3936 against u-PAR in our study, we mainly stained tumor cells 
and occasionally a few stromal cells in all lesions where u-ΡΑ protein was detected. At 
the cellular level, differences exist in distribution of u-ΡΑ and u-PAR. u-ΡΑ is mainly 
located in fibroblast-like cells and in a minority of tumor cells, u-PAR is almost exclusi­
vely present in tumor cells and almost absent in stromal cells This could suggest that 
either fibroblast-like cells secrete pro-u-PA which is bound to the invading tumor cells or 
u-ΡΑ is provided by tumor cells in an autocrine fashion 
PAI-1 protein was localized in extracellular matrix surrounding nests of tumor cells which 
contained the mRNA This is different from the situation in colon (37) where mRNA is 
produced by endothelial cells in the vicinity of the invasive front, but in agreement with 
squamous cell carcinoma (43) and breast cancer (42) Recent in vitro studies confirmed 
the attachment of free PAI-1 to the extracellular matrix (20) Particularly the extracellular 
matnx component vitronectin was found to be involved in the regulation of plasminogen 
activation in vitro as it might downregulate u-PA (7) and binds plasminogen and PAI-1 
(25) 
A high percentage of tumor cells was found positive for PAI-2 protein This could 
indicate a higher total expression level of PAI-2 relative to PAI-1 in these lesions, which 
was also found by ELISA experiments for colorectal carcinoma (46) and gastric carcino­
ma (33). However, it is probable that the importance of PAI-2 relative to PAI-1 in PA 
inhibition is less, as it is hardly secreted by cells (2) We also localized PAI-2 intracel­
lular^, whereas the localization of PAI-1 was mainly extracellular 
We previously reported a strong correlation between metastasis of human melanoma cells 
in the nude mouse model and expression of u-ΡΑ and PAI (41) In the present paper 
using fresh human cutaneous melanocyte lesions, it is shown that u-ΡΑ, u-PAR, PAI-1 
and PAI-2 appear in late stages of melanocytic tumor progression Also in this case it is 
striking that u-ΡΑ expression coincides with the expression of their regulators, u-PAR and 
PAI-1 and PAI-2 (42,46) Heterogeneity of expression of components of the piasmingen 
activation system among advanced primary melanomas (in 4 out of 11 thick melanomas 
no staining of components of the plasminogen activation system) could be of great 
interest Analogous to breast cancer (13,17) it could well be that ΡΑ-status could become 
an additional prognostic factor for progression of melanoma next to established his­
tological criteria such as Breslow thickness (6) or Clark's level of invasion (8) 
63 
Therefore, we feel that a study on plasminogen activator components in a large senes of 
melanoma lesions is warranted 
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Abstract 
We previously reported on the induction of expression of the components of the 
proteolytic plasminogen activation system in cutaneous melanocytic tumor progression. 
Plasminogen activators, their inhibitors and the receptor for urokinase were present in 
advanced primary melanomas and melanoma metastases only. Here, we report on the 
presence of tetranectin and plasmin/plasminogen, two proteins connected with 
plasminogen activation, in cutaneous melanocytic lesions. 
The distribution of tetranectin and plasminogen was studied by immunohistochemistry 
on 105 freshly frozen melanocytic lesions of common nevocellular nevi (n=24), atypical 
nevi (n=14), early (n=12) and advanced (n=20) primary melanomas and melanoma 
metastases (n=35). Both tetranectin and plasminogen were detected in a variety of 
tissue components. In all stages of melanocytic tumor progression, tetranectin was 
found in endothelium, perivascular dendritic cells and in leukocytes. Plasminogen was 
present in endothelium and in the basal cell layer of the normal skin. Tetranectin and 
plasminogen staining of fibroblastic cells at the invasive front and of extracellular 
matrix however, was restricted to malignant lesions. Co-localization of tetranectin and 
plasminogen was found in 50% of the early primary melanomas and more than 75% of 
the advanced melanomas and melanoma metastases. Our results suggest a coordinated 
role for tetranectin and plasminogen at the invasive front of melanomas. Tetranectin-
bound plasminogen could facilitate the migration of tumor cells. 
Introduction 
In the concept of invading and metastasizing tumor cells, the degradation of tissue 
barriers has been implicated In this process, several proteolytic enzyme systems can be 
recruited (18,29) One proteolytic system involved in tumor spread is the plasminogen 
activation system (10,21) In vitro (23) and in vivo (12,22,24) findings indicate that both 
tumor cells and fibroblastic stromal cells are involved in the plasminogen activation 
process at the tumor-stroma interface (1) In cutaneous melanoma lesions, urokinase 
plasminogen activator (u-ΡΑ) in particular is markedly present in tumor cells (11,12) and 
in stromal cells (12) at the periphery of tumor nodules 
Two other molecules involved in the process of plasminogen activation, which play a 
putative role in the migration process of tumor cells, are plasminogen and tetranectin 
Tetranectin is a 68 kD protein purified from plasma which binds to the kringle 4 domain 
of plasminogen (8) Plasma of cancer patients contains significantly lower levels of 
tetranectin compared to age and sex matched control groups (15,16,19). Tetranectin is 
present in a variety of cells, including monocytes (20), neutrophils (2) and fibroblasts (9) 
In breast (7), ovarian (15) and colon (30,31) tumors, tetranectin is present in the stroma 
surrounding the tumor Moreover, plasma tetranectin content and stromal lmmunoreacti 
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vity are of prognostic relevance in patients with ovarian cancer (15) 
Plasminogen is the substrate for plasminogen activators Cleavage of plasminogen by 
plasminogen activators forms the active enzyme plasmin Little is known about the 
presence of plasmin/plasminogen in cancerous tissues In colon carcinomas, it is reported 
to be present in stromal cells (3) 
Recently, we described the presence of the components of the plasminogen activation 
system in advanced stages of human cutaneous melanocyte tumor progression (12) Here, 
we present data on the distribution of tetranectin and plasminogen in cutaneous 
melanocyte lesions. 
Material and Methods 
Tissue specimens 
Representative tissue samples were freshly received from cutaneous melanocyte lesions 
excised from patients at the University Hospital, Nijmegen, The Netherlands, and from 
patients at the University Hospital, Wurzburg, Germany They were snap-frozen in liquid 
nitrogen and stored at -80°C until sectioning Based on conventional histopathologic 
examination of paraffin sections, lesions were divided into 5 classes common 
nevocellular nevus (NN, η =24), atypical nevus (AN, η = 14), early primary melanoma 
(Breslow thickness<15 mm) (ePM, n = 12), advanced primary melanoma (Breslow 
thickness>l 5 mm) (aPM, n=20) and melanoma metastasis (MM, n = 35) 
Antibodies 
Two well characterized antibodies were used Rabbit polyclonal antibody A371 against 
tetranectin (8) has been used previously in immunohistochemistry Staining with this 
polyclonal antibody compared well to the staining obtained with a monoclonal antibody 
against tetranectin (6,7) 
Rabbit polyclonal antibody against plasminogen/plasmin was affinity purified by passaging 
through a Sepharose column to which the kringle 1-3 part of plasminogen was coupled 
Others have shown that immunohistochemical staining of tissue sections with this antibody 
compared well to various monoclonal and polyclonal antibodies against 
plasmin/plasminogen (Chnstensen et al , paper submitted) 
Immunohistochemistry 
The immunohistochemical staining procedure for polyclonal antibodies was as described 
previously (12) Briefly, 4 /im cryostat sections were air-dried overnight at room 
temperature and stored at 80°C until use Upon acetone fixation, dilutions of the 
polyclonal antibodies were applied to the sections Antibody binding was visualized with a 
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peroxidase-labeled swine anti-rabbit secondary antibody and incubation with 3-amino-9-
ethylcarbazole as a substrate for peroxidase. After counterstaining the nuclei with Papani­
colaou's Harris solution, sections were mounted with Kaiser's glycerin (Merck, 
Darmstadt, Germany). An incubation where the first antibody was omitted, served as a 
negative control. Consecutive sections of the same lesion were incubated with the 
tetranectin and plasminogen antibodies. Localization similarities were judged by 
comparing the staining results of the two sections. 
Score 
For each section, the percentage of positive melanocytic cells was estimated. Each section 
was assigned to one of the following categories: 0%, 1-5%, 6-25% and 26-100% 
positivity. Positive melanocyte staining was registered when at least 1% of the 
melanocytic cells stained. Notes were taken of other staining components (fibroblast-like 
cells, extracellular matrix) among the melanocytic areas. Sections were scored 
independently by two observers (T.J. de V., P.E.J, de W.). Discrepancies were found in 
only a few cases. These cases were re-evaluated jointly until agreement was reached. 
Results 
Tissue sections of nevocellular nevi, atypical nevi, early and advanced primary 
melanomas and melanoma metastases were stained for tetranectin and plasminogen. 
Typical examples of tetranectin and plasminogen staining are shown in figures 1 and 2. 
Figure 1. Tetranectin (TN) and plasminogen (PLG) staining in melanocytic lesions, a: 
TN in perivascular dendritic cells (arrows) in an atypical nevus, b and d: TN (b) and 
PLG (d) in leukocytes in two vessels of a lymphocytic area of a lymph node metastasis, 
two adjacent sections were stained for TN and PLG, c: PLG staining of the basal layer of 
the epidermis of normal skin, e: PLG in the extracellular matrix of a metastasis lesion. 
f-h: three adjacent sections of a metastasis lesion, f H and E staining, g PLG staining 
and h TN staining. Arrows point at a band of cells near a blood vessel at the tumor-
stroma interface, positive for TN and PLG. i: PLG positive stroma at the edge of a tumor. 
The same area was TN positive (not shown), j and k: diffuse stromal staining of of PLG 
(j) and TN (к) ω the edge of a tumor. Bar equals 11 μ№ (с) or 18 μ ι^ (a,b,d) or 28 μπ 
(e-k). Abbreviations: t=tumor, s=stroma. 
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Figure 1. See also color display on page 155. 
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Tetranectin 
The various staining aspects of tetranectin in the cutaneous melanocytic lesions are 
summarized in Table 1. Tetranectin was localized in a variety of cell types. In benign 
common nevocellular nevi and in atypical nevi, scattered cells in the dermis, so-called 
perivascular dendritic cells (27), stained (Figure la). In addition, some blood vessels 
showed positive endothelium (not shown). Tetranectin positive cells were often found in 
the lumen of blood vessels, in both benign and malignant lesions (Figure lb). Staining of 
tumor cell surrounding extracellular matrix was observed in primary melanoma lesions 
and metastasis lesions only. Fibroblastic cells either did not stain or stained weakly in 
benign lesions. Staining of the stroma was frequently observed in malignant lesions and 
was much more pronounced. Especially the invasive front stained in the malignant lesions 
(Figure Ik). No tetranectin staining of melanocytic cells was encountered in the benign 
stages. Tetranectin staining of tumor cells was seen in very few malignant lesions (Figure 
2a). Staining was mainly in the 1-5% category and found in 1/12 of the early primary 
tumors, in 1/20 of the advanced primary melanoma lesions and in 4/35 of the metastatic 
lesions. One advanced primary melanoma lesion contained 6-25% tetranectin positive 
cells. 
Table 1. Tetranectin staining in melanocytic lesions 
Cell type/structure 
Melanocytic cells 
Fibroblast-hke cells 
Extracellular matrix 
Endothelial cells 
Perivascular dendritic 
cells 
Leukocytes (in blood 
vessels) 
NN' 
_г 
-l± 
-
+ 
+ 
+ 
AN 
— 
-/± 
-
+ 
+ 
+ 
ePM 
+ 
+ 
+ 
+ 
+ 
+ 
aPM 
+ 
+ 
+ 
+ 
+ 
+ 
MM 
+ 
+ 
+ 
+ 
+ 
+ 
Remarks 
Posilivily in a low per­
centage of cells in only 9% 
of (he malignant lesions. 
No or very weak staining in 
NN and AN. Frequent and 
pronounced staining in mo.st 
PM and MM. 
Posilivily in part ot the 
malignant lesions. 
Positivity in part of the 
blood vessels. 
NN= common nevocellular nevus, AN= atypical nevus, ePM= early primary melanoma, aPM = 
advanced primary melanoma, MM= melanoma metastasis 
- : no staining 
± : faint staining 
+ : clear staining 
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Plasminogen 
The various staining aspects of plasminogen in the cutaneous melanocyte lesions are 
summarized in Table 2. Plasminogen was found in the basal cell layer of the epidermis, 
both in benign and malignant lesions (Figure lc). This staining was often more 
pronounced towards the basal membrane (not shown). In all types of lesions studied, 
endothelium of blood vessels stained (not shown). The extracellular matrix around tumor 
cells stained in many advanced primary melanoma lesions and in various metastases 
(Figure le). Staining of extracellular matrix was more often seen and more intense 
compared to tetranectin. No staining or weak staining of fibroblastic cells was 
encountered in benign lesions and stronger staining of the stroma, markedly at the tumor-
stroma interface (Figure li and j), was found in primary melanoma and in metastases of 
melanoma lesions. 
Plasminogen staining of melanocyte cells was absent in the common nevocellular nevi 
and in the atypical nevi, whereas some of the malignant lesions (Figure 2b) showed 
positivity. Tumor cell staining was encountered only in a few cases of primary melanoma 
and metastases of melanoma. This staining was mainly in the 1-5% category: in 0/12 of 
the early primary tumors, in 1/20 of the advanced primary melanoma lesions and in 7/35 
of the metastatic lesions. One advanced primary melanoma lesion and one metastasis 
lesion contained 6-25% plasminogen positive cells. 
Figure 2. Tumor cell staining for tetranectin (TN) and plasminogen (PLG). a: TN 
staining of tumor cells in an advanced primary melanoma lesion, b: PLG staining of 
tumor cells in a melanoma metastasis lesion. Bar equals 14 urn. Abbreviations: t=tumor, 
s=stroma. 
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Table 2. Plasmino gen/phsmin staining in melanocytic lesions 
Cell type/structure 
Melanocytic cells 
Fibroblast-like cells 
Extracellular matrix 
Endothelial cells 
Basal keratinocytes 
Leukocytes (in blood 
vessels) 
NN 
-l± 
' 
+ 
+ 
+ 
AN 
-l± 
+ 
+ 
+ 
ePM 
+ 
+ 
+ 
+ 
+ 
+ 
aPM 
+ 
+ 
+ 
+ 
+ 
+ 
MM 
+ 
+ 
+ 
+ 
NP 
+ 
Remarks 
Positivity ш a low per­
centage of cells in only 12% 
of the malignant lesions. 
No or very weak staining in 
NN and AN. Frequent and 
pronounced Stauung, mainly 
at the tumor-stroma 
interface, ш most PM and 
MM. 
Positivity around tumor 
cells in a few ePM and 
many aPM and MM. 
Positivity in part of the 
blood vessels. 
NN= common nevocellular nevus, AN= atypical nevus, ePM= early primary melanoma, aPM = 
advanced primary melanoma, MM= melanoma metastasis, NP= not present in these lesions 
- : no Stauung 
± : faint staining 
+ : clear staining 
Co-localization of tetranectin and plasminogen 
In the majority of malignant lesions, tetranectin and plasminogen were found in 
corresponding cell types or structures in the same lesion (Table 3). Tetranectin and 
plasminogen were found together in leukocytes (Figure lb and d) in all types of lesions 
and in the extracellular matrix (not shown) and in the stroma surrounding the tumor ( Fig. 
1 g and h, j and k). 
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Table 3. Co-localization of tetranectin and plasmin/plasminogen in malignant 
melanocyte lesions 
Type of lesion1 
ePM 
aPM 
MM 
Number of cases with co-localization 
of tetranectin and 
plasmin/plasminogen 
6 
18 
27 
Total number of 
lesions 
12 
20 
35 
ePM = early primary melanoma, aPM = advanced primary melanoma, MM = melanoma 
metastasis 
Discussion 
We found evidence for a differential expression of both tetranectin and plasminogen in 
melanocyte tumor progression. Fibroblast and extracellular matrix staining for both 
proteins was clearly present in primary tumor lesions and in metastatic lesions, whereas 
benign lesions showed weak or no staining. Although less pronounced, a similar pattern 
was observed for the melanocytic cells. 
When clear expression of plasmin/plasminogen was present, co-localization in the 
extracellular matrix and in fibroblastic cells was evident in most cases. Though tetranectin 
is a plasminogen binding protein, co-localization of the two proteins was not observed in 
all lesions. Tetranectin for example is markedly present in a cell type previously 
described by Sontheimer (27) as perivascular dendritic macrophages in the dermis of 
benign lesions. These cells were immuno-negative for plasminogen. Also, plasminogen 
was detected in the basal layer of the epidermis, where no tetranectin was detected. In 
tumor tissues, the extracellular matrix staining was more often encountered in the case of 
plasminogen. As the additional cases showed weak staining for plasminogen, quantitative 
differences in expression may explain these observations. Also, apart from binding to 
tetranectin, it has been described that plasminogen adheres to a variety of extracellular 
matrix proteins, among them are fibronectin (26), laminin (25) type IV collagen (28) and 
vitronectin (17). Third, plasminogen can bind to its putative cellular receptor on the cell 
surface (4,5). 
The plasminogen present in tumor tissue could originate from plasma as proposed by 
Burtin et al. (3). Also for tetranectin, it has been postulated that increased staining around 
tumor tissue is due to deposited plasma tetranectin followed by a decrease of the level of 
plasma tetranectin in the circulation of cancer patients (15). RNA in situ hybridization of 
tumor tissue with probes specific for tetranectin and plasminogen can elucidate the origin 
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of the proteins in tumors. Wewer and Albrechtsen (31) have shown that the messenger 
RNA of tetranectin is present in fibroblasts and not in tumor cells of colonic cancer. 
Cultured embryonic fibroblasts also deposit tetranectin (9). 
Tetranectin staining at the invasive front has been described for various tumors. Many 
authors have speculated about the role of tetranectin in tumor cell migration at the 
periphery of the tumor (7,15,30). Recently, Nielsen et al. (20) showed that secreted 
tetranectin can facilitate migration of monocytes. Similarly, one can envisage that 
fibroblasts at the tumor edge which produce tetranectin can attract tumor cells in a 
paracrine fashion. Tetranectin increases plasminogen activation by tissue-type 
plasminogen activator (t-PA)(8). It is of interest that tumor cells in melanoma lesions 
show an enhanced expression of t-PA (11-13). In this respect melanoma differs from 
other tumors, as t-PA associated tumor cell staining is hardly seen in non-melanoma 
tumors. 
With respect to the "fine-tuning" of proteolytic activity, it was recently described that 
both t-PA binding sites (14) and u-ΡΑ receptor (22) are in close proximity to the receptor 
for plasminogen. We believe that in melanocyte tumors, plasminogen activation is a 
process focalized at the tumor-stroma interface. Previously, it was described that u-PA 
protein (12) and activity (11) is present at the invasive front in melanoma lesions. The co-
localization of plasminogen and tetranectin strongly suggests an anchorage role for 
tetranectin. Tetranectin-bound plasminogen could well serve as a feeder layer for 
plasminogen activator positive migrating tumor cells. In vitro experiments are needed in 
support of this hypothesis. 
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Abstract 
We recently found that the proteins of the proteolytic system of plasminogen activation 
emerge in late stages of melanocyte tumor progression. A large body of evidence 
suggests a role for two proteins, the low density lipoprotein receptor-related protein 
(LRP)/a2-macroglobulin receptor and us receptor-associated protein (RAP), in the 
internalization of components of the plasminogen activation system. Here, we present 
data on the presence of these two proteins in human melanoma cell lines which differ 
in metastatic capacity, their corresponding xenografts, and in cutaneous melanocytic 
lesions. 
Using flow cytometry, we found surface expression of LRP to be restricted to urokinase 
plasminogen activator producing, highly metastatic cell lines. These cell lines also 
produce higher levels of LRP mRNA, whereas RAP mRNA and protein is expressed at 
equal levels in all cell lines and is not present at the cell surface. Xenografts of cell 
lines producing high levels of LRP in vitro remarkably contain only a small fraction of 
LRP positive tumor cells. 
Using immunohistochemistry on frozen sections of 107 human melanocytic lesions 
comprizing the various stages of melanocytic tumor progression, we found that expres­
sion of both LRP and RAP decreased with tumor progression. Furthermore, we noted 
that LRP and RAP are co-expressed within the same lesion. Using immunofluorescence 
double staining, we found that LRP and RAP co-localize in the same cells in the lesions 
studied and in the same cell structures in the cell lines studied. In conclusion, our 
results indicate that LRP and RAP are coordinately expressed in a decreased fashion in 
melanocytic tumor progression. Based on the staining results in xenografts and in 
human melanocytic lesions, we conclude that a strong correlation between expression of 
LRP and u-ΡΑ seems not to exist in in vivo melanomas. 
Introduction 
The transition from normal melanocytes to melanoma cells involves distinct changes in 
the protein repertoire of these cells (42). Among others, proteases are elevated in malig­
nant stages of melanoma (11). In recent years, it has become clear that the inactivation of 
such proteins is a tightly regulated process. Two proteins involved in the clearance and 
cellular uptake of inactivated proteases are the low density lipoprotein receptor-related 
protein (LRP)/a2-macroglobulin receptor, also known as CD91, and its receptor-associa­
ted protein (RAP). 
LRP is a member of the LDL receptor family (reviewed in 23, 38) The gene encoding 
the enormous protein compnzes 89 exons (40), revealing a 15 kb mRNA transcript, from 
which a 600 kD precursor protein is translated, which is cleaved into a 515 kD α-chain 
and an 85 kD ß-chain. Apart from activated complexes of a2-macroglobulin, many other 
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ligands can be internalized upon binding to LRP, including ApoE and various proteins or 
complexes of proteins of the plasminogen activation system (reviewed in 2) Tissue-type 
plasminogen activator (t-PA) can bind to LRP (3) and complexes of t-PA with plasmin­
ogen activator inhibitor 1 (PAI-1) can be internalized mediated by LRP (32). LRP-
mediated internalization of complexes of urokinase-type PA (u-ΡΑ) with inhibitors occurs 
most efficiently when u-ΡΑ is bound to its receptor u-PAR (8, 17,18,31). 
RAP is a 39 kDa protein which co-punfies with LRP and other members of the LDL 
receptor family (37) RAP is restricted to the endoplasmatic reticulum and serves as a 
chaperone for LRP (6,43) By binding to LRP, RAP can prevent binding of all other 
known ligands, including (complexes of) plasminogen activators (16,19,30,41). 
In human tissues, LRP and RAP are mainly expressed in placenta, in the liver and in 
nervous tissues (4,28,44,45) Co-localization of LRP and RAP has been described for 
glioblastoma cells (5) and for human trophoblasts (9). 
Little is known about LRP and RAP expression in human tumor cell lines or in human 
tumors. In human tumor cell lines, it seems that LRP expression decreases with agressi-
veness a) tumor cells make no or less receptor for a2-macroglobulin when compared to 
non-tumor cell lines (20,35,36,39), b) LRP is present in photodynamic therapy sensitive 
tumor cells and not in therapy resistant cells (25) and c) invasive cells make less LRP 
than non-invasive cells (21). In human tumors, LRP was detected in glioma cells (32), but 
is decreased or absent in malignant lymphomas (29) and in hepatocellular carcinomas 
(14). 
We previously described the presence of the components of the plasminogen activation 
system m human melanoma cell lines (34) and in human melanocyte lesions (11). 
Expression of u-ΡΑ and PAI in human melanoma cell lines correlated with metastatic 
capacity in nude mice (34) In human lesions, the components of the plasminogen 
activation system are only expressed in the late stages of malignancy (10,11) In this 
study, we investigated the presence of LRP and RAP, two proteins involved in the 
internalization of components of the plasminogen activation system, in 7 human melano­
ma cell lines and in 107 human cutaneous melanocyte lesions 
Material and Methods 
Melanoma cell lines 
Melanoma cell lines 530, IF6, M14, Mel57, BLM and MV3 have been used before 
Previously, a correlation could be established between metastasizing capacity of the BLM 
and MV3 cell lines and their production of u-ΡΑ and PAI (34) From IF6 a subline, IF6-
m, has been isolated This subline is metastatic when injected subcutaneously into nude 
mice (Westphal et al , manuscript in preparation) A primary culture of human foreskin 
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fibroblasts (flow cytometry and immunofluorescence double labeling) and of rat fibro-
blasts (mRNA analysis) served as a positive control for LRP (39) 
Xenografts in nude rats 
2x10" IF6-m and BLM cells were injected subcutaneously into nude rats. The animals 
were sacrificed when the tumor had a diameter of approximately 1 cm. A part of the 
tumor was snap-frozen in liquid nitrogen and processed for immunohistochemistry. 
RNA isolation and Northern blotting 
Cells were washed with 10 mM NaHP04, 140 mM NaCl, pH 7.4 at 37"C and lysed in 4 
M guanidium thiocyanate, 25 mM sodium citrate, pH 7.5, 0.5% (w/v) sarkosyl, 0.1 M 2-
mercaptoethanol. All solutions were prepared using diethyl pyrocarbonate-treated water. 
RNA was isolated according to Chomczynski and Sacchi (40). The total amount of RNA 
isolated was determined by measuring the OD260 assuming that 1 OD260 unit is equivalent 
to 40 ¿tg RNA. 
RNA samples were electrophoresed on a 1.2% w/v denaturating agarose gel containing 
7.5% v/v formaldehyde and were transferred onto a nylon membrane (Hybond N, Amers-
ham, United Kingdom) using a Vacugene system (Pharmacia, Uppsala, Sweden). 
Membranes were hybridized with 32P-labeled cDNA fragments in 7% (w/v) sodium 
dodecyl sulphate (SDS), 0.5 M NaHP02, pH 7.2, 10 mM EDTA at 65°C. Blots were 
routinely washed with 2xSSC, 1% w/v SDS for 1 h at 65°C (lxSSC = 0.15 M NaCl, 
0.015 M sodium citrate). cDNA fragments were labeled using the random pnmer method 
(Megaprime; Amersham, UK), with 32P-dCTP (specific activity was approximately 109 
cpm//ig DNA). The hybridization was quantified using a phospho-imager (Fujix BAS 
1000). 
cDNA probes 
For the hybridization experiments the following cDNA fragments were used as probes: a 
full length fragment of the human RAP cDNA (16) and a 6.0 kb fragment of the human 
LRP cDNA (15) both kindly provided by Dr. J. Herz, and a 1.2 kb fragment of the 
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (13) 
Melanocytic lesions 
Representative tissue samples were freshly received from cutaneous melanocytic lesions 
excised from patients at the University Hospital, Nijmegen, The Netherlands, and from 
patients at the University Hospital, Wurzburg, Germany They were snap-frozen in liquid 
nitrogen and stored at -80°C until sectioning. Based on conventional histopathologic 
examination of paraffin sections, 107 melanocytic lesions were divided into 5 classes 
common nevocellular nevus (NN, n=22), atypical nevus (AN, n = 12), early primary 
melanoma (Breslow thickness< 1.5 mm) (ePM, n = 10), advanced primary melanoma 
82 
(Breslow thickness>1.5 mm) (aPM, n = 26) and melanoma metastasis (MM, n = 37). 
Antibodies 
Two mouse monoclonal antibodies against LRP (#3402 recognizing the α-chain and #3501 
recognizing the ß-chain) were from American Diagnostica Inc., Greenwich, CT, USA, 
and have been extensively characterized, both by Western blotting and for their use in 
immunohistochemistry (28). One rabbit polyclonal antiserum against RAP and its pre-
immune serum were prepared at the Gaubius Laboratory-TNO, Leiden, The Netherlands. 
A second rabbit polyclonal antiserum against RAP was generously provided by Dr. A.L. 
Schwartz, Department of Pediatrics, Washington University School of Medicine, St. 
Louis, MO, USA and has been characterized and used in immunocytochemistry before 
(5). NKI-beteb, a mouse monoclonal antibody recognizing the melanosomal protein gplOO 
(1) was used to determine the melanocyte origin of the lesions. A polyclonal antibody 
against a-glucosidase, a lysosomal marker (a generous gift from Dr. J. Fransen, 
Department of Cell Biology and Histology, Nijmegen University, Nijmegen, The 
Netherlands) was used in double labeling experiments. 
Characterization and testing of antibodies 
Antibodies against LRP and RAP were tested on frozen sections of placenta and liver, 
two organs known to express abundant LRP and RAP (9, 28,45). Immunolocalization 
with both LRP antibodies and with both RAP antibodies corresponded well. 
Immunohistochemistry 
The immunohistochemical staining procedure for polyclonal antibodies was as described 
previously (11,12). Antibody binding was visualized using 3-amino-9-ethylcarbazole as a 
substrate for peroxidase. Consecutive sections of the same lesion were incubated with the 
anti- LRP antibodies and the anti-RAP antisera. 
An incubation where the first antibody was omitted, served as a negative control for the 
stainings with the monoclonal antibody, an incubation with a similar dilution of the pre-
immune serum served as a negative control for the RAP antisera. 
Score 
For each section, the percentage of positive melanocyte cells was estimated. Each section 
was assigned to one of the following categories: 0%, 1-5%, 5-25%, 25-50%, 50-75% and 
75-100% positivity. Positive melanocyte staining was registered when at least 1% of the 
melanocyte cells stained. Notes were taken of other staining components (for example 
fibroblastic cells) among the melanocytic areas. 
Immunofluorescence double staining on tissue sections and cell lines 
We devised immunofluorescence double labeling experiments to test whether LRP and 
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RAP were expressed by the same cells. Thin 2μπι cryostat sections were cut from 5 
melanoma metastasis lesions, comprizing a variety of staining aspects (no tumor cells 
stained, scattered positivity or all tumor cells stained) as judged from the AEC staining of 
the same cryostat blocks. Before staining, the sections were fixed in acetone for 10 
minutes at room temperature. 
To investigate the localization of LRP and RAP at the cellular level, we cultured IF6 and 
MV3 melanoma cells and human foreskin fibroblasts. Upon culturing on microscope 
slides, the slides were washed in serum free DMEM and briefly fixed in acetone. 
Sections or cultured cells were incubated for 60 minutes with a mix of #3402 and anti-
RAP rabbit antiserum in 1% (w/v) BS A and washed in PBS. A mixture of FITC-labeled 
sheep anti-mouse Ig and TRITC-labeled swine anti-rabbit Ig (both from DAKO, Glostrup, 
Denmark) was applied for 30 minutes to detect LRP and RAP respectively. Upon washing 
in PBS, the sections were covered with glycerol containing 25% v/v Vectashield (Vector 
laboratories, Burlingame CA) and 1 μg/ml DAPI, counterstaining the nuclei. 
No fluorescence was seen when a combination of #3402 with TRITC-labeled swine anti-
rabbit conjugate or a combination of rabbit anti-RAP with FITC-labeled sheep anti-mouse 
conjugate was applied on the sections or the cells. Alternatively, double labeling experi­
ments combining mouse monoclonal NKI-beteb (a melanosomal marker) and RAP or LRP 
(#3402) with a rabbit anti-a-glucosidase (a lysosomal marker) were devised in order to 
show non- or partially overlapping epitopes on tissue sections and on cultured cells. 
Flow cytometric analysis 
To dermine cell surface expression of LRP and RAP on melanoma cell lines and human 
foreskin fibroblasts, sub-confluent monolayers were briefly trypsinized and 105 cells were 
incubated for 30 minutes at 4°C with either a dilution of antibody #3402 against LRP or 
with one of the two rabbit polyclonal anti-RAP sera in PBS containing 0.5% w/v BSA 
The bound antibodies were detected using FITC-conjugated anti-mouse or anti-rabbit 
antibodies. 
To determine the total presence of LRP and RAP, 105 briefly trypsinized cells were made 
permeable and fixed by incubating 40 minutes at room temperature in PermeaFix (Ortho 
Diagnostic Systems Inc., Beerse, Belgium, see also 33) Upon washing in PBS/BSA, cells 
were incubated with the specific antibodies following the procedure as described above 
Incubation with a similar concentration of irrelevant antibody in case of the monoclonal 
antibody or with a similar dilution of pre-immune serum in case of the two RAP antisera, 
served as negative controls. FITC-labeled cells were analyzed on an Epics Elite flow 
cytometer (Coulter, Mijdrecht, The Netherlands) 
84 
Results 
LRP and RAP in melanoma cell lines 
a) mRNA analysis 
We analyzed all cell lines for presence of LRP and RAP mRNA. Northern blotting 
revealed that LRP and RAP mRNA were expressed in all cell lines (Figure la). Relative-
ly high levels of LRP mRNA and relatively low levels of RAP mRNA were found in 
BLM, MV3 and fibroblasts compared to other cell lines (Table 1). 
Table 1: Relative mRNA intensities and LRP/RAP ratio in melanoma cell lines and 
fibroblasts. 
Cell line 
530 
1F6 
lF6-m 
M14 
Mel57 
MV3 
BLM 
Fibroblasts 
Rel LRP1 
2.94 
8.94 
2.62 
0.93 
3.13 
5.16 
7.33 
2.13 
Rel RAP 
3.49 
5.00 
2.62 
3.14 
2.46 
1.17 
1.61 
0.42 
LRP/RAP 
0.84 
1.79 
1.00 
0.30 
1.27 
4.42 
4.54 
5.06 
Relative intensities, corrected for the GAPDH mRNA intensity 
b) Flow cytometry 
Parallel to the mRNA analysis, we used flow cytometric analysis to investigate whether 
LRP and RAP are expressed on the cell surface of our panel of 7 melanoma cell lines and 
fibroblasts. In order to get an impression of the total expression of LRP and RAP (e.g. 
cell surface + cytoplasmic expression), we also permeated and fixed cells prior to 
antibody labeling. LRP was present in the cytoplasm of all cell lines studied and on the 
cell surface of BLM, MV3 and fibroblasts. No cell surface expression of RAP was 
encountered. RAP was exclusively detected intracellularly in all cell lines at similar levels 
(Figure lb). Differences between the cell lines in mRNA content roughly co-incide with 
the total protein measurement in the flow cytometric analysis (Figure 1). 
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Figure 1. LRP and RAP protein and mRNA in human melanoma cell lines and fibro-
blasts, a. Northern blot analysis of mRNA for LRP and RAP in human melanoma cell 
lines and in fibroblasts. mRNA was isolated, subjected to electrophoresis, blotted and 
visualized as described in Materials and Methods. Ten micrograms of total RNA was used 
in each lane. The filter was hybridized with cDNA fragments of human LRP and RAP. 
Hybridization with a GAPDH cDNA fragment was used as a control for loading equal 
amounts of RNA in the different lanes of the gel. b. Flow cytometric analysis of LRP and 
RAP on melanoma cell lines and human fibroblasts. Surface expression and total 
expression of LRP and RAP as determined with flow cytometry. The first 7 rows show 
staining of melanoma cell lines, the eighth row depicts human foreskin fibroblasts. The 
thin line represents the fluorescence of the negative control. Only LRP surface expression 
is observed, in cell lines BLM and MV3 and in human foreskin fibroblasts. Intracellular 
expression of LRP is variable, intracellular RAP content is less variable for the cell lines 
studied. No RAP could be detected on cell surfaces. One of three identical experiments is 
shown. Results with both RAP antibodies were identical, the fluorescence of one them is 
shown, с LRP expression in BLM xenografts. LRP protein could be detected in a few 
BLM cells (arrow). No staining was observed in the majority of the tumor cells nor in the 
rat stromal tissue. Magnification: 400x 
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Figure 2. See Û/ÎO color display on page 156. 
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c) Immunofluorescence double labeling 
The flow cytometry results revealed that LRP and RAP are mainly (LRP) or exclusively 
(RAP) present intracellularly in all cell lines studied. We futher investigated the nature of 
this intracellular localization by performing immunofluorescence double labeling for LRP 
and RAP. Cultured human foreskin fibroblasts and IF6 and MV3 melanoma cells were 
labeled for LRP (green, Figure 4e and h) and RAP (red, Figure 4f and i). At the cellular 
level, the granular staining for LRP and RAP was strikingly similar (Figure 4e-g, h-j), 
suggesting a strict intracellular co-localization for LRP and RAP: the uniform yellow 
color in Figure 4g and j indicates that LRP and RAP fully co-localize in human fibro­
blasts and to a lesser extent in MV3 cells, since a slight red color (RAP) is also observed 
in these cells. A less abundant signal for LRP was observed in the IF6 cells (not shown). 
This precise co-localization of LRP and RAP (Figure 4g and j) was affirmed when LRP 
localization was compared with a protein (a-glucosidase) of which the localization only 
partially overlapped (Figure 41). 
d) Expression of LRP in IF6-m and BLM xenografis 
Xenografts of lF6-m (low LRP expression in flow cytometry) and BLM (high LRP 
expression in flow cytometry) grown in nude rats allowed us to study LRP expression 
using mouse monoclonal antibodies in experimental tumors derived from human melano­
ma cell lines. No significant LRP expression could be detected in IF6-m xenografts 
(result not shown). Only a few scattered BLM cells stained for LRP in the BLM derived 
xenograft (Figure lc), indicating that expression is down-regulated in vivo. 
LRP and RAP in cutaneous melanocytic lesions 
a) Staining aspects 
Based on the results of our in vitro and in vivo investigations using melanoma cell lines, 
we investigated the presence of LRP and RAP in human in vivo melanocytic lesions. 
Figure 2. Immunohistochemical detection of LRP and RAP in human melanocytic 
lesions, a: LRP in melanocytic nests and in fibroblasts in a common nevocellular nevus, 
b: identical RAP staining in the adjacent section, c: LRP in intra-epidermal (arrow-head) 
and intra-dermal (arrow) groups of melanocytes in an atypical nevus, d: strong LRP 
staining in hepatocytes and weaker LRP staining in adjacent tumor cells in a melanoma 
metastasis lesion in the liver, e: fibroblasts and scattered tumor cells stain for LRP in a 
metatasis lesion, f: no LRP staining of tumor cells in this advanced primary melanoma; 
fibroblasts stain, often in a granular fashion, g: heterogeneity of LRP in tumor cells in 
this advanced primary melanoma, h and i: identical tumor cell staining for LRP and RAP 
in adjacent sections of a melanoma metastasis lesion. Magnifications: 200x (α-d) and 
800x (e-i). t= tumor, h= hepatic tissue, and 1= lymphocytes. 
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Tissue sections of common nevocellular nevi, atypical nevi, primary melanomas and 
melanoma metastases were immunohistochemically stained for LRP and RAP. Typical 
examples of immunohistochemical staining of LRP and RAP are shown in Figure 2. 
In all lesions studied, LRP and RAP staining was strong in fibroblasts (Figure 2a, b, e, e 
and 0· A granular staining pattern for LRP and RAP was noticed in fibroblasts (Figure 
2f) and occasionally in tumor cells, strongly resembling the granular staining pattern 
found in cultured cells (Figure 2f and 4 e-j). In the benign lesions (NN and AN), LRP 
and RAP were expressed by all or almost all melanocytic cells (Figure 2a, b and 3a). 
Intra-epidermal nests as well as intra-dermal nests of melanocytes stained (Figure 2c). 
The malignant lesions showed a great variety of staining aspects. Immunoreactive tumor 
cells which lay scattered in the tissue (Figure 2e), solid groups of immunopositive (Figure 
2h and i) or groups of positive and negative tumor cells within one lesion (Figure 2g) and 
negative tumors (Figure 2f) for LRP and RAP were encountered. 
b) Co-expression and co-localization 
When scoring the sections, it became apparent that LRP and RAP were often distributed 
similarly (Figure 2a and b, h and i). This tendency is also shown in Figure 3. First, 
Figure 3a shows that both LRP and RAP expression is decreased in melanocytic tumor 
progression. Secondly, in Figure 3b it can be seen that the majority of the lesions were 
scored within the same staining percentage category or in one of the bordering categories. 
This observed co-expression of LRP and RAP (e.g. similar percentage of immunoreactive 
melanocytic cells within the same lesion), made us use immunofluorescence double 
labeling to answer the question whether this co-expression is indeed co-localization (e.g. 
LRP and RAP within the same cells). From our AEC stained lesions, we chose 6 
melanoma metastasis lesions, comprizing various staining aspects (negative, scatteredly 
positive, totally positive). In all 6 lesions, strict co-localization was observed in all cells. 
Two examples of this double staining for LRP (green) and RAP (red) are shown in Figure 
4a-d. This striking co-localization was convincing, since no co-localization was observed 
when double labeling was performed with polyclonal anti-RAP antibody and a monoclonal 
antibody recognizing the melanosomal protein gp-100 in a metastasis lesion where RAP 
and LRP localization was only stromal (Figure 4k). 
Figure 3. LRP and RAP expression in melanocytic lesions as a percentage of immuno-
reactive melanocytic cells, a. Percentage of immunohistochemically stained melanocytic 
cells, expressed as percentage of the total number of lesions. NN = nevocellular nevus 
(n = 22), AN = atypical nevus (n = 12), ePM = early primary malignant melanoma with 
Breslow thickness < 1.5 mm(n = 10), aPM = advanced primary malignant melanoma 
with Breslow thickness > 1.5 mm(n = 26), MM = melanoma metastasis (n=37). For LRP 
the result with the monoclonal antibody #3402 is shown, for RAP, the results with the 
polyclonal antibody from A.L. Schwartz is shown. 
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Results with the other LRP and RAP antibodies were comparable, b. LRP and RAP 
expression in 73 malignant lesions (10 ePM, 26 aPM and 37 MM, one dot represents one 
lesion). The diagram shows that LRP and RAP are primarily expressed within the same 
category (the diagonal line in the diagram, comprizing 36 lesions (49%)) or in the same 
or a neighbouring category (the marked area, comprizing 55 lesions (75%)). Co-expressi­
on was even more prominent in the benign lesions (NN and DN), where the staining for 
LRP and RAP coincided in 26 out of 34 cases (76%), with 30 lesions (88%) being in the 
same or in a neighbouring category. 
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Discussion 
It was recently desenbed by our group (11) and by others (10) that proteins of the 
plasminogen activation system are specifically expressed in late stages of melanoma tumor 
progression. Previously, we could correlate expression of u-ΡΑ and PAI by melanoma 
cell lines with metastatic behavior in nude mice (34) Here, we studied the presence of 
LRP and RAP - two proteins involved in the internalization of components of the 
plasminogen activation system - in human melanoma cell lines as well as in human 
melanocytic lesions. 
The prevailing concept is that LRP is responsible for the internalization of u-ΡΑ in 
complex with its receptor and inhibitor (17) LRP internalizes PAI u-ΡΑ u-PAR com­
plexes, upon which u-ΡΑ and PAI are degraded in the lysozomes and u-PAR is recycled 
to the cell membrane (17,18,31) Thus, LRP could play an important role in the regenera­
tion of unoccupied u-PAR, neccesary for invasive processes This would assume a strong 
correlation between u-ΡΑ and LRP expression Our present study however, provides 
evidence that such a correlation in expression appears not to exist for melanoma There 
exists a remarkable difference between the in vitro and in vivo expression of LRP in 
melanoma cell lines The BLM cell line has high LRP expression in vitro but in xeno 
grafts only a small fraction of the tumor cells is found to contain LRP The u-PA 
expression however, is high both in all BLM cells in vitro and in all BLM tumor cells in 
rat xenograft lesions (results not shown, see also 34) Although u PA producing cell lines 
are the only cell lines which show high LRP surface expression in vitro, xenografted 
BLM cells exhibit LRP expression in only a fraction of the tumor cells Another 
discrepancy is observed in human melanocytic lesions LRP expression was high in the 
benign lesions where no u-ΡΑ protein could be detected in previous studies (10,11) Also, 
within the malignant lesions, the LRP distribution (e g staining patterns of large groups 
of tumor cells, scattered positivity or absence of staining) differs dramatically from the u-
PA distribution which was almost exclusively in tumor cells and fibroblasts at the 
Figure 4. Immunofluorescence double labeling for LRP and RAP on melanoma 
metastasis lesions and on cultured human melanoma cell lines and fibroblasts, 
a and b LRP and RAP in scattered cells of a metastasis lesion, с and d LRP and RAP in 
the stroma of a metastasis lesion, tumor cells are negative e, f, g and h, ι, j LRP (e, h; 
green), RAP (f, i, red) and both of them (g,j, yellow) in cultured fibroblasts (e-g) and in 
cultured MV3 melanoma cells (h-j) к double fluoresence staining for gplOO (green) and 
RAP (red), note that signals do not co-localize ¡n this same lesion as с and d I a-
glucosidase (red) and LRP (green), are partially overlapping in these fibroblasts In e-l 
nuclei are counterstained with DAPI (blue) Magnifications 250x (c, d, k), lOOOx (a, b) 
and 2500x (e-j, I) 
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Figure 4. See also color display on page 157. 
93 
periphery of the tumor (11). In this respect, other recently discovered receptors responsi­
ble for internalization of plasminogen activators, such as the VLDL receptor and the 
mannose receptor could be involved in melanoma cells producing u-ΡΑ and/or t-PA. 
From our cell line data, it is inconceivable to correlate LRP expression in melanoma cell 
lines with metastatic behavior as such. The non-metastatic 1F6 for instance, produces 
higher levels of LRP mRNA and protein than the metastatic variant lF6-m. 
Lack of RAP surface expression on melanoma cell surfaces is in agreement with the 
putative intracellular role for RAP. It has been postulated recently that RAP functions as 
a chaperone or escort protein for LRP (43) RAP is found exclusively in the endoplas-
matic reticulum (6). Hereby, RAP can prevent binding of other known ligands for LRP 
which are known to be localized in the same cell compartments during the secretion route 
(6,43). Our findings that LRP and RAP strictly co-localize in intracellular granular cell 
structures, support this chaperone hypothesis Our co-localization agrees with similar co-
localization reported for cultured glioblastoma cells (5) and in human trophoblasts (9). 
Using both confocal laser microscopy and immuno-electronmicroscopy, Bu et al. (5) 
showed that LRP and RAP co-localize to a great extent, mainly in the Golgi complex and 
in the endoplasmatic reticulum and not in endosomes, which were LRP-ennched. Clearly, 
our double-immunofluorescence experiments do not discriminate between subtle differen­
ces in localization between LRP and RAP (e.g. cell surface expression and intracellular 
expression). 
Our general conclusion from the present study is that LRP and RAP are coordinately 
expressed in human melanoma cell lines and in human melanocytic lesions ranging from 
common nevocellular nevi up to metastasis lesions This coordinated expression was 
shown by the fact that: a) the majority of lesions expressed equal percentages of LRP and 
RAP positive cells, b) on adjacent sections, LRP positive cells were present in identical 
areas as RAP positive cells, c) in immunofluorescence double staining on lesions, we 
could assign RAP and LRP positivity to the same cells, d) in immunofluorescence double 
staining on cultured cells, this co-localization could be established on the (sub-)cellular 
level. Our results suggest a strict co-localization of LRP and RAP in cultured fibroblasts 
and melanoma cells, although RAP is absent on the cell membranes The majority of LRP 
and RAP however, is localized intracellularly. 
Since LRP and RAP expression is inversely correlated to the expression of many known 
ligands for LRP in melanoma tumor progression, it is interesting to speculate about the 
function of LRP and RAP in the benign lesions. In this respect, the discovery of new 
ligands for LRP such as components of the extracellular matrix (27) could shed new light 
on our observation that expression of LRP and RAP is decreased in melanocytic tumor 
progression. 
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Abstract 
The Tyr-SV40E transgenic mouse model of malignant skin melanoma has been used 
here to generate melanomas in genetically identical (C57BL/6) mice for analysis of the 
plasminogen activation system during tumor development and progression. Twenty-two 
melanocytic lesions were examined by in situ zymography for plasminogen activator 
activity and by immunhistochemistry for concommitant visualization of proteins of the 
plasminogen activation system. These lesions encompassed 3 nevi and 19 primary 
melanomas ranging from melanotic through mixed tumors to amelanotic tumors. While 
urokinase-type plasminogen activator (u-ΡΑ) activity was not detected at premalignant 
stages, it began to appear early in tumorigenesis and became more prominent in later 
stages in a majority of the tumors. The activity was largely attributable to the 
endothelium of sprouting capillaries and to a lesser degree to granulocytes, fibroblastic 
cells, and occasional melanoma cells within the tumor. Tissue-type plasminogen 
activator was undetectable or low in all cases. Of the PA inhibitors, PAI-1 was seen in 
endothelial and fibroblastic cells and in the extracellular matrix, while PAI-2 occured in 
only one case and was melanoma cell-associated. The u-ΡΑ activity and the presence of 
PAI-1 in sprouting capillaries may indicate a role in angiogenesis. Thus, according to 
this mouse model, u-ΡΑ may indirectly be a potential therapeutic target against 
melanoma progression. 
Introduction 
The melanoma susceptible transgenic mouse strain Tyr-SV40E (2) affords many 
possibilities for experimental analysis of mechanisms underlying melanoma progression 
and metastasis. In the transgene, SV40 oncogenic sequences are under the transcriptional 
control of the mouse tyrosinase gene promoter As a result, the transforming sequences 
are specifically activated in pigment cells Different levels of transgene expression occur 
among Tyr-SV40E mouse lines, each of which is comprised of lineal descendants from a 
single egg injected with transgene DNA. Eye melanomas, originating chiefly in the retinal 
pigment epithelium (20), generally anse before skin melanomas and are fatal at a young 
age in mice of lines with high transgene expression. To obtain skin melanomas, pieces of 
skin were grafted from transgenic donors of a high-susceptibility and short-lived line to 
hosts of a low-susceptibility line in which eye tumors anse late In a way, the more 
susceptible skin outlives the donors (21) Melanomas reliably develop in the skin grafts 
and progress to malignancy. Their histopahogenesis strikingly resembles that of cutaneous 
melanomas and they generate regional as well as distant metastases (22) As the animals 
are all of the same standard inbred strain (C57BL/6), tumor progression can be 
characterized within the context of a constant genetic background The tumors clearly 
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undergo ал orderly señes of changes tending toward accelerated growth and diminished 
pigmentation. 
One of the biological parameters of special interest in tumor progression is the increased 
expression of proteases and their inhibitors in malignant lesions compared to the 
premalignant precursor lesions (6,10). The proteolytic system of plasminogen activation is 
one such proteolytic system and is involved in metastatic spread of tumor cells in in vitro 
models. Two plasminogen activators are known, t-PA and u-ΡΑ plasminogen activator, t-
PA is secreted as an active enzyme and u-ΡΑ is secreted as an inactive pro-enzyme and is 
activated upon binding to its receptor u-PAR. The activity of u-ΡΑ and t-PA can be 
inhibited by two specific plasminogen activator inhibitors, PAI-1 and PAI-2 (reviewed in 
6,27). 
The involvement of the PA system in metastatic spread of melanoma cells has been shown 
in various in vitro experiments using murine or human melanoma cell lines. Metastatic 
spread of B16 mouse melanoma cells can be inhibited when preincubated with anti u-PA 
antibodies (13) and be enhanced by transfecting them with the u-ΡΑ gene (36). u-ΡΑ and 
PAI-1 expression of human melanoma cell lines correlates with the capability of 
spontaneous metastatic spread in nude mice (29). Furthermore, binding of u-ΡΑ to u-PAR 
promotes migration of human melanoma cells in vitro (33). These observations are 
consistent with the expression pattern of the PA system in human cutaneous melanocyte 
lesions: plasminogen activators, u-PAR and the PAIs are absent in the premalignant 
lesions and emerge in the primary malignant melanoma lesions and in the metastatic 
lesions (7,8). Here, we describe the presence and activity of plasminogen activators and 
the presence of their inhibitors in premalignant and primary malignant cutaneous 
melanocytic lesions which arose from dermal melanocytes in transgenic Tyr-SV40E body 
skin. 
Material and methods 
Mice, grafts and tissue collection 
One-cm discs of full-thickness body skin were taken from transgenic line 8 hemizygous 
donors in most cases, or in two cases from line 9 homozygous donors, and were 
transplanted to line 12 hemizygous recipients. Mice of these lines have high, moderate, 
and low transgene expression respectively (2). In addition, some line 8 grafts were taken 
from the skin of the snout area, in which the vibrissa follicles are situated. The donor 
skin was grafted on the lateral trunk as described (21). Donor ages varied, hosts were 
young adults. Tumor-bearing animals and controls were killed by cervical dislocation and 
tumors and other tissues were dissected in cold phosphate-buffered saline (PBS). 
For in situ studies of the presence and activity of PA proteins, a piece of tissue was 
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blotted to remove excess moisture, embedded in OCT-compound, and snap-frozen in 
liquid nitrogen. Cryostat sections of the block were stained in hematoxylin and eosin for 
histological characterization in relation to nearby sections cut at 6 μιπ for in situ 
zymography and at 4 μΐη for immunohistochemistry. The sections for in situ zymography 
were immediately frozen and stored at - 80 °C. 
In situ zymography. 
The in situ zymography procedure was adapted from previously published procedures 
(8,9). Cryostat sections were covered with an overlay mixture containing 2% (w/v) 
instant non fat dry milk solution (an 8% (w/v) stock solution in PBS was heated at 95 °C 
for 30 minutes, briefly centrifuged at ЗхІО3 g, the supernatant was used), 0.9% agar 
(w/v) and 30 μg/ml plasminogen. The overlay solution was prepared at 55 °C and 110 μΐ 
was applied on freshly defrosted 6 μιτι sections and spread evenly under 24x32 mm glass 
coverslips. Slides were incubated at 37 °C in a humidified air box. Development of lysis 
was allowed for up to 10 hours, with photography at 3, 4.5, 6 and 7.5 hours of 
incubation. Serial dilutions of mouse u-ΡΑ and of mouse t-PA (#119 and #118, American 
Diagnostic Inc., Greenwich, CT) were made in small drops of agarose on a glass slide. 
Amiloride (2 mM) added to the overlay solution was found to inhibit mouse u-PA 
specifically, whereas goat polyclonal antibody against human t-PA (#387, American 
Diagnostica Inc.) was found to specifically inhibit mouse t-PA. Experiments with addition 
to the overlay mixture of 2 mM amiloride to inhibit u-ΡΑ activity or with addition of goat 
polyclonal antibody against human t-PA (#387) to specifically inhibit t-PA activity were 
performed to discriminate between the two types of plasminogen activator activities in the 
mouse melanocyte lesions. 
Antibodies 
Polyclonal antibodies against the different components of the plasminogen activation 
system are listed in Table 1. Antibodies were either against the mouse component or 
against the rat or human equivalent. Several antibodies have been used before in 
immunohistochemistry on mouse lesions (4,15,18). Human and mouse PAIs are 
immunologically related (15,34). Immunohistochemical staining for u-ΡΑ, PAI-1 and 
PAI-2 was tested on tissue sections of freshly frozen midgestational mouse placenta and 
for t-PA on mouse lung tissue. On placental tissue as well as on the melanocyte lesions, 
the staining of the two u-ΡΑ, the two PAI-1 and the two PAI-2 antibodies compared well 
with each other. In addition, three anti-human u-PAR and one anti-rat u-PAR polyclonal 
antibodies (not listed in Table 1) were tested on placental tissue. Due to the unsatisfactory 
huge variety of staining aspects on placental tissue and due to the moderate homology 
between the human and mouse u-PAR (16), u-PAR stainings were excluded from this 
study. 
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Table 1. Antibodies used in immunohistochemistry 
Antigen 
t-PA 
u-PA 
PAI-1 
PAI-2 
Antibody 
#387, goat anti-human t-PA 
Pool 6, rabbit anti-mouse u-PA 
#1189, rabbit anti-mouse u-PA 
4544, rabbit anti-human PAI-1 
#1062, rabbit anti-rat PAI-1 
goat anti-human PAI-2 
#375, goat anti-human PAI-2 
Source' 
ADI 
Finsen 
ADI 
Finsen 
ADI 
Behring Werke 
ADI 
Mouse immuno­
histochemistry 
references 
4 
18,30 
15,30 
-
1
 Abbreviations: ADI: American Diagnostica Inc., Greenwich CT, 
Finsen: Finsen Laboratory, Copenhagen, Denmark, 
Behring Werke: Behring Werke AG, Marburg, Germany. 
Immunohistochemistry 
Airdried 4 μιη cryostat sections were fixed for 10 minutes in acetone. Polyclonal 
antibodies were applied in 1% BSA in PBS on the sections for an overnight incubation at 
4 °C in a moistered air-chamber, washed three times for 5 minutes in PBS, incubated 
with peroxidase-labeled swine anti-rabbit Ig or with peroxidase-labeled donkey anti-goat 
Ig for 30 minutes and washed again three times for 5 minutes in PBS. Bound antibodies 
were visualized by using З-атіпо-9-ethylcarbazole as a substrate for peroxidase. After 
counterstaining with Meyers haematoxylin sections were mounted with Kaisers glycerin 
(Merck, Darmstadt, Germany). An incubation where the first antibody was omitted, 
served as a negative control. 
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Results 
Melano су tic lesions examined in situ 
For the in situ studies studies, 22 lesions were examined. Of these, 17 arose in the grafts 
of transgenic body skin, 2 were classified as nevi, 2 as melanotic tumors, 5 as mixed 
tumors (in which arridanone parts were much larger than melanotic ones), and 8 as 
amelanotic tumors. Five other lesions arose in the grafts of transgenic snout skin, 1 was 
classified as a nevus, 3 as mixed tumors (with substantially larger amelanotic than 
melanotic parts), and 1 as an amelanotic tumor (Table 2). 
As already noted previously (22), the earliest pigmentary change detected histologically in 
transplanted body skin of transgenic mice is melanocyte hyperplasia and 
hyperpigmentation. It is first unequivocally distinguishable in the superficial dermis. The 
possibility has not been ruled out that still earlier changes may occur in melanocytes in 
the epidermis. In mouse skin of the snout region, where the vibrissa follicles are 
especially prominent, spontaneous early melanomas have occasionally been seen within 
these follicles in Tyr-SV40E mice (2). Therefore, it seemed likely that by grafting 
transgenic skin from the snout area advanced melanomas might be experimentally 
obtained from intrafollicular melanocytes. This has proved to be the case. 
Zymographic evidence of plasminogen activity 
The results of in situ zymography to detect plasminogen activation in mouse melanocytic 
skin lesions are summarized in Table 2. Photographs taken at different times of incubation 
were examined and the time of inception of plasminogen activation-mediated lysis was 
estimated (from - to + + + +). Typical examples of the in situ zymographic records are 
shown in Figure 1. 
Figure 1. In situ zymography on fresh mouse melanocytic lesions in body skin lesions 
(rows α-e), in snout lesions (rows f-g) and in mouse lung (row h). Plasminogen 
activation was either absent or u-ΡΑ mediated in the melanocytic lesions (see also table 
2), t-PA mediated plasminogen activation was encountered in mouse lung. Row a: early 
nevus lesion, row b: melanotic melanoma lesion, row c: mixed melanoma lesion, u-ΡΑ in 
the amelanotic part, rows d and e: amelanotic melanomas, row ƒ.· snout skin with early 
lesions, row g: amelanotic snout tumor, row h: mouse lung, containing mainly t-PA. 
Columns: neg. control: casein layer without plasminogen, total PA: casein layer with 
addition of plasminogen, u-ΡΑ: casein + plasminogen + polyclonal antibody against 
human t-PA, t-PA: casein + plasminogen + amiloride. Magnification: bar equals 0.25 
cm. Incubation times at 37a: 3 hours (rows а, с and h), 4.5 hours (rows f and g) and 8 
hours (rows b and d). Optimal lysis shown. In the case of nevi and snout early lesions 
(row a andf): no t-PA or u-ΡΑ mediated lysis occured even at 7.5 hours of incubation. 
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neg. control total PA t-PA 
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u-ΡΑ 
Figure 1 
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t-PA enzyme activity was usually not detected, or was very localized, in the melanocyte 
lesions examined u-ΡΑ enzyme activity was absent in normal and transgenic body and 
snout skin It was also not detected in nevi of body skin (Figure la) or in intrafollicular 
nevi of snout skin (Figure If) While only very weak and delayed u-PA-mediated lysis 
was observed in the 2 melanotic tumors (including the one shown in Figure lb), marked 
and early u-ΡΑ activity was detected in the mixed and amelanotic tumors in body skin 
(Figure lc-e) and tumors in the vibrissa follicles (Figure lg) In a mixed tumor (Figure 
Id), lysis occurred much more rapidly m the amelanotic part of the tumor. In the group 
of mixed and amelanotic tumors in body skin, and in the group of vibrissa follicle 
tumors, heterogeneity was observed with respect to the time when lysis first occurred 
(Table 2). Within tumors, regions with early lysis occurred along with regions of delayed 
lysis or no lysis. 
In normal mouse lung, the specificity of t-PA plasminogen activation was documented by 
its virtual abolition with the t-PA inhibitory antibody #387 (Figure lh) It is noteworthy 
that the spotted lysis pattern proved to be correlated with strong t-PA immunostaining of 
the larger blood vessels with the t-PA antibody 
Immunolocalization of u-ΡΑ, PAI-1 and PAI-2 
Typical examples of the immunolocalization of u-ΡΑ, PAI-1 and PAI-2 are shown in 
figure 2 Staining of the 2 u-ΡΑ, the 2 PAI-1 and the 2 PAI-2 antibodies on melanocytic 
lesions compared well with each other 
Visualization of t-PA and u-PA 
In contrast to the strong vascular endothelial cell staining in the bigger blood vessels of 
mouse lung tissue, the melanocytic lesions hardly exhibited t-PA staining Endothelial cell 
staining was rarely encountered only 1 body skin melanoma, transgenic snout skin and 1 
amelanotic snout tumor exhibited t-PA positivity No other cell types or structures stained 
for t-PA. The immunohistochemical results were consistant with the t-PA activity results 
obtained with in situ zymography 
In the mixed and amelanotic tumors derived from body-skin grafts, u-ΡΑ staining of 
blood vessels, especially of small capilanes (Figure 2a), was striking Among these, 9 out 
of 13 showed staining of the capillary endothelium, 2 had occasional granulocyte staining 
(Figure 2b), and 5 had some u-ΡΑ positive fibroblastic cells Melanoma cells were only 
infrequently u-PA-positive, although 1 tumor had areas with appreciable numbers of u-
PA-stained melanoma cells Capillary staining was observed in all 4 tumors arising in the 
vibnssa follicles of snout skin 
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Table 2. Plasminogen activation based on in situ zymography of melanocytic lesions in 
Tyr-SV40E(C57BL/6) transgenic skin grafts 
Tissue or case no.' 
body skin 
C57BL/6 control 
Line 8 hemi. control 
320* nevus 
385* nevus 
335 
467 
Э71Р15 
306 
385* 
386 
320* 
390P1' 
390P2' 
303 
330 
305 
367 
371P2 
336 
snout skin 
C57BL/6 control 
Line 8 hemi. control 
340* nevus 
339 
340* 
338 
353 
Pigmentation2 
M A>M A 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Relative tumor size 
Small Medium Large 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Plasm, activator3 
t-PA u-PA 
+ 
+ 
+ 
+ + + 
+ + + + 
+ + + 
+ + + + 
+ + + + 
+ + 
+ + + + 
+ + 
+ + 
+ + + 
+ + + + 
+ + + ' 
+ + + 
+ + 
+ + + + 
Entries listed only by case numbers are melanomas 
Pigmentation of the melanoma lesion, based on examination at 15x magnification. 
M = melanotic, A>M = amelanotic part greater than melanotic, A = amelanotic 
Graded visually as -, no lysis; + + + + , + + +, + + , +, lysis present after 3, 4.5, 6 or 7.5 
hours respectively 
Comparison of a melanoma with premahgnant lesions in adjacent skin of a numbered case 
Independent primary melanomas (PI and P2) in the same skin graft of a numbered case 
t-PA mediated lysis was localized 
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Visualization of PAI-1 and PAI-2 
PAI-1 staining was observed in extracellular matrix (Figure 2d), endothelial cells (not 
shown) and fibroblastic cells (not shown). In mixed and amelanotic body skin tumors, 
extracellular matrix staining was observed in 6 out of 13 tumors, small vessels stained in 
2 cases, and fibroblastic cells in 5 cases. Endothelial cell staining was encountered in 1 of 
the tumors obtained in snout skin. Except for an epidermal stain in most lesions, no PAI-
2 could be detected in the melanocytic lesions themself. PAI-2 was present in tumor cells 
in 1 lesion (Figure 2 h). 
Plasminogen activation system near ulcerated skin 
Staining for u-ΡΑ, PAI-1 and PAI-2 at edges of the thickened epidermis near ulcerations 
caused by the tumor lesion was striking. An example of u-ΡΑ positive keratinocytes 
(Figure 20 and PAI-1 extracellular matrix staining (Figure 2e and g) within the same 
lesions is shown. 
Figure 2. Immunohistochemistry of components of the plasminogen activation system 
(u-ΡΑ, PAI-1 and PAI-2) on fresh mouse melanoma lesions. Typical staining examples 
for u-ΡΑ, PAI-1 and PAI-2 are shown. u-ΡΑ was found in cappilary sprouts in most 
melanoma lesions (a), in two cases in granulocytes (cells with lobed nuclei, b), and in 
the stroma (c). PAI-1 was found in the extracellular matrix (d), PAI-2 was rarely 
encountered, an example of tumor cell staining is shown in h. e-g: enhanced staining for 
PAI-1 (e, with a detail in g) and u-ΡΑ (f) at the thickened epidermis (arrow heads in e) of 
an ulcerated tumor, a-c, f: u-ΡΑ staining, d, e and g: PAI-1 staining, h: PAI-2 staining. 
Examples of u-ΡΑ stainings in a, b and с are from the same lesions as shown in the 
zymography composition, rows e, с and d respectively of figure I. Magnifications: bar 
equals 13 μχη (α-d and h), 26 μηι (fand g), or 67 μη (e). 
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Discussion 
The plasminogen activation system has been implicated in melanoma metastasis through 
experiments based on human or mouse melanoma cell lines and on models in which the 
cultured cells were introduced into mice (13,19,29,33,36). Established cell lines are in 
fact likely to be homogeneous with respect to production of certain proteins, whereas 
melanomas may be heterogeneous. For example, in human melanomas only a minonty of 
tumor cells, often at the periphery of the tumor, produce u-PA (7,8). Moreover, different 
components of the plasminogen activation system may vary quantitatevely among 
melanocytic lesions, depending on their stage in tumor progression. We report here the 
first in vivo investigation of the plasminogen activation system in an animal model of 
melanoma. 
The melanocytic lesions observed in this study arose in genetically uniform transgenic 
mice (2,21) and represent different stages in tumor progression. Intra- and intertumoral 
heterogeneity were found with respect to plasminogen activation. Within tumors, some 
regions exhibited earlier ΡΑ-mediated lysis than others. The time of onset of lysis also 
differed greatly among tumors. u-PA-mediated plasminogen activation predominated in 
the melanomas. With the methods used, it was undetectable in the premahgnant lesions 
represented by nevi, and also in normal or transgenic mouse skin. u-ΡΑ activity has also 
not been detected in human premahgnant lesions (7,8). By using adjacent sections of the 
transgenic mouse lesions for in situ zymography and immunohistochemistry, we could 
establish that u-ΡΑ activity was spatially associated with the presence of the protein. 
Immunohistochemical localization of u-ΡΑ in the endothelium of sprouting capillaries in 
the large majority of mouse melanomas was particularly striking. PAI-1 was also present 
in capillaries, albeit less frequently. This localization of mouse u-ΡΑ and PAI-1 in 
growing capillaries suggests a role in angiogenesis. Indeed, in models relying on cell 
lines, u-PA (24,35), its receptor (26) and PAI-1 (26) have been found to be expressed in 
angiogenesis. u-PA and PAI-1 are also believed to be involved in angiogenesis under 
physiological conditions (1). Little is known about the involvement of the plasminogen 
activation system in tumor angiogenesis, although PAI-1 mRNA has been found in 
vascular endothelial cells at the tumor-stroma interface in colon cancer (28), and 
angiogenesis is thought in general to facilitate growth and metastasis of tumors (reviewed 
in 11). 
Melanoma cells in the transgenic mouse tumors rarely showed u-PA activity, except for 
one tumor in which areas had appreciable numbers of u-PA positive cells. This may 
signal some difference between mouse and human melanomas, as in the latter a larger 
minority of the tumor cells produce u-PA. Possibly the melanoma cells do not directly use 
u-PA for metastasis and depend for this function on other proteases. Experimentally gene-
deficient mice lacking both u-PA and t-PA, or lacking PAI-1, are in fact capable of 
fibrinolysis and are healthy (3,4). 
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u-ΡΑ and the PAIs were also concurrently found at the thickened epidermal edges 
bordering sites of tumor ulceration, thereby implying a role in wound healing, as has 
been proposed for the PA system (12,30-32). 
In contrast to the u-ΡΑ results, t-PA was absent or low in the mouse melanocytic lesions, 
based on in situ zymography and immunohistochemistry. This was especially noteworthy 
in view of the abundant t-PA expresssion in melanoma cell lines and in human uveal 
melanoma (5,7-9,17,29). In the present study, t-PA protein and activity were detected by 
visual criteria only in the larger blood vessels of normal lung. Apparently, t-PA is very 
low in the smaller calibre blood vessels of mouse tissues but may be seen in small human 
vessels (7,8). 
u-ΡΑ is the paramount plasminogen activator in the in vivo mouse melanoma model, and 
its presence and activity increase with malignant progression. As u-ΡΑ (and to a lesser 
extent PAI-1) are predominantly localized in the endothelial cells of new vascular sprouts 
rather than in the melanoma cells, u-ΡΑ or both u-ΡΑ and PAI-1 might provide an 
experimental therapeutic target against neo-angiogenesis in melanomas and 
indirectly against melanoma progression. A caveat is the low expression at early stages 
and the variable expression within and among melanomas. 
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Abstract 
In tumor development, proteases like plasminogen activators (PAs) play a role in 
degradation of the extracellular matrix and other tissue barriers. Recently, we demon­
strated that plasminogen activators, their inhibitors, and urokinase receptor emerge in 
late stages of cutaneous melanocytic tumor progression. In this study we investigated 
the expression and distribution of the various components of the PA system and the 
presence of PA enzyme activity in 45 freshly frozen primary uveal melanomas with 
known follow-up (14 spindle- and 31 non-spindle-type) and in metastases (n =5). Tissue-
type PA (t-PA) was found in endothelium of blood vessels and in tumor cells in almost 
all lesions. t-PA was markedly present at the invasive front (towards the sclera and 
Bruch's membrane), but no correlation with tumor related death could be established. 
Urokinase PA (u-ΡΑ) was expressed focally, only by 5 non-spindle cell melanomas and 
in all metastases. u-ΡΑ expression correlated with occurrence of metastasis. u-PA 
receptor (u-PAR) was present in one third of all lesions examined. Plasminogen 
activator inhibitors (PAI-1 and PAI-2) were only found focally in approximately ten per­
cent of the lesions. In all metastases staining of t-PA, u-ΡΑ and PAI was observed. 
We conclude that in uveal melanoma, u-ΡΑ expression may be associated with metasta­
tic disease and accordingly with poor prognosis. Further research on a large group of 
tumors with known follow-up is needed to establish whether u-ΡΑ positivity is of 
additional prognostic value in uveal melanoma. 
Introduction 
To migrate from the primary tumor into blood vessels and to home and grow at a distant 
site in the body, tumor cells need an extensive repertoire of proteins (19). For migration 
through and breakdown of tissue barriers, proteases are required (37) An important 
proteolytic system involved in tumor progression comprizes the proteins of the plasmin­
ogen activation system (5,24). The two known plasminogen activators (PAs) are tissue-
type plasminogen activator (t-PA) and urokinase type plasminogen activator (u-ΡΑ). PA 
activity can be inhibited by specific PA inhibitors, PAI-1 and PAI-2 (17). u-ΡΑ activity 
can be focused at the cell surface by binding to its receptor (u-PAR) Also, u-ΡΑ activity 
can be enhanced by binding to the receptor, as the conversion of the inactive pro-u-PA to 
active u-ΡΑ is facilitated on the cell surface (10,15) Furthermore, by rapid internalization 
of u-PAR saturated with u-PA:PAI-l and recycling of u-PAR, the availability of u-PAR 
for u-ΡΑ binding is ensured (4,14,22) The saturation of the u-PAR is either autocrine or 
paracrine (1,26,27). 
The actual involvement of PAs in tumor cell migration and metastasis formation has been 
shown in several model systems (21,23,28). Elevated levels of u-ΡΑ, u-PAR and PAI in 
human malignant tumor tissue relative to the benign precursor lesion or normal tissue 
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have been reported for tumors of diverse origin (7,8,16,25,30,33). Furthermore, u-PA 
content has shown to be a valuable prognostic marker for mammary carcinoma (11,16). 
The role of t-PA in tumor progression however, is more ambiguous. Lower levels of t-
PA in tumors compared to benign lesions have been reported for tumors of the mammary 
gland (39) and the ovary (25). Regarding cutaneous melanoma, some reports indicate a 
high expression of t-PA in melanoma cell lines (18,20,28) and cutaneous melanoma 
lesions (6,18,20). 
We recently demonstrated both in a nude mouse model (28) and in fresh human cutaneous 
melanocyte lesions (8) a possible role for the plasminogen activation system in melanoma 
tumor progression. u-ΡΑ and PAI expression was related with high metastatic capacity of 
melanoma cell lines in nude mice (28). This was reflected in the in vivo situation in fresh 
human melanocyte lesions- u-ΡΑ, PAI-1 and PAI-2 but also t-PA and u-PAR emerge in 
late stages of cutaneous melanocyte tumor progression (8). 
In this study, we extended our investigation on the involvement of the plasminogen 
activation system in melanoma tumor progression to melanoma of the uvea. Melanoma of 
the uvea is the most common primary intraocular malignancy in adults (9). Several 
factors have been found to influence the prognosis. These include tumor cell type (spindle 
cell type has a better prognosis than non-spindle cell type) and tumor diameter. Uveal 
melanoma differs from cutaneous melanoma in several aspects. Uveal melanomas spread 
hematogeneously, preferentially to the liver, whereas cutaneous melanomas primarily 
metastasize lymphogenic. The estimated 5-year-survival rate for uveal melanoma is 75% 
(13) and comparable with cutaneous melanoma (34). The aim of this study was to 
investigate the expression of the different components of the plasminogen activation 
system in uveal melanoma. The presence of these proteins was studied on fresh human 
lesions of primary uveal melanoma and metastases of uveal melanoma using lmmuno-
histochemistry and in situ zymography. 
Material and Methods 
Tissue specimens 
Specimen from primary uveal melanomas were obtained from 45 patients treated at the 
Department of Ophthalmology, Erasmus University Rotterdam, The Netherlands, between 
1987 and 1992. The enucleated eyes were transported on melting ice to the Department of 
Pathology. After transillumination, the eyes were cross-sectioned through the tumor and 
part of the tumor was snap-frozen in OCT compound (Tissue-tek) and stored at -70°C 
The remainder of the eye was fixed in formalin and embedded in paraffin 
Five uveal melanoma metastases were from three patients from the skin (n=2), the heart 
(n=2) and from the liver (n=l) From 4 metastases, no primary tumor was available. 
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From one metastasis, the primary tumor was also included in this study. Metastases were 
from the Departments of Pathology of Nijmegen (n=4) and Rotterdam (n = l). 
Antibodies 
Rabbit anti-human t-PA and u-ΡΑ polyclonal antibodies were from the Gaubius Institute, 
Leiden, The Netherlands and have been used in earlier studies (8,28). Monoclonal anti­
bodies against human u-PAR (Jt 3936) and human PAI-1 (Jf 380) were purchased from 
American Diagnostica Inc., Greenwich CT, USA. The rabbit and goat polyclonal 
antibodies against human PAI-2 were a generous gift from E. Schuler, Behring Werke 
AG, Marburg, Germany. All antibodies against components of the plasminogen activaion 
system were used in a previous study (8). In that study, using parallel sections for mRNA 
in situ hybridization, we established with these antibodies that cells producing the mRNA 
also contained the protein. Detection of the melanocytic differentiation marker gplOO with 
monoclonal antibody NKI-beteb (38) was used to establish the melanocytic origin of the 
tumors. 
Immunohistochemistry 
For immunohistochemistry, 4 μπι cryostat sections were air-dried overnight at room 
temperature and stored at -80°C until use. Dilutions of the antibodies and staining 
procedure were as used before (8). Stainings with monoclonal antibodies were developed 
with an ABC technique, polyclonal antibodies with peroxidase-labeled anti-rabbit or anti-
goat secondary antibody. Bound antibodies were visualized by using 3-amino-9-ethylcar-
bazole as a substrate for peroxidase. After counterstaining the nuclei with Papanicolaou's 
Harris solution, sections were mounted with Kaisers glycerin (Merck, Darmstadt, 
Germany). A lymph node metastasis from a cutaneous melanoma, previously found to 
express abundant u-ΡΑ, u-PAR and PAI-1 protein, was used as a positive control; for 
t-PA, the staining of blood vessels served as internal control and for PAI-2, staining of 
sections from fresh human placenta served as positive control An incubation where the 
first antibody was omitted, served as a negative control. 
Score 
For each section, the percentage of positive melanocytic cells was estimated. Each section 
was assigned to one of the following categories: 0%, 1-5%, 5-25% and 25-100% 
positivity. Notes were taken of other staining components (fibroblast-like cells, extracel­
lular matrix) among the melanocytic areas. Sections were scored independently by two 
observers (CM. M., M.R. v. В.). Discrepancies were found in only a few cases. These 
cases were re-evaluated jointly until agreement was reached. 
118 
In situ zymography 
The technique has been described in great detail by Sappino et al. (31) and De Vnes et 
al. (8). Briefly, 8 /tm cryostat sections were covered with an overlay mixture containing 
dry milk, plasminogen and agar. At spots where plasminogen activation occurs, lysis of 
the gel takes place, making the gel transluminent. Addition of polyclonal antibodies 
against t-PA or u-ΡΑ to the gel allows discrimination between the two plasminogen 
activators. In addition, amiloride also inhibits u-ΡΑ specifically. With each incubation 
session, xenograft lesions of the human melanoma cell lines BLM or MV3, known to 
express abundant u-ΡΑ and hardly any t-PA (28), were included as positive control. 
Results 
Clinico-pathological data 
Histopathologic^ diagnosis was obtained on paraffin-embedded tissues. Cell type of the 
tumors was classified with the presence or absence of any epithelioid cells as criterium-
spindle (n=14, tumors containing only spindle cells) or non-spindle (n = 31, a combinati­
on of mixed and purely epithelioid tumors) (34). As other variables we measured: largest 
tumor diameter; tumor height, presence of episcleral growth, and presence of vascular 
invasion. All but two specimens examined, contained more than 50% viable tumor cells. 
Follow-up was available from all patients included in this study; from one of these 
patients a freshly frozen subcutaneous mestatane lesion was obtained. Eight out of 45 
patient died due to tumor related death (TRD), 3 died of other causes. The total mean 
follow-up was 34.7 months. 
In 10 eyes extrascleral growth was noted; 3 melanomas showed obvious vascular 
ingrowth. 
Immunohistochemistiy 
All primary tumors and metastases stained with NKI-beteb (38), recognizing gplOO, a 
melanocyte differentiation marker (not shown). 
Tissue sections were stained for t-PA, u-ΡΑ, u-PAR, PAI-1 and PAI-2. Typical examples 
of immunohistochemical staining are shown in Figure 1. The total number of lesions 
which stained for the different components is summarized in Table 1. In Figure 2, the 
percentage of stained melanocytic cells per cell type of uveal melanoma is displayed. 
t-PA 
In all lesions abundant t-PA immunoreactivity was found in the wall of blood vessels 
(Figure la). The correlation between t-PA expression and cell type is shown in Figure 2: 
42 out of 45 tumors contained t-PA, however a moderate to abundant staining ( > 5 % 
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tumor cells, n = 16) was seen predominantly for non-spindle cell type tumors (14/16). 
Interestingly, in 4 tumors t-PA staining was strikingly in nests of pleomorphic epithelioid 
cells. These cells were located perivascular at both invasive fronts, towards the sclera 
(Figure lb) and towards Bruch's membrane (Figure lc). There was no relationship 
between percentage of t-PA positivity and TRD. All metastases contained t-PA. 
u-ΡΑ and u-PAR 
While no u-ΡΑ expression could be detected in any spindle cell type tumor tested, focal 
u-ΡΑ staining (<5%) of tumor cells as well as staining of fibroblast-like cells was 
detected in 5 non-spindle cell tumors. In 2 cases u-ΡΑ expression correlated with TRD, 
one patient is known to have metastases, and for 2 patients follow-up was short (32 and 
18 months). All 5 metastases expressed u-ΡΑ protein (Figure Id). 
Focal u-PAR immunoreactivity (<5%) was seen in 15 tumors; 11 out of 15 were non-
spindle cell tumors. Both tumor cells (Figure le) and stromal cells showed a cytoplasmic 
staining aspect. Two metastases contained u-PAR. 
PAI-1 and PAI-2 
PAI-1 protein was observed in only 6 primary tumors (3 were of the spindle cell type), 
but in the majority of metastasis lesions (4 out of 5). The localization was in tumor cells 
and in the extracellular matrix (Figure If)· 
PAI-2 protein was observed in 5 out of 45 tumors and was found only in lesions of the 
non-spindle cell type. PAI-2 was expressed both by tumor cells and fibroblast-like cells 
(Figure lg). One metastasis contained PAI-2. 
Figure 1. Immunohistochemical staining of components of the plasminogen activation 
system in fresh human uveal melanoma lesions. Typical staining examples in primary 
lesions (a-c, e-g) and a metastasis (d) are shown, a: t-PA protein in blood vessels, b: t-
PA present in tumor cells at the scleral (Sc) invasive front and c: in tumor cells adjacent 
to the retinal pigment epithelium where Bruch 's membrane (Br) is ruptured (rupture not 
seen), d: u-ΡΑ is present in tumor cells in this metastasic lesion, e: u-PAR is located at 
the invasive front towards the sclera in this lesion, f: network-like PAI-1 distribution in 
the extracellular matrix surrounding tumor cells, g: PAI-2 was found focally in the stroma 
and in tumor cells (not shown). Cell types: spindle cell tumors (a) and non-spindle cell 
tumors (b-c, e-g). 
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Figure 1. See also color display on page 159. 
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In 2 out of 5 u-ΡΑ positive tumors, u-PAR and PAI were found in the same lesion, both 
patients died from metastatic disease. One of these two patients showed expression of all 
five components. A trend towards higher expression (higher percentage of immunoreacti-
ve cells) and a higher percentage of positive lesions in non-spindle compared to spindle 
cell lesions for t-PA, u-ΡΑ, u-PAR and PAI-2 can be deduced from figure 2. 
t-PA u-ΡΑ u-PAR 
PAI-1 PAI-2 
[ 3 1-5 % ^Ш 5-25 % ^ В 25-100 %, tumor cel ls 
f _J total percentage of lestons with immunoreactivity 
Figure 2. Percentage of immunohistochemically stained tumor cells and percentage of 
immunoreactive lesions including staining of extracellular matrix and stroma cells (e 
and s in Table 1), expressed as percentage of the total number of lesions. Fourteen 
tumors had purely spindle cell type (spindle) morphology and 31 tumors (either of mixed 
origin or purely epithelioid) contained epithelioid cells (non-spindle). In non-spindle cell 
melanomas, a higher percentage of positive lesions and higher percentages of positive 
cells is observed for t-PA, u-ΡΑ, u-PAR and PAI-2. Metastases are excluded from this 
diagram due the low numbers included in this study. See also Table I. 
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Table 1. Immunohistochemical staining of the components of the plasminogen activati-
on system in primary uveal melanomas and in metastases of uveal melanoma. 
Primary uveal melanoma (n • 
Spindle (n = 
t-PA 
u-PA 
u-PAR 
PAM 
PAI-2 
Non-spindlt 
t-PA 
u-PA 
u-PAR 
PAM 
PAI-2 
Metastases 
t-PA 
u-PA 
u-PAR 
PAI-1 
PAI-2 
-14) 
>(n = -31) 
=45) 
of uveal melanoma (n • 
t' 
13 
0 
3 
2 
0 
29 
5 
12 
1 
5 
=5) 
4 
5 
2 
3 
0 
s 
3 
0 
1 
2 
0 
16 
2 
5 
3 
3 
1 
4 
0 
1 
1 
e 
3 
0 
0 
1 
0 
5 
0 
0 
2 
1 
3 
1 
0 
1 
0 
toti 
13 
0 
3 
3 
0 
29 
5 
14 
3 
5 
5 
5 
2 
4 
1 
't = staining of tumor cells, s = stromal cells, e = extracellular matrix stained in these 
lesions 
In situ zymography 
In situ zymography was performed on sections of all lesions studied In all cases, t-PA 
activity was found, often in a dotty pattern (Figure 3, first row) By comparing the lysis 
pattern with the hematoxylin and eosin stained sections, we could assign t-PA activity to 
blood vessels. Lysis in tumors with t-PA immunoreactivity in the highest category (25-
100%) occured faster and more general throughout the section (compare Figure 3, first 
and second row). Also in a few metastases we could detect t-PA activity in an area with 
mainly tumor cells (Figure 3, third row) Except for the positive control BLM and MV3 
xenografts (Figure 3, fourth row), no u-PA activity could be detected in all lesions 
studied. 
123 
neg. t-PA+ t-PA u-PA 
control u-PA 
Figure 3. In situ zymography on fresh uveal melanocytic lesions. Plasminogen activation 
was t-PA mediated in all cases studied and located in blood vessels and in tumor cells. 
Examples are shown of three cases. One non-spindle uveal melanoma had t-PA immuno-
reactivity in blood vessels but not in tumor cells (first row). One non-spindle uveal 
melanoma where 5-25 % of the tumor cells stained for t-PA in immunohistochemistry 
(second row); note that lysis is more abundant at the sclera site (arrow). Also a metasta-
sis of uveal melanoma (third row) showed more generalized t-PA mediated lysis. A u-PA 
positive MV3 xenograft, where t-PA mediated lysis had not yet occured, is included 
(fourth row). Columns: neg. control: casein layer without plasminogen; u-PA + t-PA: 
casein layer with addition of plasminogen; t-PA: casein layer + plasminogen + polyclo-
nal antibody against u-PA; u-PA: casein layer + plasminogen + polyclonal antibody 
against t-PA. Incubation times at 37°C: 5 hours in all uveal melanoma cases (top three 
rows) and one hour (fourth row). 
Discussion 
We recently studied the involvement of plasminogen activation in melanoma tumor 
progression both in a nude mouse system and in the in vivo situation on sections of fresh 
human cutaneous melanocytic lesions. u-PA, PAI-1 and PAI-2 expression in human 
melanoma cell lines correlated with a high metastatic capacity in nude mice. All cell lines 
contained t-PA and u-PAR (28). In human cutaneous melanocytic lesions, u-PA, PAI-1 
and PAI-2 but also t-PA and u-PAR were found in the most malignant lesions only 
(advanced primary melanomas and melanoma metastases) (8). Here, we extended our 
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study on the involvement of the plasminogen activation system in melanocyte lesions to 
uveal melanoma. Once the diagnosis of metastatic disease in uveal melanoma is made, 
(usually by fine needle aspiration), the following median survival is only 2-4 months 
(29,32) Therefore metastatic tissue is hard to access and only five metastases were stu­
died Little is known about the presence of proteases in uveal melanoma lesions. The 
involvement of proteases in metastatic spread of uveal melanoma has recently been 
suggested by Cottam et al (3), who detected the 72 and 92 kD type IV collagenase in 
culture medium of 15 primary cultures of uveal melanomas Furthermore, t-PA activity in 
supernatants of primary cultures of uveal melanoma seemed to correlate with scleral 
invasion in the tumor lesion, whereas no u-ΡΑ activity could be detected (2) Interestin­
gly, the choroid itself expresses t-PA (35) and u-PA (36) 
In our study, t-PA protein was expressed by tumor cells in the vast majority of the 
lesions Expression of t-PA in uveal melanoma therefore does not differ from previous 
reports on melanoma as a source for t-PA abundant t-PA was found in melanoma cell 
lines (9,18,20,28) and in cutaneous melanocyte lesions (18) t-PA was expressed in a 
larger percentage of the tumor cells in non-spindle cell tumors Immunoreactive cells 
often had a perivascular localization Also, the localization of t PA positive cells at both 
the scleral and Bruch's membrane invasion front was remarkable This observation is in 
agreement with Cottam et al (2), who found that elevated t-PA activity in primary cultu­
res of uveal melanoma correlated with scleral invasion t-PA positivity was noted in 
varying percentage (0% up to 25-100% categories) in patients which already died from 
TRD as well as in patients which were still alive No relationship between extent of t-PA 
positivity and TRD could be established 
u-ΡΑ expression was found focally in only 5 primary uveal melanomas Interestingly, all 
these lesions were of the non spindle type In 2 cases u-ΡΑ expression correlated with 
TRD, one patient is known to have metastases and for two patients, follow-up was 
relatively short Also, all metastases contained u-ΡΑ positive cells Therefore, a clear 
association with progression of disease exists, as could be found for some other types of 
tumors (7,16,25,33), including cutaneous melanoma (8) Furthermore, u-ΡΑ positivity 
might be an additional prognostic marker for uveal melanoma Nevertheless, six cases 
with TRD did not display u-ΡΑ positivity Therefore, though the relation between u-PA 
positivity and progression of disease could be demonstrated in this study, a more extensi­
ve study has to be performed lo determine whether u-PA is a valuable prognostic marker 
for uveal melanoma 
With in situ zymography, we were only able to detect t-PA (both blood vessel and tumor 
cell-associated) and no u-PA activity, which is in agreement with findings in primary 
cultures of uveal melanoma (2) Apparently, the u-PA detected by immunohistochemistry 
is either of the inactive pro-form or inactivated by PAI This view is supported by the 
fact that the staining was only cytoplasmic, where u-PA is normally in the inactive form 
Also, the in situ zymography with region sensitivity rather than cellular sensitivity, might 
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be too insensitive to detect less than 5% scattered u-ΡΑ positive cells. 
The expression of u-PAR in by far more lesions than u-ΡΑ is remarkable, though it is in 
agreement with our earlier findings in human melanoma cell lines (28), where all cell 
lines, including the non-metastatic ones, expressed u-PAR. u-PAR was found cytoplas­
mic, indicating that at least a portion of u-PAR was not available for binding pro-u-PA 
(14). Receptor-bound pro-u-PA is more efficiently converted to active u-PA (10,27). 
For t-PA, u-ΡΑ, u-PAR and PAI-2, a higher expression (higher percentage of staining as 
well as a higher number of lesions involved) was found in the non-spindle cell uveal 
melanomas (Figure 2) as compared to the spindle cell melanomas which have a better 
prognosis. These observations and the fact that these components were also frequently 
detected in metastases, suggest a tendency with progression of disease in this study. 
Surprisingly, though 4 out of 5 metastases were positive, in primary tumors, this 
tendency could not be established for PAI-1, which is a prognostic marker for mammary 
carcinoma (30). 
By comparing the involvement of the plasminogen activation system in uveal and 
cutaneous melanoma (8), we can summarize the following differences: 1) Using the same 
polyclonal antibody, t-PA was found in almost all primary and metastatic lesions of uveal 
melanoma, whereas in cutaneous melanoma, only a few metastases contained t-PA 
positive tumor cells. 2) In cutaneous melanoma, lesions expressing u-ΡΑ expressed also 
u-PA's regulators u-PAR and PAI. For uveal melanoma, this co-expression was not as 
profound (Figure 2). 3) Uveal melanomas express u-ΡΑ, PAI-1 and PAI-2 in approxima­
tely 10% of the lesions, whereas in cutaneous melanoma approximately 60% of the 
thicker primary lesions were positive. In addition, less tumor cells stained in uveal 
immunoreactive lesions (all u-ΡΑ, PAI-1 and PAI-2 positive lesions were scored in the 1-
5% category). Similar to cutaneous melanoma, u-ΡΑ is associated with progression of 
disease in uveal melanoma. In uveal melanoma, other proteolytic systems could be of 
more importance in metastatic spread, compared to cutaneous melanoma. 
From our study, we conclude that in uveal melanoma, u-ΡΑ expression may be associated 
with metastatic disease and accordingly with poor prognosis. In our opinion, it would be 
worthwhile to extent research on the presence of u-ΡΑ in uveal melanoma to a large 
group of tumors with known follow-up. In this way, it could be established whether u-PA 
positivity is of additional prognostic value in uveal melanoma. 
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Chapter 7 
General discussion 
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Part of this chapter is accepted for publication in Melanoma Research as "The 
plasminogen activation system in melanoma cell lines and in melanocytic lesions - a 
review" 
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In recent years, the localization of mRNAs and proteins of the plasminogen activation 
system and of related proteins in cutaneous melanocytic tumor progression has been 
elucidated. In 1979, Fraki and co-workers were the first to find elevated levels of 
plasminogen activators in extracts of primary melanomas and melanoma metastases 
compared to extracts of nevi (14) Until recently however, although the possible role of 
the plasminogen activation system in metastatic spread of melanoma cell lines had been 
well established, no extensive study on plasminogen activation compnzing all stages of 
melanocytic tumor progression existed The first few studies on plasminogen activation 
included a limited senes of lesions (18, 19, 22, see Table 1) In these early studies, the 
presence of both t-PA and u-ΡΑ in melanoma tissue was well recognized (19, 22) In a 
small senes, Markus et al could attribute 77% of the plasminogen activator activity to u-
PA (19). This is interesting in the light of recent findings, where it was descnbed that 
melanoma cells in cutaneous primary lesions producing t-PA mRNA, often also make the 
mRNA for PAI-1. Contrasting this, u-ΡΑ positive melanoma cells are located beyond the 
front of melanoma cells which produce the PAI-1 mRNA (7) It was also descnbed that 
only a minonty of melanoma cells produce u-ΡΑ and that these cells are often localized at 
the edge of a tumor (7, 8) The PAI-1 protein in these u-ΡΑ positive melanomas is often 
localized in the extracellular matrix within the tumor, surrounding nests of tumor cells, 
thus probably protecting the intratumoral extracellular matrix from degradation (8) 
From recent studies on plasminogen activation in cutaneous melanoma, it becomes clear 
that the presence of the components of the plasminogen activation system contributes to 
the acquired phenotype, since these components emerge in melanocytic tumor 
progression Using a sensitive mRNA in situ hybridization technique, Delbaldo et al 
could detect mRNA for u-ΡΑ and PAI-1 already in atypical nevi, although no u-PA 
enzyme activity could be detected (7) In a parallel study, u-ΡΑ mRNA, protein and 
activity could only be detected in late stages of melanocytic tumor progression (8) Also 
in uveal melanoma, a similar induction was seen When comparing uveal melanomas with 
only spindle cells and uveal melanomas, containing epithehod cells in the lesions (which 
have a worse prognosis), expression of t PA, u-ΡΑ, u-PAR and PAI-2 was either absent 
(u-ΡΑ and PAI-2) or expression was decreased (t-PA, u-PAR) in the first group 
Furthermore, u-ΡΑ and PAI were expressed in all metastases included in that study A 
stnking difference in uveal melanomas compared to cutaneous melanomas is the high 
expression of t-PA found in all lesions (9) 
The predominant presence of PAI-1 in the extracellular matrix relative to the presence in 
tumor cells, is a consistent finding in various melanoma lesions This is observed in 
cutaneous melanomas (8), in uveal melanomas (9), in xenografts of PAI-1 producing 
human melanoma cell lines (11) and in mouse melanomas (10) 
Two proteins related to and closely associated with the plasminogen activation system are 
plasminogen and tetranectin Plasminogen is the substrate for plasminogen activators, 
which can be converted into active plasmin Tetranectin is a plasminogen binding protein 
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Table 1: Literature survey of studies on components of the plasminogen activation system and related 
proteins in human cutaneous melanocyte lesions. 
Ref. 
14 
19 
18 
22 
8 
7 
12 
13 
Type of 
lesions1 
9NN 
6 PM 
5 MM 
16 MM 
5 PM 
5 MM 
4 PM 
25 NN 
16 AN 
8ePM 
11 aPM 
17 MM 
11 NN 
8 AN 
6 SSM 
6 NM 
24 NN 
14 AN 
12ePM 
20aPM 
35 MM 
22 NN 
12 AN 
lOePM 
26aPM 
37 MM 
Techniques 
employed2 
PA activity 
assay 
PA activity 
assay, 
IHC 
IHC 
IHC 
IHC, RISH, 
ISZ 
RISH, ISZ 
IHC 
IHC 
Components 
included 
PA' 
t-PA, u-PA 
t-PA 
t-PA, u-PA, 
PAI-1, 
PAI-2, PAI-3 
t-PA, u-PA 
u-PAR, 
PAI-1, PAI-2 
t-PA, u-PA, 
PAI-1, PAI-2 
plasminogen/ 
plasmin, 
tetranectin 
LRP, RAP 
Major findings4 
- PA activity ΡΜ,ΜΜ > NN 
- 77% PA activity u-PA in metastases 
- u-PA is membrane-associated ш tumor 
cells; weak stromal staining 
- t-PA present in tumor cells in all 
lesions studied 
- t-PA intense in 3 lesions, u-PA in 
minority of tumor cells in 1 case, 
- PAI-1 absent, PAI-2 faint in one case, 
PAI-3 in areas of necrosis 
- upregulation of all components in 
progression of disease· components are 
present in late stages of melanocyte 
tumor progression 
- u-PA, PAI-1 mRNA already in AN, 
- u-PA producing cells beyond front PAI-1 
producing cells 
- plasminogen/plasmin and tetranectin 
co-localize at the invasive front of 
melanomas, 
- hardly any tumor cell staining 
- decreased expression of LRP and RAP 
in melanocyte tumor progression, 
- LRP and RAP are co-expressed and 
co-localized 
' NN = (common) naevocellular nevus, AN = atypical nevus, ePM = early primary melanoma, 
Breslow < 1.5 mm, aPM = advanced primary melanoma, Breslow ^ 1.5 mm, SSM = superficial 
spreading melanoma, NM = nodular melanoma, MM = metastasis of melanoma 
:
 IHC = lmmunohistochemistry, RISH = mRNA in situ hybridization, ISZ = in situ zymography 
3
 No discrimination was/could be made between t-PA and u-PA, ' See text for details 
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in the extracellular matrix (5, 6). In cutaneous melanocyte tumor progression, we found 
elevated expression of both tetranectin and plasmin/plasminogen. Both proteins exhibited 
a similar tissue distribution and by using parallel sections, we could demonstrate that the 
two proteins co-localize (12). A similar co-distribution was recently described for 
colorectal cancer (20). Interestingly, and significant for understanding plasminogen 
activation in tissue sections, both proteins were only rarely associated with tumor cells. 
Their localization was around tumor nodules and mainly stromal, often in fibroblastic 
cells or more diffuse, and occasionally in the extracellular matrix. In tumors of the 
mammary gland (4) and in tumors of the ovary (17), a similar fibroblast-distribution for 
tetranectin has also been reported. 
Since the low density lipoprotein receptor-related protein (LRP) was recently described as 
a protein to be involved in binding and internalization of (inactivated) plasminogen 
activators (1, 15, 16), we recently studied the presence of LRP and its receptor-associated 
protein (RAP) in human cutaneous melanocyte lesions. RAP co-purifies with LRP and 
other members of the LDL receptor family and is a chaperone protein of LRP (3, 21). In 
human melanocyte lesions, we found a strong co-expression of LRP and RAP. 
Surpnzingly, and not in line with our expectations, we found high LRP and RAP 
expression in benign stages of cutaneous melanocytic tumor progression and a lower 
expression when expressed as a percentage of positive melanocytic cells in primary tumor 
and in metastases (13). In addition, the distribution in primary melanoma lesions and in 
metastases was quite different from the u-ΡΑ distribution. Therefore, a correlation 
between u-ΡΑ and LRP expression in cutaneous melanocytic tumor progression seems not 
to exist. However, the u-ΡΑ producing and highly metastatic human melanoma cell lines 
BLM and MV3 produce large amounts of LRP at the cell surface. 
The spatial relationship of the proteins of the plasminogen activation system could reflect 
movement or retardation of cells within the tissue. When we focus mainly on u-ΡΑ, its 
receptor u-PAR, its zymogen plasminogen, and its inhibitor PAI-1 at the invasive front, 
Figure 1: Spatial relationship between the components of the plasminogen activation 
system in a human invasive melanoma. The spana! distribution of the components u-PA, 
u-PAR, PAI-1 and plasminogen/tetranectin is depicted in this scheme, based on 
immunohistochemical and RNA in situ hybndizanon observations in human lesions. 
Detached tumor cells and fibroblasts are u-ΡΑ positive. These tumor cells also make u-
PAR, although the expression of u-PAR was not only found at the invasive front. Also 
fibroblasts produce u-PAR occasionally. Tetranectin and plasminogen are found in 
fibroblasts at the invasive front, PAI-1 is found in the extracellular matrix deeper in the 
tumor, surrounding nests of tumor cells. See text for details 
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we can summarize the following spatial relationship (Figure 1). In the process of 
dissemination, active u-ΡΑ (bound to u-PAR) is present at the edge of a tumor, where no 
PAI-1 is present. PAI-1 is present in the extracellular matrix deeper in the tumor, often 
surrounding small groups of tumor cells. u-PAR is also present in fibroblasts but to a 
lesser extent as u-ΡΑ. u-PAR is also present in tumor cells, at the periphery of the tumor 
and deeper in the tumor in a minority of the tumor cells. The u-ΡΑ positive tumor cell 
can utilize plasminogen which is found in fibroblasts surrounding the invading tumor 
cells. Since fibroblasts also produce u-ΡΑ, we would like to propose an escort function 
for fibroblasts which surround invading tumor cells. These tumor cells can take up u-PA 
produced by these fibroblasts in a paracrine fashion (see 2). Since plasminogen and 
tetranectin co-localize, it is likely that plasminogen is bound to tetranectin. This 
tetranectin-bound plasminogen can act as a feeder layer for migrating tumor cells: 
migrating u-ΡΑ positive tumor cells can utilize the plasminogen present in their direct 
surroundings. Fibroblasts themselves, on the other hand, can also use u-ΡΑ bound to u-
PAR, tetranectin and plasminogen for fibroblast migration into or around the tumor. 
This thesis clearly demonstrates that in melanocytic tumor progression, the presence of 
the various components of the plasminogen activation system is associated with 
malignancy, like has previously been shown for various tumors. Whether the presence 
and the extent of expression of these components in a human primary melanoma lesion 
can inform the physician more about the prognosis of the patient is the current topic of 
investigation. 
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Summary 
The foremost cause of death of cancer patients is metastatic disease The involvement of 
proteases in metastatic spread of tumor cells has been known for some time This thesis 
describes the presence of one protease system in the various stages of melanocytic tumor 
progression. 
The proteolytic system studied here is the system of plasminogen activation Two 
plasminogen activators are known, tissue-type plasminogen activator (t-PA) and urokina-
se-type plasminogen activator (u-ΡΑ) u-ΡΑ can bind to a specific receptor, u-PAR, at the 
cell surface. u-ΡΑ is thought to play a role in cell migration, t-PA has a dominant role in 
fibrinolysis. Both plasminogen activators can be inhibited by two plasminogen activator 
inhibitors, PAI-1 and PAI-2. Plasminogen is the inactive protease which is converted to 
the active enzyme plasmin upon cleavage by plasminogen activators This protease can 
either directly degrade the extracellular matrix or can activate other inactive proteases 
Thus, one can envisage plasminogen activators as key-proteases at the beginning of a 
proteolytic cascade. 
Chapter ƒ is a review of the literature and describes the role of the components of the 
plasminogen activation system in invasive and metastatic processes Invasion of tumor 
cells can be mimicked in the laboratory Tumor cell lines can be cultured from freshly 
removed tumors These cell lines can be characterized with respect to their protease 
content. By adding inhibitors of plasminogen activators in in vitro invasion assays, the 
role of plasminogen activators in this process can be studied The presence of the various 
components of the plasminogen activation system in human tumors is also described in 
chapter la. From assays using tumor sections or tumor homogenates, a general opinion 
on the presence of the plasminogen activation system in various types of tumors has been 
established. Compared to the surrounding tissue and compared to benign precusor lesions, 
most tumors contain elevated levels of u-ΡΑ, u-PAR and PAI-1 t-PA and PAI-2 are 
elevated in some tumors, but often the reverse phenotype is encountered 
In chapter lb, the specific question is addressed whether u-ΡΑ but also t-PA can 
contribute to the invasive and metastatic behavior of melanoma cells In many tumors, u-
PA and not t-PA has been associated with metastatic behavior and thus a poor prognosis 
for the patient With respect to plasminogen activation, melanoma cell lines differ from 
cell lines from tumors of a different origin. Apart from secretion of u-ΡΑ, melanoma cell 
lines make abundant t-PA Chapter lb reviews the possible role of t-PA and u-ΡΑ in 
invasion and metastasis experiments using melanoma cell lines 
The presence of t-PA, u-ΡΑ, PAI-1 and PAI-2 in human cutaneous melanocytic lesions is 
described in chapter 2 Surgically removed common and atypical nevi, early (thin) and 
advanced (thick) primary melanoma and metastatic lesions were analyzed with respect to 
the presence of these components 
Three techniques were employed 
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- in situ zymography to detect t-PA and u PA enzyme activity , 
- immunohistochemistry to determine protein expression and localization of t-PA, u-PA, 
u-PAR, PAI-1 and PAI-2, 
- RNA in situ hybridization to study expression and localization of the corresponding 
mRNAs. 
All three techniques were applied on all types of melanocyte lesions 
We concluded that all five components emerge in late stages of melanocytic tumor 
progression. We could only detect these components in advanced primary melanomas 
(with a thickness ^ 1 5 mm) and in metastasis lesions Apart from this, t-PA could be 
detected in the endothelium of blood vessels in all lesions studied Not only tumor cells at 
the edge of a tumor, but also fibroblasts contained u-ΡΑ PAI-1 was produced by tumor 
cells and the protein could be detected mainly in the extracellular matrix 
Chapter 3 describes the presence of plasminogen/plasmin and the plasminogen-binding 
protein tetranectin in human cutaneous melanocytic lesions Tetranectin and plasminogen 
could be detected in comparable cell types and structures, mainly in the malignant stages 
of melanocytic tumor progression Both proteins were found in fibroblasts and in the 
extracellular matrix of tumors and hardly in tumor cells A mechanism is proposed where 
migrating u-ΡΑ producing tumor cells use the tetranectin bound plasminogen around the 
tumor 
u-ΡΑ and t-PA can bind to and can be internalized by LRP (low density lipoprotein 
receptor-related protein) LRP is shuffled towards the membrane in the constant company 
of the chaperone protein RAP (receptor associated protein) By binding to LRP, RAP 
avoids premature binding of other hgands for LRP in the secretion route The presence of 
LRP and RAP in melanoma cell lines and in human cutaneous melanocytic lesions is 
described in chapter 4 LRP is present in all cell lines, but elevated levels are found in u 
PA producing cell lines. In xenografts of these cell lines in immune deficient mice, only a 
fraction of the u-ΡΑ positive cells also produce LRP Expression of LRP and RAP is high 
in the benign melanocytic lesions and is down regulated with malignancy LRP and RAP 
co-localize in melanocytic lesions and in cultured melanoma cell lines From the results 
dexcnbed in this chapter, it can be concluded that a correlation between u-ΡΑ and LRP 
production seems not to exist in melanocytic lesions and in melanoma cell lines 
The plasminogen activation system is thought to be a potential target for cancer therapy 
(see also chapter la) Valid animal models for human tumors are required to enable 
testing of potential therapeutics Most animal models are based on tumor cell lines, which 
are often very homogeneous with respect to expression of a certain protein repertoire A 
heterogeneous animal model for melanoma is the Tyr SV40 transgenic mouse model The 
melanocytic lesions which occur in this model comprize nevi, pigmented and non-
pigmented melanomas and metastases of melanoma In chapter 5, the presence of t-PA, 
u PA, PAI-1 and PAI-2 in these lesions is studied, using immunohistochemistry and in 
situ zymography Although no t-PA and hardly any PAI-2 was detectable, a clear 
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tendency was observed towards higher u-ΡΑ expression in more malignant, less differenti­
ated tumors. u-ΡΑ was mainly found in sprouting endothelial cells, suggesting a role in 
angiogenesis. 
Melanocytes are also found in the uvea, the connective tissue of the eye. From these 
melanocytes, a uveal melanoma can arise. The presence of t-PA, u-ΡΑ, u-PAR, PAI-1 
and PAI-2 in these types of lesions is described in chapter 6. Based on histology, uvea 
melanomas can be subdivided into two categories, those which contain only spindle cells 
and have a good prognosis, and those containing epitheloid cells which have a poor 
prognosis. Only in the latter category u-ΡΑ and PAI-2 could be detected. Furthermore, 
these tumors also contain more t-PA and u-PAR. All metastasis lesions contained u-PA. 
Also in uveal melanomas, expression of the various components of the plasminogen 
activation system is correlated with the more aggressive type of tumor. 
The spatial relationship between u-ΡΑ, u-PAR, PAI 1, tetranectin and plasminogen is 
discussed in chapter 8 A hypothesis about the integrated concerted action of these 
components is given. 
The main conclusion of this thesis is that the components of the plasminogen activation 
system in three types of melanomas (cutaneous, uveal and an animal model for cutaneous 
melanoma) are associated with malignancy. Future work should learn us whether these 
components are useful as prognostic markers in melanoma patients 
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Samenvatting 
Het menselijk lichaam is opgebouwd uit organen, organen bestaan uit verschillende 
weefsels en weefsels op hun beurt zijn opgebouwd uit cellen. Cellen zijn omringd door 
een extracellulaire matrix van structuureiwitten. Deze matrix verleent de cellen, weefsels 
en organen stevigheid. Tijdens verschillende processen in het menselijke lichaam vormt 
deze matrix een barrière. Bij wondgenezing bijvoorbeeld, zullen cellen aan de rand van 
de wond naar het centrum van de wond willen migreren om zo de wond te kunnen 
dichten. Ook bij de eisprong migreert de rijpe oocyt door het ovariumweefsel heen 
voordat de oocyt vrijkomt. Deze migrerende cellen zullen de hen omliggende extracellu-
Iaire matrix moeten afbreken om zich te kunnen verplaatsen. Voor dit proces van afbraak 
maakt de cel een speciaal type eiwit: een protease. Dit type eiwit kan door de cel 
uitgescheiden worden en zo kan de extracellulaire matrix afgebroken worden. 
Lichaamscellen kunnen ontsporen. Ze gaan ongecontroleerd groeien en delen en zo 
ontstaat een tumor. Tumorcellen kunnen de oorspronkelijke tumor verlaten en kunnen de 
bloedbaan bereiken en via deze uitzaaien naar andere organen. Om de bloedbaan te 
kunnen bereiken, moet eerst de extracellulaire matrix van het bloedvat afgebroken 
worden. Ook deze uitzaaiende tumorcellen produceren proteasen en kunnen zo migreren 
door het omringende weefsel. 
Het grootste orgaan van de mens is de huid. Een laag percentage cellen in de opperhuid 
produceert het pigment melanine dat ons tegen het zonlicht beschermt. Deze gespeci-
aliseerde cellen heten melanocyten. Soms vermeerderen ze zich plaatselijk en worden 
hierbij zichtbaar als moedervlekken. De tumor die ontstaat uit deze pigmentcellen heet 
melanoom. Van de vele tumorsoorten die bekend zijn is het melanoom één van de 
kwaadaardigste en slechtst te genezen. Bovendien komt het melanoom steeds vaker voor, 
mogelijk veroorzaakt door een toegenomen blootstelling aan zonlicht. 
Dit proefschrift beschrijft de aanwezigheid van een proteasesysteem, het plasminogeen 
activatie-systeem, in verschillende stadia van ontwikkeling van het melanoom. Dit 
systeem is een proteolytisch systeem dat bestaat uit twee proteasen, een receptor en twee 
remmers van de proteasen. De twee proteasen heten plasminogeen aclivatoren, en heten 
weefseltype plasminogeen activator (t-PA, naar het Engels: tissue-type plasminogen 
activator) en urokinase-type plasminogeen activator (u-ΡΑ). Het uitgescheiden u-ΡΑ kan 
aan de buitenkant van de cel binden aan een specifiek bindingseiwit, de u-ΡΑ receptor (u-
PAR). t-PA speelt vooral een rol in de bloedstolling. Het zorgt er voor dat het bloed 
vloeibaar blijft. Twee eiwitten kunnen de plasminogeen activatoren remmen, PAI-1 en 
PAI-2 (plasminogen activator inhibitor). Plasminogeen activatoren zetten het inactieve 
protease plasminogeen om in actief piasmine. Dit protease kan de om cellen gelegen 
extracellulaire matrix afbreken en andere, inactieve proteasen activeren. Aan de plasmin­
ogeen activatoren wordt een sleutelrol toegedicht in de afbraak van de extracellulaire 
matrix. 
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Hoofdstuk 1 is een literatuuroverzicht waarin de rol van de componenten van het 
plasminogeen activatie-systeem in invasief gedrag en tijdens uitzaaien (metastaseren) van 
tumoren wordt beschreven. Invasief en metastaserend gedrag van tumorcellen kan in het 
laboratorium nagebootst worden. Uit chirurgisch verwijdererde tumoren kunnen tumor­
cellijnen gekweekt worden. Deze kunnen gekarakteriseerd worden met betrekking tot hun 
protease-productie. Door in invasie-experimenten plasminogeen activator-remmende 
stoffen toe te voegen aan deze cellijnen kan nagegaan worden of plasminogeen activatie 
inderdaad een bijdrage kan leveren aan het invasieve gedrag van tumorcellen. Verder 
geeft hoofdstuk la een overzicht van de plasminogeen activatie-literatuur in verschillende 
tumoren. Uit bepalingen op coupes (dit zijn dunne plakjes weefsel) en uit bepalingen in 
tumorextracten kan een min of meer algemeen beeld voor tumoren afgeleid worden. 
Vergeleken met het normale omliggende weefsel of ten opzichte van goedaardig weefsel 
bevatten bijna alle tumoren verhoogde u-ΡΑ-, u-PAR- en PAI-1-spiegels. t-PA en PAI-2 
komen soms verhoogd voor in maligne of kwaadaardige tumoren, maar vaak komen deze 
componenten juist minder voor in maligne tumoren ten opzichte van het normale omlig­
gende weefsel of de benigne of goedaardige afwijking. 
Ook hoofdstuk lb is een literatuuroverzicht. Hierin wordt specifiek ingegaan op de vraag 
of niet alleen u-ΡΑ maar ook t-PA een bijdrage kan leveren aan het invasief en metastase­
rend vermogen van melanoomcellen. Voor veel typen tumoren geldt dat vooral het 
voorkomen van u-ΡΑ en niet van t-PA samenhangt met invasief gedrag, met metasta­
serend vermogen en dus ook met een slechte prognose voor de patient. Cellijnen van het 
melanoom onderscheiden zich van andere tumorcellijnen doordat ze naast u-ΡΑ ook veel 
t-PA maken. De rol van u-ΡΑ en t-PA in invasie- en meiastaseringsexperimenten met 
humane en muismelanoomcellijnen wordt belicht 
In hoofdstuk 2 wordt de aanwezigheid van t-PA, u-ΡΑ, u-PAR, PAI-1 en PAI-2 in 
humane cutané melanocytaire lesies beschreven. Van operatief verwijderde moedervlek-
ken of nevi (benigne lesies, onder te verdelen in gewone en dysplastische nevi) en cutané 
melanomen en metastasen daarvan (maligne lesies) werden dunne plakjes (4/1000 van een 
millimeter dun) gesneden. In deze plakjes (coupes) konden de volgende aspecten zichtbaar 
gemaakt worden: 
a) in welk type lesies t-PA en/of u-ΡΑ protease activiteit voorkomt, 
b) in welk type lesies en in welke celtypen de eiwitten t-PA, u-ΡΑ, u-PAR, PAI-1 en 
PAI-2 voorkomen, 
c) in welk type lesies de verschillende RNAs (voorloper-moleculen van de eiwitten) voor 
de verschillende componenten voorkomen 
Er kon geconcludeerd worden dat alle componenten pas voorkomen in late stadia van 
melanocytaire tumorontwikkeling. Alleen in verder gevorderde melanomen (met een dikte 
groter dan 1,5 mm) en in metastasen konden de verschillende componenten aangetoond 
worden. t-PA kon behalve in de binnenste cellen van bloedvaten (endotheelcellen) ook in 
melanoomcellen aangetoond worden. u-ΡΑ komt niet alleen in melanoomcellen voor maar 
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ook in die bindweefselcellen (fibroblasten) die de tumor direct omgeven. PAI-1 wordt 
geproduceerd door tumorcellen en deels afgezet in de extracellulaire matnx binnenin de 
tumor, waar het deze mogelijk beschermt tegen afbraak 
In hoofdstuk 3 wordt de vraag beantwoord waar plasminogeen/plasmine en het plasmin-
ogeen-bindend eiwit tetranectine voorkomen in cutané melanocytaire lesies. Beide eiwitten 
komen voornamelijk voor in de maligne stadia van de melanocytaire ontwikkehngsreeks, 
aan het invasieve front van de tumoren en metastasen Tetranectine en plasminogeen 
komen in vergelijkbare celgroepen voor, namelijk in de fibroblasten die de invasieve 
tumor omgeven en niet of nauwelijks in de tumorcellen zelf Een mechanisme waar 
migrerende, u-ΡΑ producerende tumorcellen plasminogeen aangeleverd knjgen door de 
fibroblasten wordt voorgesteld 
LRP (naar het Engels- low density lipoprotein receptor-related protein) is een eiwit 
waarvan ongeveer drie jaar geleden bekend werd dat het een rol kan spelen bij het 
internaliseren (het opnemen in de cel) van u-ΡΑ en t-PA, al dan met in complex met u-
PAR en/of PAI In de route naar de celmembraan toe, wordt LRP begeleid door het eiwit 
RAP (naar het Engels receptor-associated protein), dat voorkomt dat andere eiwitten 
vroegtijdig binden aan LRP Hoofdstuk 4 beschrijft het voorkomen van LRP en RAP in 
humane melanoomcellijnen en in cutané melanocytaire lesies LRP komt voor in alle 
melanoomcellijnen, maar meer in u PA producerende cellijnen In tumoren van deze 
cellijnen (zogenaamde xenografts) die gevormd zijn in immuundeficiente muizen, vindt er 
reductie plaats van LRP-productie slechts een fractie van de u-ΡΑ positieve tumorcellen 
in deze artificiële tumoren maakt LRP In humane melanocytaire lesies komen LRP en 
RAP vooral voor in benigne stadia en veel minder in melanomen en metastasen Ook 
correleert het expressie-patroon niet met het eerder gevonden u-ΡΑ expressie-patroon 
LRP en RAP colocahseren Dit betekent dat ze in dezelfde cellen (in coupes) en 
subcellulaire structuren (in gekweekte cellen) voorkomen Naar de betekenis van de 
verlaagde LRP expressie in melanocytaire tumorontwikkeling kan slechts gegist worden 
In elk geval staat vast dat een direct verband met u-ΡΑ expressie niet gelegd kan worden 
Er wordt vaak vanuit gegaan dat het plasminogeen activatiesysteem aangrijpingspunten 
voor kankertherapie zou bieden (zie ook hoofdstuk la) Goede diermodellen voor tumoren 
zijn dan ook noodzakelijk om dit te kunnen testen De meeste modelsystemen zijn 
gebaseerd op cellijnen van een tumorsoort Deze cellijnen zijn vrij homogeen elke cel 
van een cellijn maakt ongeveer hetzelfde repertoire aan eiwitten Een heterogeen 
proefdiermodel voor het melanoom is het Tyr SV40 transgene muismodel De in dit 
model ontstane melanocytaire lesies omvatten zowel nevi als gepigmenteerde en niet-
gepigmenteerde melanomen In hoofdstuk 5 wordt dit model onderzocht met betrekking 
tot expressie van de activatoren en de Inhibitoren van het plasminogeen activatiesysteem 
Hoewel geen t-PA en PAI-2 geproduceerd wordt door de lesies, is er een duidelijke 
tendens van toenemende u-ΡΑ expressie in meer maligne, ongedifferentieerde tumoren 
u-ΡΑ wordt echter hoofdzakelijk in zeer jonge, spruitende bloedvaatjes gevonden 
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Mogelijk speelt u-ΡΑ dus een rol in de vaatnieuwvorming in deze tumoren. 
Behalve in de huid, komen melanocyten ook in de uvea, het bindweefsel van de oogbol 
voor. Uit deze melanocyten kan een uveamelanoom ontstaan. Het voorkomen en de 
localisatie van verschillende componenten van het plasminogeen activatie systeem in dit 
type melanoom zijn weergegeven in hoofdstuk 6. Histologisch kunnen oogmelanomen 
ingedeeld worden in melanomen met alleen spoelvormige cellen en in melanomen met 
spoelvormige en epithehoide cellen. Laatstgenoemde categorie heeft een slechtere 
prognose. Alleen in lesies met epithehoide cellen komt u-ΡΑ en PAI-2 voor. Verder 
bevatten deze melanomen meer t-PA en u-PAR. Alle geteste metastasen van uveamelano-
men maken u-ΡΑ. Ook in uveamelanomen is expressie van de componenten van het 
plasminogeen activatiesysteem gerelateerd aan de meest agressieve vormen van de tumor. 
De ruimtelijke relatie tussen u-ΡΑ, u-PAR, PAI-1, tetranectine en plasminogeen wordt 
beschreven in hoofdstuk 7. Een hypothese over hoe deze componenten, geproduceerd door 
verschillende celtypen, kunnen samenwerken in invasieve processen staat hier weergege­
ven. 
De hoofdconclusie van dit proefschrift is dat de componenten van het plasminogeen 
activatiesysteem in drie typen melanomen (cutaan melanoom, een diermodel voor het 
cutané melanoom en oogmelanoom) vooral voorkomen in meer maligne melanocytaire 
lesies. Onderzoek aan lesies van een grote groep melanoompatienten van wie het beloop 
van de ziekte nauwkeurig in kaart gebracht is, zal ons in de toekomst leren of het 
voorkomen van de verschillende componenten van het plasminogeen activatiesysteem iets 
zegt over het ziektebeloop van de patient. 
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Nawoord 
Ruim een halfjaar duurt de slotfase van het promoveren waar 'het' telkens bijna af is. Nu 
is dan mijn wetenschappelijk kind geboren. Vanaf de middelbare school bestaat het leven 
uit duizenden interessante keuzemomenten, vaak is het moeilijk kiezen. Elke keer ga je 
een bepaalde richting uit, en dan ineens, tja ... - ik kan het niet meer ontkennen na het 
voltooien van dit proefschrift - ben je wetenschapper. 
Eindelijk mag ik even - op deze meest gelezen bladzijden van het proefschrift - het 
formele geformuleer achter me laten. Voor mij is het goed kunnen functioneren erg 
afhankelijk van het type werk dat ik doe maar vooral ook van mijn werkomgeving. Over 
het werk kan ik kort zijn: het is absoluut noodzakelijk om betrokkenheid en affiniteit met 
je onderwerp te hebben. Vanuit de affiniteit komen de ideëen tot je. Het bomen over de 
fundamentele vraag hoe tumoren uitzaaien is een erg bevredigende bezigheid. Hoe 
paradoxaal het ook moge klinken: tumorkleuringen kunnen de verwondering bij je 
oproepen. Dit aspect van de verwondering, die schaarse momenten waarop je even denkt 
te weten hoe de vork in de steel zit, is voor mij een belangrijke motivator geweest. Maar 
even belangrijk was mijn werkomgeving. Vooral door de mensen die mijn werkomgeving 
bepaalden, kijk ik met veel plezier terug op de afgelopen vier jaar. 
Allereerst wil ik mijn copromotor Goos van Muijen en mijn promotor Dirk Ruiter 
bedanken. Goos, je hebt me vaak goede suggesties gegeven, en je hebt me het arti-
kelschrijf-metier bijgebracht. Het was ook prettig dat ik bijna altijd zomaar bij je kon 
binnenlopen als ik iets met je wilde bespreken. Dirk, hoewel de momenten van samen 
naar melanoomcoupes kijken schaars waren, heb ik van deze sessies veel geleerd. Ik dank 
je ook voor het gedeelde enthousiasme en voor de snelle correcties van subfinale 
manuscripten en het altijd bemoedigende commentaar daarbij. 
Beide parelnimfen, Kiek en Aicha, hebben veel tot mijn werkvreugde bijgedragen. Kiek 
(OKiek), ik wil je graag bedanken voor de immunokleuringen die je helemaal in het begin 
van het project gedaan hebt. Verder heb je me als 'baasje' opgevoed en ook nadat je 
tijdelijk gestopt bent met werken heb je niet verzuimd me halfjaarlijks allerlei lekkere 
likeuren en whiskeys voor te schotelen die bij voorkeur in willekeurige volgorde 
gedronken horen te worden. Aicha, al sta je niet bij de u-PA-artikelen: dankzij jouw 
voorwerk ben ik de komende drie jaar van de straat. Onze MAGE-droom zullen we snel 
verwerkelijken. 
Ine, Kees, Annemieke, Cilia, Winny, Han, Erik: met jullie heb ik heel wat gezelligheid 
beleefd en quality time doorgebracht. Inderdation, jullie waren, veel meer nog dan drop 
en repen, essentieel voor mijn werkplezier! Michael van Balken, je was mijn beste en 
leukste (ex-) student. Er viel goed met je te lachen en je documenteerde je gegevens heel 
goed en zelfstandig. 
Natuurlijk mag ik de 'in situ's' niet vergeten. Jullie waren de afgelopen 4 jaar mijn 
tweede lab. In het begin, tijdens de mRNA in situ periode, waren jullie mijn 
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noodzakelijke steun als de proefjes weer eens mislukten, en ook daarna heb ik vaak hele 
goede adviezen van jullie gehad bij dubbel- of triplekleunngen. Marylène Denijn, bedankt 
voor je deskundige begeleiding bij die rottechniek die pas na lang zwoegen en veel 
recepten proberen slechts enkele mooie plaatjes opleverde. 
Niets is zo veranderlijk als de naam van het Gaubius Instituut in Leiden. Onveranderlijk 
gedegen was jullie plasminogeen activatie-kennis. Vooral bij mijn eerste artikel heb ik 
veel aan jullie gehad, met name hoe je een wetenschappelijke boodschap moet verkopen 
heb ik van jullie geleerd. Paul Quax, Jan Verheijen en Anton de Bart: bedankt! 
Neeltje Mooy, bedankt voor het leren kijken naar oogmelanoomcoupes. Hein Verspaget, 
bedankt voor het bemiddelen van antihchamen en voor je kritische commentaar bij sub-
finale versies van artikelen waarbij je betrokken was. Peter de Wit, bedankt voor de 
patholoog-controle op mijn tetranectine/plasminogeen sconngswerk. 
I want to thank Catherine Delbaldo and dr. Sappino, Geneva, for teaching me and 
adapted in situ hybridization procedure and for teaching me in situ zymography, a 
beautifull technique which furnishes three of my publications. I thank Inge Clemmensen 
posthumously for her advice and suggestions in the tetranectin chapter It is a pity we 
could never meet. Beatrice Mintz, I thank you for allowing me in your laboratory and for 
the very interesting scientific and social discussions we had. 
Hoewel ik het promoveren met alle poespas eromheen als een hoogtepunt in mijn leven 
ervaar, zie ik ook de betrekkelijkheid ervan in. Veel belangrijker in je leven zijn je 
duurzame fans. Mijn ouders staan al 30 jaar geduldig en bemoedigend langs de zijlijn, 
zonder ooit een stempel op mijn leven te willen drukken. Met mijn koormaatjes heb ik 
heel wat aangename vibraties beleefd, tijdens het zingen en in de kroeg na de repetitie. Ik 
vind deze momenten erg waardevol en ook inspirerend voor het werk Tenslotte, mijn 
vriendinnen en vnenden geven meer kleur aan mijn leven dan de fluorescentiefoto op de 
kaft aan mijn proefschrift. 
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Stellingen behorende bij het proefschrift 
The piasmingen activation system in melanocytic tumors 
-1-
De expressie van componenten van het plasmmogeen aciivatie-systeem correleert met het 
verworven maligne fenotype van melanocytaire tumoren 
Dit proefschrift. 
-2-
Plasminogeen, het centrale eiwit in het plasmmogeen activatie-proces en in de afbraak van 
extracellulaire matrix, komt bij melanomen en andere tumoren uitsluitend in het tumor 
omringende bindweefsel voor. Dit weefsel speelt derhalve een grote rol bij invasieve 
processen van tumoren. 
Dit proefschrift; 
Burtin et al 1985, Int J Cancer 35 307-314; 
Wewer en Alhrechtsen 1992, Lab Imest 67 253 262 
-3-
In tegenstelling tot in naakte muizen gekweekte tumoren, is het niet waarschijnlijk dat het 
van plasmmogeen afgeleide vaatmeuwvorming-reinmende eiwit angiostatine door humane 
tumorcellen geproduceerd wordt in spontane tumoren 
Dit proefschrift; 
O'Reilly et al. 1994, Cell 79 315 328 
-4-
Om inzicht te verkrijgen in de precíese locahsatie van proteolytische processen in humane 
tumoren, is hel nodig ïmmunohistochemische en in situ zymografische technieken te 
ontwikkelen die onderscheid kunnen maken tussen de verschillende (activiteits-)vormen 
van de proteasen en protease-geassocieerde componenten 
-5 
De rol van urokinase plasmmogeen activator (u-ΡΑ) in locale proteolytische processen 
zoals invasieve groei van tumorcellen en metastasering, kan los gezien worden van de 
aanwezigheid van de urokinase receptor 
Yu en Schultz 1990, Cancer Res 50. 7623-7633; 
Tapiovaara et al. 1993, Blood 82 914-919, 
Bugge et al. 1995, J Biol Chem 270 16886-16894; 
Plesner et al. 1995, Am J Clin Pathol 102 835 841 
-6-
Een tumorcellijn noemen naar de koningin (Queens melanoma) is een bedenkelijke blijk 
van waardering voor het koningshuis' 
Ahzadeh et al. 1995, Current Eye Res 14 449-458. 
7 
In verband met hun functionele implicaties horen moleculair biologische, biochemische en 
celbiologische bevindingen, waar mogelijk, getoetst ie worden aan een cel- of weefselpre 
paraat 
-8-
Het is wenselijk de naamgeving van veel pas ontdekte eiwitten na verloop van tijd te 
herzien, omdat de naam vaak alleen verwijst naar die eigenschap van het eiwit die bekend 
was bij de ontdekking en daardoor vaak misleidend is 
-9-
In veel goed toegeruste tumorcelbiologische laboratoria zijn niet zowel nietjes als welle­
tjes aanwezig 
-10 
Financieel gezien merkt een AIO in dienst van een katholieke universiteit niets van het 
rijke Roomse leven 
11-
Een Matteus of een Johannes met een (vrouwelijke) allsolist heeft meer Passie 
12 
Vorderingen op het gebied van de volksgezondheid worden deels teniet gedaan door de 
uitbreiding van Schiphol 
-Π-
Wetenschappelijk werk is de betaalde hobby die je in principe overdag beoefent 
14-
De uitzondering bevestigt de regel niet 
-15-
Het afronden van een proefschrift met veel Deense referenties is eerder een kwestie van 
streepjes door de o dan van puntjes op de ι 
Teun de Vries, juni 1996 
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